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ABSTRACT 
 
In the injured adult mammalian central nervous system (CNS), severed axons fail to 
undergo spontaneous regeneration, leading to permanent neurological deficits, such as paralysis 
following spinal cord injury, and cognitive impairment following traumatic brain injury or 
stroke.  A large body of work has established that neuron intrinsic and extrinsic mechanisms 
pose barriers to efficient CNS repair.  Inhibitory molecules, including myelin-associated 
inhibitors (MAIs) and chondroitin sulfate proteoglycans (CSPGs), are expressed by injured CNS 
tissue and complex with neuronal surface receptors to prevent regenerative growth of axons.  
Following retro-orbital crush injury to the mouse optic nerve, injured retinal ganglion cell (RGC) 
axons do not normally grow beyond the injury site.  Deletion of multiple CSPG receptors enables 
significant, though modest, regeneration of RGC axons. In these mice, RGC axon regeneration 
can be greatly enhanced by  induction of a local immune response. The underlying mechanisms 
of immune-mediated neurorepair are poorly understood.  Here I show that post-injury 
manipulation of specific immunomodulatory pathways promotes extensive growth of injured 
RGC axons.  Intraocular injection of zymosan, a yeast cell wall extract, leads to a rapid 
accumulation of blood-derived immune cells in the vitreous, and enables robust RGC axon 
regeneration by engaging the pattern recognition receptors dectin-1 and Toll-like receptor-2 
(TLR2).  Dectin-1 is expressed by retina-resident microglia and dendritic cells, but not by RGCs. 
Dectin-1 is also present on blood-derived myeloid cells that accumulate in the vitreous.  
Intraocular injection of the dectin-1 ligand curdlan (a particulate form of beta-glucan) elicits
! xvii!
robust regeneration in WT, but not in dectin-1−/− mice. Studies with dectin-1−/−/WT reciprocal 
bone marrow chimeric mice revealed a requirement for dectin-1 on both retina-resident immune 
cells and bone-marrow derived cells for beta-glucan-elicited optic nerve regeneration.  
Collectively, these studies identify a molecular framework for how innate immunity enables 
repair of injured central nervous system neurons.  
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CHAPTER I 
Introduction:  
Regeneration in the adult mammalian central nervous system: inhibitory mechanisms and 
strategies for repair 
1.1  Abstract 
In the injured adult mammalian central nervous system (CNS), severed axons fail to 
undergo spontaneous regeneration. This limited regenerative capacity leads to permanent 
neurological deficits, such as paralysis following spinal cord injury, and cognitive impairment 
following traumatic brain injury or stroke.  A large body of work has established that neuron 
intrinsic and extrinsic mechanisms pose barriers to efficient CNS repair.  The intrinsic growth 
potential of injured CNS neurons is extremely poor.  In addition, inhibitory molecules expressed 
by injured CNS tissue complex with neuronal surface receptors to prevent regenerative growth of 
axons.  The majority of the work in the field of CNS regeneration has focused on antagonizing 
inhibitory mechanisms and stimulating intrinsic growth programs in an effort to identify key 
molecular targets that may be manipulated therapeutically to promote functional recovery.  
Recently, a number of studies reported that, under certain conditions, barriers to CNS repair can 
be surmounted by the induction of a local immune response after injury.  A deeper understanding 
of the cellular and molecular basis of immune-mediated neurorepair may lead to the 
identification of specific biochemical pathways that can be targeted to promote regeneration 
following nervous system injury or disease. 
2"
 1.2 The Limited Regenerative Capacity of the CNS 
Spinal cord injury is a devastating form of CNS injury that typically results in lifelong 
neurological deficits.  Recorded incidences of spinal cord injury and attempts at treatment date 
back thousands of years to Ancient Greece.  While advances in modern medicine have extended 
the life span of spinal cord injury patients, the extent of functional recovery remains extremely 
limited.  In the early 20th century, work by Santiago Ramón Y Cajal provided the first insights 
into the limited regenerative capacity of the CNS.  Cajal observed that injured CNS axons can 
extend processes into a peripheral nerve graph (Tello, 1907), suggesting that the CNS 
environment is inhibitory towards regenerative growth. Additional grafting experiments by 
Albert Aguayo in the 1980s confirmed these findings (Richardson et al., 1980).  Subsequent 
studies in the last several decades have identified molecular mechanisms that contribute to 
growth inhibition, and revealed additional barriers to repair, such as the poor intrinsic growth 
potential of injured CNS neurons. 
Spontaneous regeneration of severed axons can occur in the peripheral nervous system 
(PNS).  Several differences between the extrinsic environment of the PNS and CNS might help 
explain their differing regenerative capacities.  Axons in both the PNS and CNS are enwrapped 
with myelin sheaths, allowing for rapid propagation of action potentials and metabolic support of 
axons.  In the PNS, axons are myelinated by Schwann cells.  Following injury, Schwann cells 
perform many tasks, including secreting factors to promote cell survival, directing axon 
regeneration, and remyelinating axons (Brosius Lutz and Barres, 2014).  Importantly, they also 
help recruit macrophages to clear away myelin debris, highlighting a beneficial aspect of the 
immune system in promoting nervous system repair (Gaudet et al., 2011).  Oligodendrocytes 
(OLs) are the myelinating cells of the CNS.  In contrast to the PNS,  OLs in the CNS do little to 
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promote axon regeneration.  Myelin debris from damaged OLs in the CNS is not well cleared 
(George and Griffin, 1994).  Damaged OLs express multiple growth inhibitory ligands which 
complex with axonal surface receptors to inhibit sprouting and regenerative growth (Giger et al., 
2008).  Rather than helping to clear myelin debris, macrophages exacerbate cell death and 
damage (Gaudet et al., 2011).  In addition to OLs, astrocytes in the CNS become reactive 
following injury, secreting growth inhibitory ligands such as chondroitin sulfate proteoglycans 
(CSPGs) (Morgenstern et al., 2002).  Furthermore, reactive astrocytes form a glial scar at the site 
of injury which poses a physical barrier towards regenerative growth. 
The intrinsic growth potential of adult CNS neurons is very poor.  Neonatal rat retinal 
ganglion cells (RGCs) undergo a profound loss of intrinsic axon growth ability (Goldberg et al., 
2002), and injured RGC axons in adult rodents do not normally regenerate.  However, 
manipulating growth promoting pathways in RGCs has proven a successful method for 
stimulating regenerative growth (Leibinger et al., 2009, Belin et al., 2015).  For example, genetic 
deletion of phosphatase and tensin homolog (PTEN) in RGCs prior to optic nerve crush injury 
results in robust regeneration distal to the injury site (Park et al., 2008).  PTEN is an upstream 
inhibitor of several growth promoting signaling molecules, such as mTOR complex 1 
(mTORC1), a serine-threonine protein kinase that regulates protein translation and promotes cell 
growth (Maehama and Dixon, 1998, Gingras et al., 2001).  The enhanced regeneration observed 
with PTEN deletion is abolished by treatment with the mTORC1 inhibitor rapamycin (Park et al., 
2008).  Manipulation of members of the Krüppel-like factor (KLF) family of transcription factors 
in RGCs also enables axon regeneration.  KLF4 and KLF9 suppress, and KLF6 and KLF7 
enhance RGC axon growth (Moore et al., 2009). Extensive work by Mark Tuszynski’s laboratory 
has shown that increasing levels of neurtrophic factors following CNS injury, through infusion or 
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gene therapy, is another viable strategy for stimulating regenerative growth (Hollis and 
Tuszynski, 2011, Blesch et al., 2012)  Collectively, the poor intrinsic growth capability of 
injured CNS axons, combined with the growth inhibitory environment of CNS tissue results in a 
severely limited regenerative capacity in the injured adult mammalian CNS.  
 
1.3 CNS Regeneration Inhibitors and Their Receptors 
The growth inhibitory environment of injured adult mammalian CNS tissue constitutes a 
major barrier to robust axonal outgrowth and functional recovery following trauma or disease.  
CNS tissue is resident to a large and diverse array of inhibitory molecules, including the  
prototypic myelin-associated inhibitors (MAIs) NogoA, oligodendrocyte myelin glycoprotein 
(OMgp), and myelin-associated glycoprotein (MAG), and the astrocyte-secreted CSPGs. These 
structurally diverse molecules strongly inhibit neurite outgrowth in vitro, and have been most 
extensively studied in the context of injured brain and spinal cord in vivo. 
 
NogoA 
NogoA is a membrane-associated protein that belongs to the reticulon family (GrandPre 
et al., 2000).  Originally identified as a neurite growth inhibitory “activity” enriched in a spinal 
cord white matter fraction (Caroni et al., 1988, Caroni and Schwab, 1988), three laboratories 
described the molecular identity of Nogo-A more than 15 years ago (Chen et al., 2000, GrandPre 
et al., 2000, Prinjha et al., 2000).  NogoA is expressed by many cell types, though its expression 
is highest in OLs and principal neurons in brain regions with a heightened degree of network 
plasticity, including the hippocampus and neocortex (Huber et al., 2002, Zhang et al., 2014). 
NogoA harbors at least two distinct growth inhibitory motifs, Nogo-66 (Fournier et al., 2001) 
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and NogoΔ20 (Oertle et al., 2003).  In the injured spinal cord, acute antibody blockade of NogoA 
promotes axonal sprouting and is associated with improved behavioral outcomes (Merkler et al., 
2001, Liebscher et al., 2005).  Nogo66 receptors include the Nogo receptor (NgR) family 
member NgR1 (Fournier et al., 2001), and paired Ig-like receptor B (PirB) (Atwal et al., 2008).   
In vitro studies showed that blockade of NgR1 and PirB attenuates Nogo-66 or myelin-mediated 
inhibition of neurite outgrowth (Atwal et al., 2008).  Loss of NgR1 in vivo does not result in 
enhanced regenerative growth of the mouse optic nerve (Dickendesher et al., 2012) or spinal 
cord (Zheng et al., 2005), though this finding is contested by another study that reported 
enhanced optic nerve regeneration in a different NgR1 mutant mouse (Wang et al., 2011).  
Further studies are needed to assess the contribution of PirB to growth inhibition in vivo.  The 
NogoΔ20 domain of NogoA does not interact with PirB or members of the Nogo receptor 
family.  A recent study identified sphingosine 1 phosphate receptor 2 (S1PR2) as a novel 
receptor for NogoΔ20 that participates in neurite outgrowth inhibition in vtiro (Kempf et al., 
2014).   
 
OMgp 
OMgp is a 110-kDa leucine-rich repeat protein linked to the cell membrane by a  
glycosylphosphatidylinositol (GPI)-anchor.  OMgp is expressed by OLs and neurons in the CNS 
(Vourc'h et al., 2003) and also found in astrocytes (Zhang et al., 2014).  Two independent studies 
identified OMgp as a potent growth inhibitory molecule enriched in CNS myelin (Kottis et al., 
2002, Wang et al., 2002).  Similar to Nogo66, OMgp interacts with both NgR1 and PirB 
(Fournier et al., 2001, Wang et al., 2002, Atwal et al., 2008, Filbin, 2008).    Despite the 
inhibitory activity of OMgp towards neurite outgrowth in vitro, studies with two different OMgp 
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knockout mice did not show any significant regeneration in the corticospinal tract following 
spinal cord injury (Ji et al., 2008, Lee et al., 2010), though one of these studies did observe 
enhanced growth of serotonergic and dorsal column sensory axons (Ji et al., 2008). 
 
MAG 
The neurite outgrowth inhibitory properties of MAG were discovered independently by 
the laboratories of Marie Filbin (Mukhopadhyay et al., 1994) and Peter Braun (McKerracher et 
al., 1994) more than 20 years ago.  MAG is a type-1 transmembrane protein and a prominent 
member of the family of sialic acid-binding Ig superfamily (siglec) proteins.  MAG is expressed 
by myelinating glia, Schwann cells in the periphery and OLs in the CNS.  MAG is abundant in 
the CNS and is enriched in Schmidt-Lanterman incisures and the periaxonal membrane of 
myelin sheath, allowing for complexes with receptors to form on the axonal surface (Trapp et al., 
1989). Several receptors for MAG have been identified including the gangliosides GD1a and 
GT1b (Yang et al., 1996), NgR1 (Domeniconi et al., 2002, Liu et al., 2002), NgR2 (Venkatesh et 
al., 2005), paired Ig-like receptor B (PirB) (Atwal et al., 2008), β1-integrin (Goh et al., 2008), 
and low density lipoprotein receptor-related protein 1 (LRP1).  Except for the interaction with 
LRP1, MAG binds to its neuronal receptors in a sialic acid-dependent manner (Robak et al., 
2009, Stiles et al., 2013).  In vivo, loss of MAG enhances compensatory sprouting of 
corticospinal and raphespinal serotonergic axons, but does not lead to enhanced regenerative 
growth following spinal cord injury (Cafferty et al., 2010, Lee et al., 2010).  Surprisingly, the 
combined loss of MAG, NogoA, and OMgp is not sufficient to promote regenerative growth of 
injured axons following spinal cord injury, as mice lacking NogoA, MAG, and OMgp (NMO- 
mice) showed no significant regeneration of injured corticospinal or raphespinal serotonergic 
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axons (Lee et al., 2010).  However, this finding remains somewhat controversial, as another 
study reported significant regeneration of injured spinal cord axons in NMO- mice (Cafferty et 
al., 2010).  Overall, these in vivo findings suggest that manipulation of MAI inhibition by itself is 
not sufficient to promote robust functional repair following CNS injury.  
 
CSPGs 
Another prominent group of CNS regeneration inhibitors, chondroitin sulfate 
proteoglycans (CSPGs), are extracellular matrix (ECM) proteoglycans consisting of a protein 
core with covalently attached glycosaminoglycan (GAG) side chains (Properzi et al., 2003).  
CSPGs are secreted by astrocytes, neurons, and OLs (Ogawa et al., 2001), and they are strongly 
enriched at the glial scar after CNS injury where they inhibit regenerative growth and restrict 
plasticity (Bradbury et al., 2002, Morgenstern et al., 2002, Silver and Miller, 2004).  Degradation 
of CSPGs using the enzyme chondroitinase ABC (ChABC) promotes compensatory sprouting 
and functional recovery in the injured rodent spinal cord (Bradbury et al., 2002).  A number of 
neuronal surface receptors bind CSPGs and inhibit neurite outgrowth in vitro, including NgR1, 
NgR3, leukocyte common antigen-related protein (LAR), and its homolog receptor protein 
tyrosine phosphatase sigma (RPTPσ) (Shen et al., 2009, Fisher et al., 2011, Dickendesher et al., 
2012).  Studies with LAR mutant mice and RPTPσ mutant mice revealed enhanced regenerative 
growth of injured spinal cord axons (Fry et al., 2010, Xu et al., 2015).  The Nogo receptor family 
members provide a molecular link between the two major groups of CNS inhibitors, MAIs and 
CSPGs, and therefore may be promising therapeutic targets to promote CNS repair.  In vivo 
regeneration studies with mice lacking multiple CSPG receptors are the focus of the second 
chapter of this dissertation. 
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1.4 Immune-Mediated Neurorepair 
Despite the inhibitory nature of adult CNS tissue, a number of investigators have 
observed that, under certain conditions, barriers of CNS regeneration are surmounted by the 
induction of a local immune response (David et al., 1990, Richardson and Lu, 1994, Donnelly 
and Popovich, 2008, Benowitz and Popovich, 2011).  Hence, inflammation induced near the cell 
body of injured dorsal root ganglion (DRG) neurons (Lu and Richardson, 1991) or retinal 
ganglion cells (RGCs) (Leon et al., 2000, Fischer et al., 2001) can activate endogenous repair 
mechanisms, enhance neuroprotection, and promote axonal regeneration.  The therapeutic 
potential of immune-mediated neurorepair is underscored by the observation that axonal growth 
is even more effective when inflammation is initiated several days after the insult (Yin et al., 
2003).  While the ability of the immune system to promote regeneration was discovered over 15 
years ago, the underlying molecular and cellular mechanisms are poorly understood.  A deeper 
understanding of these mechanisms may lead to the identification of specific biochemical 
pathways that can be targeted to promote regeneration following nervous system injury or 
disease.   
 
Overview of the Innate Immune System  
The innate immune system provides a rapid and generic immune response to defend the 
body against invading pathogens.  This is unlike the adaptive immune system, which provides 
highly specialized responses to specific pathogens and generates a long-term immunological 
memory.  The innate immune system consists of several different types of white blood cells, or 
leukocytes.  These include: 1) phagocytic cells such as monocytes, macrophages, neutrophils, 
9"
and dendritic cells (DCs),  2) Natural killer cells, 3) mast cells and 4) basophil and eosinophil 
granulocytes.  Cells of the innate immune system are found circulating in the blood, and, in the 
case of macrophages and DCs, in various tissue-resident populations (Lech et al., 2012).  In the 
CNS, microglia are the primary tissue-resident immune cell.  While micrgolia share several 
properties with cells of the monocyte/macrophage lineage, they are a distinct cell type, 
originating from the primitive yolk sac, and not from the hematopoietic stem cell lineage (Salter 
and Beggs, 2014).  In addition to their immunological function, microglia have recently been 
shown to play important roles in the development and refinement of synaptic connections of 
neuronal networks (Bilimoria and Stevens, 2014). 
 The cells of the innate immune system express surface pattern-recognition receptors 
(PRRs) which recognize and respond to common molecular patterns on invading pathogens, so-
called pathogen-associated molecular patterns (PAMPs). PRRs also recognize host-derived 
danger-associated molecular patterns (DAMPs) which are released near sites of tissue damage or 
injury (Tang et al., 2012).  Binding of PAMPs or DAMPs to PRRs on tissue-resident 
macrophages stimulates the release of cytokines and chemokines, generating an inflammatory 
response in the tissue and attracting additional blood-derived immune cells, such as neutrophils 
and monocytes, to the site of inflammation (Newton and Dixit, 2012).  Additionally, binding of 
PAMPs to PRRs on phagocytic cells results in phagocytosis and destruction of invading 
pathogens (Kapetanovic and Cavaillon, 2007).  The influx of blood-derived immune cells into 
inflamed tissue helps the resident-immune cells to destroy invading pathogens, or delay them 
long enough for the adaptive immune system to mount a response.  Additionally, activation of 
the innate immune system can help to repair damage associated with injury or infection, as 
discussed below. 
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Positive and Negative Consequences of Inflammation in the CNS 
The immune system and the nervous system are in constant dialogue, but details of how 
they are integrated and functionally cooperate in health and disease are only now being revealed. 
Activation of the innate immune system in the brain or spinal cord occurs not only in response to 
invading pathogens, but also in response to injury or chronic disease. Depending on the extent 
and nature of the inflammation that ensues, the innate immune response can have either negative 
(neurodestructive) or beneficial (neuroprotective) consequences (Gensel et al., 2009, Rivest, 
2009, Lang et al., 2014).  At sites of CNS injury, activated macrophages and microglia promote 
regeneration with concurrent neurotoxicity (Gensel et al., 2009).  In some instances, innate 
immunity protects the CNS from further damage (Bsibsi et al., 2006, Glezer et al., 2006), while 
in others, excessive inflammation exacerbates damage and contributes to neurological 
dysfunction (Gonzalez-Scarano and Baltuch, 1999, Lehnardt et al., 2003).  A great deal is known 
about the types of immune cells and factors that have detrimental effects in the brain (King et al., 
2009, Ashhurst et al., 2014).  Less is known about the immune pathways that promote the 
survival and regeneration of injured nerve cells (Yin et al., 2006, Muller et al., 2009, Vidal et al., 
2013).  A key question is whether the neurotoxic effects and the pro-regenerative effects of 
neuroinflammation can be dissociated at the molecular level. This is an important pre-requisite 
for any strategies aimed at targeting and harnessing immune-based repair mechanisms.  
 
Immune-mediated regeneration in the rodent optic nerve 
A well-established animal model to study neuronal responses to CNS injury is retro-
orbital crush injury to the optic nerve in adult mice or rats (Berry et al., 2008).   Following 
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axonal injury, the majority of RGCs die within a week (Levin, 1999, Lukas et al., 2009), and 
only a few subtypes survive (Duan et al., 2015). RGCs that survive the optic nerve crush are 
unable to extend their axons beyond the lesion site, resulting in permanent vision loss on the 
operated side (Berry et al., 2008).  Intra-ocular (i.o.) injection of compounds or viral vectors into 
the vitreous of the eye allows direct access to RGC cell bodies, and has been used extensively to 
manipulate the growth behavior of injured RGC axons.  Regenerative growth of severed RGC 
axons is greatly enhanced following induction of intraocular inflammation via lens trauma (Leon 
et al., 2000, Lorber et al., 2005), i.o. administration of crystallins (Fischer et al., 2008), oxidized 
galectin-1 (Okada et al., 2005), zymosan (a yeast cell wall extract) (Yin et al., 2003) or Pam3Cys 
(Hauk et al., 2010).  Similar to the visual system, zymosan-elicited inflammation promotes 
axonal growth of DRG neurons transplanted into the adult rat spinal cord (Gensel et al., 2009).  
Moreover, injection of zymosan into DRGs combined with chondroitinaseABC treatment drives 
growth of injured sensory afferents into the spinal cord to a greater extent than either treatment 
alone (Steinmetz et al., 2005).  In spite of numerous reports on the beneficial effects of 
inflammation on neural repair, relatively little is known about molecular mechanism of immune-
mediated axonal regeneration.  
 
Many Unanswered Questions for Immune-Mediated CNS Repair 
 Understanding the molecular mechanism of immune-mediated neurorepair is vital to 
understanding whether the pro-regenerative and neurotoxic aspects of neuroinflammation can be 
dissociated and, furthermore, manipulated therapeutically to promote functional recovery with 
minimal side effects.  Since zymosan promotes robust CNS regeneration with simultaneous 
neurotoxicity, it is well suited as a tool for studying the mechanisms underlying immune-
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mediated neurorepair.  Zymosan is a yeast cell wall extract composed of carbohydrates, proteins, 
and lipids (Di Carlo and Fiore, 1958).  Zymosan contains highly conserved molecular structures 
that are associated with fungal pathogens not found in mammalian cells, and generates an 
experimental, sterile inflammation.  PAMPs in zymosan engage several different PRRs, 
including toll-like receptor (TLR)2, complement receptor 3 (CR3), and the C-type lectin family 
members CLEC7A (dectin-1) and CLEC6A (dectin-2) (Frasnelli et al., 2005, Tsoni and Brown, 
2008).  Several different PAMP/PRR interactions have been implicated in zymosan-mediated 
immune activation.  It will be important to identify which PPRs and signaling pathways are 
activated by zymosan to elicit axon regeneration following nervous system injury, and to 
determine whether these same biochemical pathways do or do not lead to concurrent 
neurotoxicity in the CNS. 
Intraocular injection of zymosan causes a large and diverse population of immune cells to 
infiltrate the eye.  The identification of the immune cells responsible for neural repair is 
complicated by the dynamic heterogeneity of the myeloid cell population. Evidence suggests 
involvement of blood-derived immune cells e.g. macrophages (Yin et al., 2003, Kigerl et al., 
2009, Hawthorne and Popovich, 2011) and neutrophils (Kurimoto et al., 2013).  In addition, 
retina-resident cells (Muller et al., 2007) have been shown to participate in inflammation-
mediated neurorepair.  At present, the use of cell surface typing to identify functionally distinct 
myeloid subsets in situ is at an early stage of development, and there has been no consensus in 
the field on how to classify myeloid cells in vivo  (Leon et al., 2000, Lawrence and Natoli, 2011).  
In vitro, macrophages can be polarized to assume different functional roles.  Subtypes of 
polarized macrophages include classically-activated macrophages (M1), which release pro-
inflammatory cytokines and have neurotoxic properties (Gordon, 2003), and alternatively-
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activated macrophages (M2a, M2b, and M2c), that are associated with wound healing, tissue 
repair, and suppression of destructive immunity (Novak and Koh, 2013). Growing evidence 
suggests that, similar to macrophages, microglia can be differently activated and may exist in a 
dynamic continuum (Town et al., 2005, Zhou et al., 2012).  It is currently unknown if analogous 
subtypes of myeloid cells exist in vivo and participate in inflammatory responses that elicit 
neurorepair pathways. 
How activation of the innate immune system enables growth of injured RGC axons 
remains a mystery.  PAMPs and DAMPs may engage PRRs expressed on retina-resident and 
blood-derived immune cells, activating them to produce pro-regenerative cytokines and growth 
factors, or to recruit a specific subtype of inflammatory cells with growth promoting properties.   
Immune cells may interact directly with RGCs and promote growth through a contact-mediated 
mechanism, or they may secret pro-regenerative cytokines and other growth factors which bind 
to receptors on RGCs to activate growth programs.  Alternatively, neurons themselves may 
express PRRs that engage PAMPs and DAMPs, and thus, regenerate through a cell-autonomous 
mechanism, with inflammation playing a secondary role.  Several growth factors and signaling 
pathways have been implicated in CNS axon regeneration (Muller et al., 2009, Belin et al., 2015, 
Duan et al., 2015).  Whether any of these molecules are involved in immune-mediated 
neurorepair remains to be explored.  Chapter three of this dissertation provides novel insights 
into the mechanisms of immune-mediated CNS repair. 
 
1.5 Concluding Remarks 
Many barriers oppose the regenerative growth and repair of injured CNS axons.  MAIs 
and CSPGs potently inhibit neurite outgrowth in vitro through multiple overlapping receptor 
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mechanisms.  Based on studies with single and compound mutant mice, the contribution of these 
ligands and their receptors towards inhibiting regenerative growth in vivo has been 
underwhelming (Lee et al., 2010).  However, the high degree of functional redundancy among 
growth inhibitory mechanisms could lead to genetic compensation in germline knockout mice, 
making it difficult to assess the contribution of individual ligands and receptors towards growth 
inhibition.  For the development of therapeutic strategies, it will be necessary to determine 
whether acute manipulation of these molecules can be accomplished after injury without major 
adverse consequences.  Since many CNS regeneration inhibitors play important physiological 
roles in the development, refinement, and maintenance of synaptic connections in the healthy 
brain (Mironova and Giger, 2013), manipulating these molecules to promote neurorepair could 
affect the integrity and function of intact neural networks.  
Manipulation of the innate immune system is an attractive strategy to promote 
neurorepair in the injured CNS.  Injection of zymosan into the eye following injury to the mouse 
optic nerve elicits a robust regenerative response, much greater than what is achieved by deletion 
of inhibitory ligands or their receptors.  Importantly, zymosan has a large therapeutic window, as 
enhanced regeneration is observed when zymosan is injected up to three days after injury (Yin et 
al., 2003). Since zymosan promotes regeneration with concurrent toxicity, further studies are 
necessary to determine whether the beneficial and detrimental aspects of neuroinflammation can 
be uncoupled at the molecular level.  My thesis provides novel insights into the molecular and 
cellular mechanisms that govern immune-mediated neuroprepair.  The work described in the 
following chapters provides a strong platform for future studies aimed at understanding the cross 
talk between the immune system and the nervous system, and how this may be exploited to 
promote repair following injury or disease.  
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CHAPTER II: 
 
Contribution of CNS Regeneration Inhibitors to Growth Inhibition in vivo 
 
2.1 Abstract 
 In the adult mammalian central nervous system (CNS), chondroitin sulfate proteoglycans 
(CSPGs) and myelin-associated inhibitors (MAIs) stabilize neuronal structure and restrict 
compensatory sprouting following injury.  The Nogo receptor family members NgR1 and NgR2 
bind to MAIs and have been implicated in neuronal inhibition.  Recent work from our laboratory 
revealed that NgR1 and NgR3 bind with high affinity to the sugar moiety of CSPGs and 
participate in CSPG inhibition in cultured neurons.  Here we show that Nogo receptor triple 
mutants (NgR123-/-), but not single mutants, display enhanced axonal regeneration following 
retro-orbital optic nerve crush injury.  The combined loss of NgR1 and NgR3 (NgR13-/-), but not 
NgR1 and NgR2 (NgR12-/-), is sufficient to mimic the NgR123-/- regeneration phenotype.  
Regeneration in NgR13-/- mice is further enhanced by simultaneous ablation of RPTPσ, a known 
CSPG receptor.  In growth-enabled RGCs, loss of multiple CSPG receptors greatly enhances 
regenerative growth.  Collectively, these results identify NgR1 and NgR3 as functional receptors 
mediating CSPG inhibition in vivo, and demonstrate functional redundancy among CSPG and 
MAI receptors. 
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2.2 Introduction 
 In the adult mammalian CNS, structural neuronal plasticity is restricted by a number of 
extrinsic (environmental) and cell-intrinsic growth-inhibitory mechanisms (Liu et al., 2006; Park 
et al., 2008).  While such mechanisms are believed to be important for stabilization of intricate 
networks of neuronal connectivity in CNS health, they also limit adaptive neuronal growth and 
sprouting following brain or spinal cord injury (SCI).  Spontaneous repair following severe CNS 
injury is incomplete and commonly associated with permanent neurological deficits.  Thus, a 
detailed understanding of the mechanisms that block neuronal growth and repair is of great 
interest, both biologically and clinically.  
 A large number of CNS inhibitory cues have been identified (Silver and Miller, 2004, Liu 
et al., 2006, Winzeler et al., 2011). In experimental animal models of SCI, acute blockage of 
MAIs (Bregman et al., 1995, Li et al., 2004) or enzymatic degradation of CSPGs with 
chondroitinase ABC (Ch’aseABC) (Bradbury et al., 2002, Massey et al., 2006, Garcia-Alias and 
Fawcett, 2012) promotes neuronal sprouting and correlates with improved behavioral outcomes.  
The best characterized MAIs are the reticulon family member Nogo, myelin-associated 
glycoprotein (MAG), and oligodendrocyte myelin glycoprotein (OMgp) (Liu et al., 2006). Three 
isoforms of Nogo have been identified, all of which contain a 66 amino acid loop (Nogo66) that 
signals neuronal inhibition.  Mechanistic studies identified the Nogo66 receptor-1 (NgR1) and 
paired immunoglobulin (Ig)-like receptor B (PirB) as functional receptors for MAIs (Fournier et 
al., 2001, Atwal et al., 2008).  NgR1 and its close relative NgR2 show overlapping, yet distinct 
binding preferences toward MAIs.  Nogo66 and OMgp bind selectively to NgR1 (Liu et al., 
2006), while MAG associates with NgR1 and NgR2 (Venkatesh et al., 2005).  NgR3 does not 
interact with Nogo, MAG, or OMgp.   In vitro, loss of NgR1 renders neurons more resistant to 
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Nogo66-, MAG-, and OMgp-induced growth cone collapse, but not to longitudinal neurite 
outgrowth inhibition on substrate-bound inhibitors (Kim et al., 2004, Zheng et al., 2005, 
Chivatakarn et al., 2007).  MAIs activate RhoA, RockII, and conventional isoforms of protein 
kinase C (PKC) to destabilize the neuronal cytoskeleton (Schweigreiter et al., 2004, 
Sivasankaran et al., 2004).  Similar to NgR1, PirB supports binding of Nogo66, MAG, and 
OMgp.  In culture, functional ablation of PirB promotes neurite outgrowth on substrate-bound 
MAIs and crude CNS myelin.  Interestingly, the combined perturbation of PirB and NgR1 
signaling leads to a further release of neurite outgrowth inhibition on crude CNS myelin, but not 
on recombinant Nogo66 or MAG (Atwal et al., 2008). 
 CSPGs are a diverse class of extracellular matrix molecules that influence axonal growth 
and guidance of developing neurons (Kantor et al., 2004).  Following injury to the adult CNS, 
CSPG expression is upregulated and abundant in reactive astrocytes associated with glial scar 
tissue (Silver and Miller, 2004).  CSPGs are comprised of a protein core with covalently attached 
glycosaminoglycan (GAG) side chains.  CSPG inhibition is largely abrogated by bacterial 
Ch’aseABC, indicating that CS-GAGs are important for neuronal growth inhibition (Bradbury et 
al., 2002, Pizzorusso et al., 2002, Garcia-Alias and Fawcett, 2012). Similar to MAIs, CSPG-
mediated inhibition depends on activation of RhoA and conventional PKCs (Powell et al., 2001, 
Schweigreiter et al., 2004, Sivasankaran et al., 2004).  Mechanistic studies recently identified the 
receptor protein tyrosine phosphatase sigma (RPTPσ) as a high-affinity receptor for CSPGs 
(Shen et al., 2009).  RPTPσ is a member of the leukocyte common antigen-related protein (LAR) 
family that also includes LAR and RPTPδ.  RPTPσ binds to CS-GAG chains and the structurally 
related heparan sulfate (HS)-GAG chains via its first Ig-like domain (Aricescu et al., 2002, Shen 
et al., 2009).  The association of RPTPσ with CS- and HS-GAGs critically depends on the 
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presence of an evolutionarily conserved cluster of basic amino acid residues.  Functional ablation 
of RPTPσ enhances neurite outgrowth in the presence of CSPGs in vitro, and, following CNS 
injury, promotes growth of sensory afferents (Shen et al., 2009), corticospinal tract axons (Fry et 
al., 2010), and retinal ganglion cell axons (Sapieha et al., 2005).  The incomplete release of 
CSPG inhibition in RPTPσ-deficient neurons suggests the existence of additional mechanisms of 
CSPG inhibition.   
 Recent work from our laboratory revealed that NgR1 and NgR3 are receptors for CSPGs 
(Dickendesher et al., 2012).  NgR1 and NgR3 bind directly and with high affinity to select types 
of CS-GAGs and operate as functionally redundant CSPG receptors.  Loss of individual NgR 
family members is not sufficient to overcome CSPG inhibition in vitro; however, the combined 
loss of NgR1 and NgR3 leads to a significant release of CSPG inhibition.  Here I describe the in 
vivo studies performed in mutant mice lacking various CSPG receptors individually or in 
combination.  
 
2.3 Results 
Regeneration is enhanced in NgR123-/- and NgR13-/- mice 
 In the adult mouse retina, NgR1, NgR2, and NgR3 are all strongly expressed in RGCs 
(Figure 2.1a).  Retinal stratification (Figure 2.1b) and optic nerve myelination (Figure 2.1c) in 
NgR123-/- mice appear normal.  To assess RGC axon targeting to the superior colliculus, the 
suprachiasmatic nucleus, and the lateral geniculate nucleus, the right eye of adult WT and 
NgR123-/- mice was injected with Alexa 594-conjugated Cholera Toxin β (CTB-red) tracer, and 
the left eye with Alexa 488-conjugated Cholera Toxin β (CTB-green) tracer.  No defects in RGC 
axon central projections or target innervation were observed (Figure 2.1d-f).  Thus, germline 
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ablation of all three NgRs does not appear to compromise retinal stratification, optic nerve 
myelination, or RGC axonal pathfinding.   
 To assess whether NgRs contribute to the regenerative failure of injured CNS axons, we 
performed retro-orbital optic nerve crush injury in Nogo receptor single and compound mutant 
mice.  Compared to injured wild-type controls, NgR123-/- mice show a modest but significant 
(P< 0.001, one-way ANOVA, Tukey’s post hoc) increase in RGC axon regeneration (Figure 
2.2).  At two weeks post-injury, more GAP-43-positive fibers are observed at 0.2-1.0mm distal 
to the injury site in NgR123-/- mice compared to WT mice.  Because NgR1 and NgR2 are known 
to associate with MAIs, the NgR123-/- regeneration phenotype may be a reflection of (i) 
decreased Nogo, MAG and OMgp inhibition, (ii) decreased CSPG inhibition, or (iii) a 
combination thereof.  To address this issue, we directly compared regeneration of NgR1-/-,  
NgR2-/-, and NgR3-/- single mutants, as well as NgR12-/- and NgR13-/- double mutants, to  
NgR123-/- triple mutants.  Loss of NgR1, NgR2, or NgR3 alone, or the combined loss of NgR1 
and NgR2 (NgR12-/-), does not result in substantially enhanced RGC axon regeneration 
compared to WT mice (Figures 2.2, 2.3; Table 2.1).  However, NgR13-/- mice show a similar 
degree of axon regeneration as NgR123-/- mice.  This suggests a novel role for NgR3 in signaling 
neuronal growth inhibition.  When coupled with our neurite outgrowth studies in vitro, showing 
that NgR1 and NgR3 operate as functionally redundant CSPG receptors, this suggests that the 
optic nerve regeneration in NgR13-/- and NgR123-/- mice is at least in part a reflection of 
decreased CSPG inhibition.   
 As RPTPσ is expressed in adult RGCs (Sapieha et al., 2005), we examined whether the 
combined loss of NgR1 and NgR3 on an RPTPσ-/- background (NgR13/RPTPσ-/-) results in a 
further increase of regenerating axons.  Few regenerating axons were observed in RPTPσ-/- single 
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mutants, with no significant difference compared to WT controls (P> 0.05).  Compared to 
NgR13-/- double mutants, NgR13/RPTPσ-/- triple mutants show a further increase in the number 
of regenerating axons (P< 0.001, one-way ANOVA, Tukey’s post hoc), suggesting a genetic 
interaction among these receptors (Figures 2.2, 2.3; Table 2.1).   
 
In growth-enabled RGCs, loss of all NgRs greatly enhances optic nerve axon regeneration   
 An advantage of optic nerve regeneration studies is that the growth potential of RGCs can 
be sensitized by intraocular (i.o.) injection of the yeast cell wall extract zymosan, resulting in the 
release of RGC survival and growth-promoting factors, including oncomodulin (Yin et al., 
2009), ciliary neurotrophic factor (CNTF), and leukemia inhibitory factor (LIF) (Leibinger et al., 
2009).  WT mice that receive i.o. zymosan show greatly enhanced regeneration of RGC axons, 
exceeding the regeneration observed in non-zymosan-treated NgR123-/- and NgR13/RPTPσ-/- 
mice (Figure 2.2).  Importantly, NgR123-/- mice that receive i.o. zymosan show significantly 
more (P< 0.05, one-way ANOVA, Tukey’s post hoc) regenerating axons than WT, NgR1-/-, 
NgR2-/-, NgR3-/-, or RPTPσ-/- single mutants, as well as NgR12-/- double mutants, subjected to i.o. 
zymosan.  NgR13-/- and NgR123-/- mice with i.o. zymosan show a similar regeneration 
phenotype.  At several distances from the injury site, NgR13/RPTPσ-/- triple mutants with i.o. 
zymosan show a further increase in the number of regenerating axons compared to NgR123-/- 
mice with i.o. zymosan (P< 0.05, one-way ANOVA, Tukey’s post hoc) (Figures 2.2, 2.3; Table 
2.1). 
 In mice, optic nerve injury leads to the death of ~ 70% of RGCs by two weeks post-injury 
(Figure 2.4).  The enhanced regeneration observed in NgR123-/- mice is not a result of increased 
RGC survival, as similar numbers of injury-induced RGC death were observed in WT and 
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NgR123-/- triple mutants.  Intraocular zymosan administration partially protects RGCs from 
axotomy-induced cell death; however, the protective effect of zymosan is similar in WT and 
NgR123-/- mice (Figure 2.4).  Consistent with the view that a decrease in RGC death is not 
sufficient to promote axonal regeneration, p53-deficient RGCs are more resistant to injury-
induced cell death but fail to show enhanced regeneration (Park et al., 2008).  
 
Combined Loss of MAI receptors does not enhance regenerative growth, even in growth-
enabled RGCs 
 As discussed above, CNS regeneration inhibitors elicit growth inhibition through several 
overlapping receptor mechanisms.  While the combined loss of NgR1 and NgR2 does not lead to 
enhanced regeneration (Figure 2.3), the contribution of additional MAI receptors to growth 
inhibition in vivo is not known.  PirB is a functional receptor for Nogo, MAG, and OMgp (Atwal 
et al., 2008).  To determine whether PirB contributes to inhibition of regeneration in vivo, we 
performed optic nerve crush on PirB-/- mice (Figure 2.5).  Loss of PirB alone did not enhance 
regeneration.  Furthermore, the combined loss of NgR1, NgR2, and PirB (NgR12/PirB-/-) did not 
improve regenerative growth, even with intraocular administration of zymosan (Figure 2.5).  
Another recently identified receptor for MAG is LDL receptor-related protein 1 (LRP1) (Stiles et 
al., 2013).  Germline knockout of LRP1 is embryonic lethal, therefore to assess the contribution 
of LRP1 to growth inhibition in vivo, we depleted LRP1 from the retinas of LRP1f/f mice by 
injecting AAV2-GFP-Cre two weeks before optic nerve crush injury.  Loss of LRP1 did not 
significantly enhance optic nerve regeneration (Figure 2.5). 
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2.4 Discussion  
One of the main findings of this work is that NgR1 and NgR3 contribute to inhibition of 
regenerative growth in vivo.  However, the relatively modest regenerative growth that results 
from loss of multiple CSPG receptors (NgR1, NgR3, and RPTPs) is unlikely to have functionally 
significant outcomes.  Furthermore, loss of multiple MAI receptors (NgR1, NgR2, PirB) does 
not enhance regeneration in vivo.  Collectively, these results show that, by itself, genetic deletion 
of multiple inhibitory mechanisms is insufficient to surmount the limited regenerative capacity of 
the CNS, and may not be a viable therapeutic option.  However, the greatly enhanced 
regeneration that occurs by combining intraocular zymosan injection with loss of CSPG 
receptors suggests that manipulating extrinsic and intrinsic inhibitory mechanism concurrently 
may be an effective strategy for neurorepair. 
 
Additive effects of manipulating extrinsic and intrinsic pathways   
The mild regenerative growth observed in NgR123-/- and NgR13/RPTPσ-/- mice at two 
weeks post-injury, could be explained by compensatory mechanisms that arise in germline 
knockout mice.  Perhaps acute blockade of multiple inhibitory mechanisms will have a more 
robust affect.  Alternatively, the contribution of the inhibitory CNS environment to growth 
inhibition may be relatively minor.  Our results are consistent with previous studies showing that 
expression of a dominant negative form of NgR1 in RGCs (Fischer et al., 2004a) or blocking of 
RhoA with C3 transferase (Fischer et al., 2004c) is not sufficient to promote substantial 
regeneration of severed optic nerve axons.  Similarly, removal of one or several MAIs results in 
inconsistent and often poor regeneration in spinal cord-injured mice (Cafferty et al., 2010, Lee et 
al., 2010).  Collectively, mouse genetic studies indicate that germline ablation of multiple 
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growth-inhibitory ligands or receptors is not sufficient to promote robust and long-distance 
regeneration in different fiber tracts of the injured adult CNS.   
 However, combining genetic manipulations with activation of RGC intrinsic growth 
programs revealed a significant impact of environmental inhibitory signals on limiting axon 
regeneration.  On an NgR13-/-, NgR123-/-, or NgR13/RPTPσ-/- background, i.o. zymosan injection 
results in significantly enhanced axonal growth distal to the injury site compared to WT, NgR12-
/-, RPTPσ-/-, or NgR12/PirB-/- mutant mice with i.o. zymosan.  While the additive effects of 
simultaneous release of growth-inhibitory mechanisms and activation of intrinsic growth 
programs have been reported (Fischer et al., 2004a, Kadoya et al., 2009) our data show that in 
growth-enabled RGCs, members of the NgR family and LAR family collaborate to negatively 
impact the number and length of regenerating axons following CNS injury. 
   
Implications for experience-dependent neural plasticity 
 While it has been known for some time that MAIs and CSPGs share similar downstream 
signaling pathways (Schweigreiter et al., 2004, Sivasankaran et al., 2004),  the level at which 
MAI and CSPG signaling cascades converge to regulate neuronal cytoskeletal dynamics has not 
yet been determined.  Here we identify NgR1 and NgR3 as novel and functionally redundant 
CSPG receptors.  We provide evidence that Nogo, MAG, OMgp, and CSPGs share receptor 
components and perhaps signal through related receptor complexes to block neuronal plasticity, 
sprouting, and axonal regeneration.  In support of this idea, the myelin inhibitor Nogo-A shares 
structural and sequential similarities with neurocan, an inhibitory CSPG implicated in blocking 
neuronal regeneration (Shypitsyna et al., 2011), suggesting a common origin for two seemingly 
unrelated  inhibitors of growth.  The newly discovered connection between CSPGs and NgRs is 
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not only relevant for neuronal repair, but may also provide a mechanistic explanation for why 
two seemingly unrelated manipulations, such as Ch’aseABC infusion into the mature visual 
cortex and germline ablation of NgR1 or Nogo, result in enhanced ocular dominance plasticity 
following monocular deprivation (Pizzorusso et al., 2002, McGee et al., 2005).  Mounting 
evidence suggests that mechanisms that limit neuronal growth and plasticity following CNS 
injury and disease resemble those that negatively regulate neuronal growth and synaptic structure 
under physiological conditions (Lee et al., 2008, Zagrebelsky et al., 2010).   
 The identification of NgRs as shared receptors for MAIs and CSPGs provides new 
insights into how a diverse group of inhibitory cues regulates neuronal structure and function 
under physiological conditions and following injury.  We propose that Nogo receptors are part of 
a multicomponent receptor system that serves as a signaling platform to initiate pathways that 
limit neuronal growth and increase structural stability of synapses.  When combined with recent 
findings that NgR1and its ligands Nogo and OMgp influence synaptic transmission (Raiker 
(Raiker et al., 2010), experience-dependent network refinement (McGee et al., 2005), and spatial 
memory (Karlen et al., 2009), the present findings expand the function of these molecules 
beyond neural repair, and shed light on a vital part of the neuronal machinery that limits growth 
and plasticity in CNS health and disease 
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2.5 Methods 
Transgenic mice: All animal handling and surgical procedures were performed in compliance 
with local and national animal care guidelines and approved by the University of Michigan 
Committee on Use and Care of Animals (UCUCA).   RPTPσ-/-, NgR1-/-, NgR2-/- PirB-/-, and 
LRP1f/f mice have been described (Zheng et al., 2005, Syken et al., 2006, Li et al., 2010).  NgR3-/- 
germline mutants were generated by Lexicon Genetics and kindly provided by M. Greenberg 
(Harvard Medical School).  NgR1 and NgR2 conditional mutants have been described elsewhere 
(Williams et al., 2008).  NgR3 conditional knockout mice were generated by flanking exon2 with 
loxP sites.  To generate germline deletion mutants, conditional knockouts were crossed with 
protamine-cre transgenic mice and then intercrossed with each other, or onto an RPTPσ-/- 
background, to generate double and triple mutants. 
Optic nerve surgery: Adult mice (6-8 weeks of age) of either sex were anesthetized with an 
intraperitoneal injection of Ketamine (100mg/kg; Fort Dodge Animal Health) and Xylazine 
(10mg/kg; Akorn, Inc.).  The optic nerve was exposed through an incision in the conjunctiva and 
compressed for 10 seconds with angle jeweler’s forceps (Dumont #5; Fine Science Tools) at 
approximately 1mm behind the eyeball.  Care was taken not to damage or rupture the ophthalmic 
artery.  For intraocular injection of Zymosan, 5µl of a suspension (12.5µg/µl in sterile PBS; 
Sigma) was injected manually using a Hamilton syringe with a 30 gauge removable needle.  
Following optic nerve surgery, the operated eye was rinsed with sterile PBS and ophthalmic 
ointment was applied (Butler AHS).  All surgeries were performed under aseptic conditions.  
Fourteen days after optic nerve injury, mice were given a lethal dose of anesthesia and perfused 
through the heart with PBS followed by ice-cold 4% paraformaldehyde (with the exception of 
mice used for electrophysiology studies).  For deletion of LRP1 in LRP1f/f mouse RGCs, 2µl of 
AAV2-GFP (Vector Biolabs) was injected into the left eye and 2µl of AAV2-GFP-Cre (Vector 
Biolabs) was injected into the right eye, 14 days prior to optic nerve injury.   
Immunohistochemistry: For immunohistochemical procedures, cryosections of adult retina 
were stained with anti-calbindin (Swant; 1:2500 dilution) or anti-calretinin (Swant; 1:2500 
dilution), and then counterstained with Hoechst 33342 (1:30000 dilution).  For retinal whole-
mount immunostaining, eyes were post-fixed in 4% paraformaldehyde overnight at 4°C, and 
retinal “cups” were dissected out and fixed in 4% paraformaldehyde for 30 minutes at 4°C.  
Retinas were washed with PBS, blocked in 10% goat serum and 0.2% Triton X-100 for 1 hour, 
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incubated with primary antibodies (anti-GFP, Invitrogen; anti-phospho-S6, Cell Signaling) for 1-
2 days at 4°C, and washed with PBS.  Following incubation with the appropriate Alexa Fluor-
conjugated secondary antibodies (Invitrogen) overnight at 4°C and another round of washing 
with PBS, retinas were mounted onto slides for imaging.  To assess axon density and 
myelination, optic nerves were embedded in epon and stained with Toluidine Blue.  To assess 
retinal ganglion cell death at various time points following optic nerve injury, retinal sections 
were stained with anti-class III β-tubulin (TuJ1), and in some instances, with anti-active caspase-
3 (Promega).  For intraocular injections of anterograde tracer, 6-week-old mice received bilateral 
injections (2ml) of 1mg/ml Alexa 488- and Alexa 594-conjugated Cholera Toxin β (Invitrogen) 
in the left and right eye, respectively.  Five days post-injection, mice were perfused 
transcardially, and their brains were dissected, post-fixed in 4% paraformaldehyde overnight, and 
cryoprotected in 30% sucrose overnight.  Brain tissue was embedded in OCT Tissue-Tek 
Medium (Sakura Finetek) and coronal sections (50µm thickness) were imaged.To visualize 
regenerating axons in the injured optic nerve, eyes with optic nerves attached were dissected, 
post-fixed, and cryoprotected.  Optic nerves were embedded and longitudinal sections (14µm 
thickness) were stained with anti-GAP-43 and/or anti-GFP.  The appropriate Alexa Fluor-
conjugated secondary antibodies (Invitrogen) were then used for fluorescent labeling.  Images 
were acquired using an inverted microscope (IX71; Olympus) attached to a digital camera 
(DP72; Olympus). 
Quantification and Statistical Analysis: To assess regenerative axonal growth, the number of 
GAP-43-positive axons at prespecified distances from the injury site was counted in at least three 
sections per nerve.  These numbers were converted into the number of regenerating axons per 
nerve at various distances as described previously (Fischer et al., 2004a).  All data were analyzed 
using one-way analysis of variance followed by Tukey’s post hoc comparisons.  All statistics 
were performed using GraphPad Prism 5.00 (GraphPad Software).  Our finding that loss of all 
three NgRs elicits significant retinal ganglion cell regeneration is based on two independently 
generated data sets produced by two independent surgeons (K.T.B. and Y. Koriyama).  Both data 
sets were analyzed separately and lead to the same conclusions (Table 2.1).  In addition, no 
significant differences (P> 0.05) in axon regeneration following injury (with or without 
intraocular Zymosan injection) were observed between mice on three different genetic 
backgrounds (129, C57BL/6, BALB/c) (Figure 2.6).   
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Figure 2.1: Retinal stratification, optic nerve myelination, and RGC central projections 
appear normal in NgR123-/- mice 
(a) Sections of adult WT and Nogo receptor triple mutant (NgR123-/-) mouse retina were 
subjected to in situ hybridization with digoxigenin-labeled cRNA probes specific for NgR1, 
NgR2, and NgR3 transcripts. All three receptors are strongly expressed in the ganglion cell layer 
(arrow) and the inner nuclear layer, but are absent from the outer nuclear layer of the retina. No 
signal was detected on parallel-processed sections of NgR123-/- retina. (b) Hoechst 33342 nuclear 
staining, as well as anti-calbindin and anti-calretinin immunolabeling, of adult WT and NgR123-/- 
retina did not reveal any noticeable differences in retinal organization among the two genotypes. 
(c) Toluidine Blue labeling of epon-embedded adult WT and NgR123-/- optic nerve cross sections 
reveals a comparable number of axons and degree of myelinated fibers. (d-f) The fidelity of 
RGC central projections in six-week-old WT and NgR123-/- mice was assessed by anterograde 
fiber tracing.  Five days after injection of Alexa 594-conjugated Cholera Toxin β into the right 
eye and Alexa 488-conjugated Cholera Toxin β into the left eye, mice were sacrificed, perfused, 
and brain sections analyzed by fluorescence microscopy. Right eye (red) and left eye (green) 
RGC projections to the (d) superior colliculus, (e) suprachiasmatic nucleus and (f) lateral 
geniculate nucleus in NgR123-/- mice are indistinguishable from age-matched WT controls. Scale 
bar: a, b, 80µm; c, 5µm; d, 100µm; e, f, 60µm. 
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Figure 2.2: NgR123-/- and NgR13/RPTPσ-/- compound mutants show enhanced fiber 
regeneration following crush injury to the optic nerve 
Two weeks following injury, regenerating axons in optic nerve sections were visualized by anti-
GAP-43 immunolabeling. The injury site is marked with an asterisk. (a) WT mice show very 
limited regenerative axonal growth following injury. (b) In NgR123-/- mice, many GAP-43-
positive fibers grow beyond the lesion site. (c) In NgR13/RPTPσ-/- (NgR13/σ-/-) mice, a further 
increase of GAP-43-positive fiber growth is observed. (g) Quantification of the number of GAP-
43-positive axons at 0.2 to 1.2mm distal to the lesion site. Light gray bars (WT, n=6); black bars 
(NgR1-/-, n=7); purple bars (RPTPσ-/-, n=5); dark gray bars (NgR123-/-, n=8); blue bars (NgR13/σ-
/-, n=4). (d) Intraocular injection of Zymosan enhances regenerative axonal growth in WT mice. 
A further increase is observed in (e) NgR123-/- mice, which is further enhanced in (f) NgR13/σ-/-, 
mice. (h) Quantification of the number of GAP-43-positive axons at 0.2 to 1.6mm distal to the 
lesion site in Zymosan-injected mice. Light gray bars (WT + Zymosan, n=6); black bars (NgR1-/- 
+ Zymosan, n=6); purple bars (RPTPσ-/- + Zymosan, n=4); dark gray bars (NgR123-/- + Zymosan, 
n=8); blue bars (NgR13/σ-/- + Zymosan, n=3). Results are presented as mean ±SEMs. ** P< 0.05 
(one-way ANOVA, Tukey’s post hoc). Scale bar, 200µm. 
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Figure 2.3: In adult mice, the combined loss of NgR1 and NgR3, but not NgR1 and NgR2, is 
sufficient to significantly enhance axon regeneration following retro-orbital optic nerve 
crush injury 
(a-i) 2 weeks following optic nerve injury, regenerative axonal growth was assessed by anti-
GAP-43 immunolabeling of longitudinal optic nerve sections. (a’-i’) To assess whether RGCs in 
a growth-activated state show an additive growth effect when combined with genetic ablation of 
Nogo receptors, a separate group of animals received an intraocular injection (i.o.) of Zymosan 
at the time of optic nerve injury. Anti-GAP-43 immunolabeling of injured optic nerve from (a) 
WT, (b) NgR1-/-, (c) NgR2-/-, (d) NgR3-/-, (e) RPTPσ-/-, and (f) NgR12-/- mice fails to identify 
significant regenerative growth of axons beyond the lesion site (asterisk). (g) NgR13-/- and (h) 
NgR123-/- mice show increased and comparable axonal regeneration, which is further enhanced 
in (i) NgR13/RPTPσ-/- (NgR13/σ-/-) triple mutant mice. Following i.o. Zymosan injection, (b’) 
NgR1-/-, (c’) NgR2-/-, (d’) NgR3-/-, (e’) RPTPσ-/-, and (f’) NgR12-/- mice do not show enhanced 
regeneration compared to (a’) WT mice with i.o. Zymosan. An additive effect of i.o. Zymosan 
with genetic manipulation was observed for (g’) NgR13-/- and (h’) NgR123-/- mice. (i’) Loss of 
NgR1, NgR3 and RPTPσ (NgR13/σ-/-) combined with i.o. Zymosan resulted in a further increase 
of fiber growth. Scale bar, 200µm.  
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Figure 2.4: Optic nerve injury-induced retinal ganglion cell death is similar in WT and 
NgR123-/- triple mutants 
(a) To assess cell loss in the RGC layer 14 days after nerve crush injury, coronal sections of WT 
and NgR123-/- retina were immunolabeled with TuJ1 and compared to uninjured retina.  
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Intraocular injection of Zymosan increased the density of TuJ1-labeled cells in the RGC layer; 
however, this effect was independent of the Nogo receptor genotype. (b) Quantification of the 
density of TuJ1+ cells in the RGC layer per field of view as a percentage of the uninjured WT 
control. Cell counts were performed on at least 15 sections per condition (n=3 independent 
experiments). Gray bars (WT); black bars (NgR123-/-). Results are presented as mean ±SEMs 
(one-way ANOVA, Tukey’s post hoc), n.s.=not significant. (c) Time course of RGC death 
following optic nerve injury. Shown is the quantification of the density of TuJ1+ cells in the 
RGC layer per field of view (at 0, 3, 5, 7, 9, 14, and 19 days following injury) as a percentage of 
the uninjured retina. The majority of cell death occurs by 7 days post-optic nerve injury. Cell 
counts were performed on at least 10 sections per condition. Results are presented as mean 
±SEMs. (d-e) Time course of caspase-3 activation following optic nerve injury. The number of 
RGCs labeled for activated caspase-3 is shown as a percentage of the total number of cells 
(TUJ1-positive) per field of view at each time point (0, 3, 5, 7, 9, 14, and 19 days following 
injury). The peak of activated caspase-3 labeling is seen between 3 and 5 days post-injury. Cell 
counts were performed on at least 10 sections per condition. Results are presented as mean 
±SEMs. Scale bar: a, 30µm; d, 60µm. 
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Figure 2.5: Loss of multiple MAI receptors is not sufficient to enhance axon regeneration 
following retro-orbital optic nerve crush injury 
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(a) 2 weeks following optic nerve injury, regenerative axonal growth was assessed by GAP-43 
immunolabeling of longitudinal optic nerve sections. GAP-43 immunolabeling of injured optic 
nerve from WT, PirB-/-, and NgR12/PirB-/- mice fails to identify regenerative growth of axons 
beyond the lesion site (asterisk). Similarly, LRP1f/f mice with intravitreal injections of AAV2-
GFP or AAV2-GFP-Cre show no substantial axon regeneration. (b) To test whether growth-
activated RGCs show an additive regenerative effect when combined with genetic ablation of 
MAG receptors, a separate group of animals received an intravitreal injection of Zymosan at the 
time of optic nerve injury. Following Zymosan injection, PirB-/-, NgR12/PirB-/- LRP1f/f; AAV2-
GFP, and LRP1f/f; AAV2-GFP-Cre mice do not show enhanced regeneration compared to WT 
mice with Zymosan. (c) Quantification of the number of GAP-43-positive axons at 0.2 to 0.8mm 
distal to the lesion site. Light gray bars (WT, n=5); black bars (PirB-/-, n=6); purple bars 
(NgR12/PirB-/-, n=5); dark gray bars (LRP1f/f; AAV2-GFP, n=6); blue bars (LRP1f/f; AAV2-
GFP-Cre, n=6). (d) Quantification of the number of GAP-43-positive axons at 0.2 to 1.2mm 
distal to the lesion site in Zymosan-injected mice. Light gray bars (WT, n=5); black bars (PirB-/-, 
n=5); purple bars (NgR12/PirB-/-, n=5); dark gray bars (LRP1f/f; AAV2-GFP, n=6); blue bars 
(LRP1f/f; AAV2-GFP-Cre, n=5). Results are presented as mean ±SEMs. Scale bar, 200µm. 
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Figure 2.6: The genetic background of wild-type mice does not significantly influence RGC 
axon regeneration 
(a) Quantification of the number of GAP-43-positive axons at 0.2 to 0.6mm distal to the lesion 
site in 129 (light gray bars, n=6), C57BL/6 (black bars, n= 6), and BALB/c (dark gray bars, n= 4) 
wild-type mice 2 weeks following optic nerve injury revealed no significant differences. (b) 
Quantification of the number of GAP-43-positive axons at 0.2 to 1.6mm distal to the lesion site 
following intraocular Zymosan injection in 129 (light gray bars, n=6), C57BL/6 (black bars, 
n=7), and BALB/c (dark gray bars, n=3) wild-type mice, 2 weeks following optic nerve injury. 
No significant differences at any distance were observed. Results are presented as mean ±SEMs 
(one-way ANOVA, Tukey’s post hoc). 
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Table 2.1: Summary of optic nerve regeneration studies.  (a) 2 weeks following injury, 
regeneration in NgR123-/-, NgR13-/-, and NgR13/RPTPσ-/- compound mutant mice is significantly 
increased compared to WT mice at 0.2 and 0.4mm distal to the injury site. Compared to WT 
mice, regeneration in NgR1-/-, NgR2-/-, NgR3-/-, NgR12-/-, or RPTPσ-/- at 0.2 and 0.4mm is not 
significantly enhanced. *** P< 0.001 (one-way ANOVA, Tukey’s post hoc), n.s.= not 
significant. (b) Following intraorbital Zymosan injection, regeneration in NgR123-/-, NgR13-/-, 
and NgR13/RPTPσ-/- compound mutant mice is significantly enhanced compared to WT mice at 
0.2 and 0.8mm distal to the injury site. There is no significant difference in axon regeneration 
between WT mice and NgR1-/-, NgR2-/-, NgR3-/-, NgR12-/-, or RPTPσ-/- mutant mice. *** P< 
0.001, ** P< 0.01 (one-way ANOVA, Tukey’s post hoc), n.s.= not significant. (c) 2 weeks 
following injury, regeneration in NgR123-/- mice is significantly increased compared to WT, 
NgR1-/-, NgR2-/-, NgR3-/-, NgR12-/-, and RPTPσ-/- mice, and decreased compared to 
NgR13/RPTPσ-/- mice, at 0.2 and 0.4mm distal to the injury site. There is no significant 
difference in the regeneration phenotype of NgR123-/- and NgR13-/- compound mutants. *** P< 
0.001, ** P< 0.01 (one-way ANOVA, Tukey’s post hoc), n.s.= not significant. (d) Following 
intraocular Zymosan injection, axon regeneration in NgR123-/- mice is significantly increased 
compared to WT, NgR1-/-, NgR2-/-, NgR3-/-, NgR12-/-, and RPTPσ-/- mice at 0.2 and 0.8mm distal 
to the injury site. There is no significant difference in axon regeneration between NgR123-/- and 
NgR13-/- or NgR13/RPTPσ-/- mutant mice (with intraocular Zymosan injection) at these distances. 
At distances 0.4, 0.6, 1.0, 1.2, and 1.4mm beyond the injury site, axon regeneration in 
NgR13/RPTPσ-/- mice is significantly greater than in NgR123-/- mice (with intraocular Zymosan 
injection). *** P< 0.001, ** P< 0.01, * P< 0.05 (one-way ANOVA, Tukey’s post hoc), n.s.= not 
significant. (e) For an unbiased assessment of the optic nerve regeneration phenotype in Nogo 
receptor single and compound mutants, two independent data sets were generated by two 
independent surgeons: K. Baldwin (University of Michigan) and Y. Koriyama (visiting scientist 
from Kanazawa University). Both surgeons were originally trained in the laboratory of L. 
Benowitz. A total of 84 mice (K.B. - 51 mice, Y.K. - 33 mice) were operated on, and each 
surgeon performed crush injury on the following genotypes: WT, NgR1-/-, and NgR123-/- mice. 
Only optic nerves from mice that showed no bleeding, infection, degeneration, or other 
complications of the operated eye were included for quantification of regenerating axons. The 
two data sets were then compared and analyzed for any significant differences between them, 
comparing the total number of GAP-43-positive axons for each genotype at two prespecified 
distances (0.4mm, 1.0mm) beyond the lesion site (unpaired t test). While there is some variation 
in the number of regenerating fibers, the principal findings of the two independently generated 
data sets are very comparable: WT mice (129 background or C57BL/6 background) show 
minimal regeneration of GAP-43-positive retinal ganglion cell axons. Regeneration in NgR1-/- 
mice is not enhanced compared to WT mice. Both data sets show a modest but significant 
increase in regenerating axons in NgR123-/- mice (P< 0.001, K.B; P< 0.05, Y.K.). WT mice that 
received Zymosan show greatly enhanced axon regeneration compared to WT mice that did not 
receive Zymosan. Notably, regeneration in Zymosan-treated WT mice is significantly enhanced 
compared to NgR123-/- mice without Zymosan (P< 0.001 for both data sets). Importantly, both 
data sets show significantly enhanced fiber growth at 0.2-1.4mm beyond the injury site in 
NgR123-/- mice with Zymosan compared to WT mice with Zymosan (P< 0.05 at 1.0, 1.2, and 
1.4mm; P< 0.01 at 0.8mm; P< 0.001 at 0.2, 0.4, and 0.6mm - K.B.; P< 0.05 at 0.4 and 0.6mm; 
P< 0.01 at 0.2, 1.2, and 1.4mm; P< 0.001 at 0.8 and 1.0mm - Y.K.).  
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CHAPTER III: 
 
Neuroinflammation triggered by β-glucan/dectin-1 signaling enables CNS  
 
axon regeneration 
 
 
 
3.1 Abstract 
Innate immunity can facilitate nervous system regeneration, yet the underlying cellular 
and molecular mechanisms are not well understood. Here we show that intraocular injection of 
lipopolysaccharide (LPS), a bacterial cell wall component, or the fungal cell wall extract 
zymosan both lead to rapid and comparable intravitreal accumulation of blood-derived myeloid 
cells. However, when combined with retro-orbital optic nerve crush injury, lengthy growth of 
severed retinal ganglion cell (RGC) axons occurs only in zymosan-injected mice, and not in 
LPS-injected mice. In mice deficient for the pattern recognition receptor dectin-1, but not Toll-
like receptor-2 (TLR2), zymosan-mediated RGC regeneration is greatly reduced. The combined 
loss of dectin-1 and TLR2 completely blocks the proregenerative effects of zymosan. In the ret- 
ina, dectin-1 is expressed by microglia and dendritic cells, but not by RGCs. Dectin-1 is also 
present on blood-derived myeloid cells that accumulate in the vitreous. Intraocular injection of 
the dectin-1 ligand curdlan [a particulate form of β(1,3)-glucan] promotes optic nerve 
regeneration comparable to zymosan in WT mice, but not in dectin-1−/− mice. Particulate β(1, 3)-
glucan leads to in- creased Erk1/2 MAP-kinase signaling and cAMP response element- binding 
protein (CREB) activation in myeloid cells in vivo. Loss of the dectin-1 downstream effector 
caspase recruitment domain 9 (CARD9) blocks CREB activation and attenuates the 
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axon-regenerative effects of β(1,3)-glucan. Studies with dectin-1−/−/WT reciprocal bone marrow 
chimeric mice revealed a requirement for dectin-1 in both retina-resident immune cells and bone 
marrow-derived cells for β(1,3)-glucan–elicited optic nerve regeneration. Collectively, these 
studies identify a molecular framework of how innate immunity enables repair of injured central 
nervous system neurons. 
 
3.2 Introduction 
Following injury to the adult mammalian central nervous system (CNS), severed axons 
fail to undergo spontaneous regeneration.  The limited and transient growth response of injured 
CNS neurons is, in part, responsible for poor clinical outcomes following brain or spinal cord 
trauma. Neuron intrinsic (Sun et al., 2011) and extrinsic mechanisms (Fawcett et al., 2012) pose 
barriers to efficient CNS repair.  However, there is accumulating evidence that, under certain 
circumstances, endogenous repair mechanisms can be unleashed by the induction of a local 
innate immune response (Yin et al., 2003, Gensel et al., 2012).  
Retro-orbital optic nerve crush (ONC) is widely used as a rodent model to investigate 
factors that influence axonal growth in the injured CNS (Leon et al., 2000).  Normally, retinal 
ganglion cells (RGC), the neurons that give rise to the optic nerve, do not extend lengthy axons 
beyond the injury site.  However, robust axonal growth occurs following induction of intraocular 
inflammation via lens trauma (Leon et al., 2000) or intra-ocular (i.o.) injection of zymosan (Yin 
et al., 2003, Leibinger et al., 2009), Pam3cys (Hauk et al., 2010), or oxidized galectin-1 (Okada 
et al., 2005).  This phenomenon is not restricted to the visual system, since injection of zymosan 
into dorsal root ganglia or spinal cord parenchyma triggers local inflammation and growth of 
injured or transplanted sensory neurons (Steinmetz et al., 2005, Gensel et al., 2009).  
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Macrophages (Yin et al., 2003, Gensel et al., 2009), neutrophils (Kurimoto et al., 2013) and 
astrocytes (Muller et al., 2007) have been implicated in the pro-regenerative effects of 
inflammation.  The benefits of neuroinflammation on axonal growth can be undermined by 
concurrent toxicity (Gensel et al., 2009).  A deeper understanding of these opposing effects will 
be important for exploiting immuno-modulatory pathways to promote neural repair while 
minimizing bystander damage.   
In the current paper we investigate the pathways that drive innate immune mediated axon 
regeneration following ONC.  We induced sterile inflammation in the vitreous on the day of 
injury by i.o. administration of zymosan or constituents of zymosan classified as pathogen 
associated molecular patterns (PAMPs).  PAMPs are highly conserved microbial structures that 
serve as ligands for pattern recognition receptors (PRRs).   PRRs for zymosan are widely 
expressed on innate immune cells and include toll-like receptors (TLR) 1 and 2, complement 
receptor 3 (CR3), and the C-type lectin family members CLEC7A (dectin-1) and CLEC6A 
(dectin-2) (Frasnelli et al., 2005, Tsoni and Brown, 2008).  Engagement of PRRs on myeloid 
cells, such as monocytes, macrophages, neutrophils, and myeloid dendritic cells (DCs), results in 
their activation and induces phagocytosis and oxidative burst, as well as cytokine and chemokine 
production.  The mechanism by which PRR signaling confers regenerative properties to myeloid 
cells is poorly understood.  Here we elucidate the PAMP-PRR interactions critical for zymosan-
mediated axonal regeneration, and thereby introduce a novel panel of signaling molecules that 
may be targeted to promote post-traumatic neurorepair. 
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3.3 Results 
Zymosan, but not LPS, enables immune-mediated axon regeneration   
Intra-ocular (i.o.) injection of the yeast cell wall extract zymosan into the posterior 
chamber of the mouse eye triggers a local inflammatory response.  Flow cytometric analysis of 
the cellular composition of vitreous infiltrates, at 7 days post- zymosan injection and ONC, 
revealed accumulation of large numbers of monocytes/macrophages (Yin et al., 2003), 
neutrophils (Kurimoto et al., 2013), and dendritic cells (DCs).  Small numbers of B-cells, CD4+ 
and CD8+ T-cells, and natural killer cells were also observed (Fig. 3.1a).  We found that i.o. 
injection of lipopolysaccharide (LPS), a cell wall component of Gram-negative bacteria and 
selective ligand for TLR4 (Underhill et al., 1999, McGettrick and O'Neill, 2010), induced 
vitreous infiltrates with a similar cellular composition to those induced by zymosan.  Moreover, 
no differences in ROS production of macrophages in eyes injected with LPS or zymosan was 
observed (Fig. 3.2).  Remarkably, i.o. zymosan induced lengthy regrowth of severed RGC axons 
(Yin et al., 2003), while i.o. LPS failed to do so (Fig 3.1b-e). Because zymosan and LPS are 
recognized by different PRRs, this suggests that engagement of specific immune receptors is 
required to generate an inflammatory milieu conducive for CNS axon regeneration.  
 
TLR2 and MyD88 are not necessary for zymosan-elicited axon regeneration  
Zymosan has been used to induce sterile inflammation in animal models of peritonitis 
and arthritis. In these experimental paradigms, zymosan stimulates activation of myeloid cells 
via the TLR2/MyD88 pathway (Underhill et al., 1999, Frasnelli et al., 2005, Choi et al., 2011). 
TLR2 signaling has also been implicated in RGC axon regeneration since repeated i.o. injections 
of Pam3Cys, a synthetic agonist of TLR2, promotes axon growth following ONC (Hauk et al., 
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2010).  However, the importance of the TLR2/MyD88 pathway in zymosan-mediated axonal 
regeneration has not been explicitly demonstrated.  Myeloid cells, but not lymphocytes, that 
infiltrate the eye 7 days following i.o. zymosan and ONC, express TLR2 (Fig. 3.3a-b).  Retina-
resident DCs and microglia both express TLR2 during homeostasis (Fig. 3.3c-d).  The number of 
TLR2+ microglia and DCs increases by 4- and 14-fold, respectively, by day 7 post-ONC without 
i.o. zymosan (Fig. 3.3e-f). This shows that ONC alone, in the absence of i.o. PAMPs, is 
sufficient to activate retinal immune cells.   Surprisingly, i.o. administration of zymosan depleted 
of all its TLR2-stimulating properties (“depleted zymosan”) caused robust regeneration of 
GAP43+ RGC axons (Fig. 3.3i).  The majority of TLR family members signal through the 
downstream adaptor MyD88.  However, similar to TLR2-/- mice, i.o. zymosan in MyD88-/- mice 
subjected to ONC results in robust axonal regeneration, indistinguishable from WT mice (Fig. 
3.3j-l). I.o. PBS failed to elicit axonal extension beyond the lesion site in WT, TLR2-/- or MyD88-
/- mice (Fig. 3.4).  Collectively, these studies demonstrate that TLR2 and MyD88 are dispensable 
for zymosan-elicited RGC axon regeneration.  
 
Zymosan promotes axon regeneration through dectin-1 
In addition to TLRs, several other zymosan receptors have been identified including the 
β-glucan binding transmembrane proteins CR3 (Thornton et al., 1996) and dectin-1 (Tsoni and 
Brown, 2008).  Regrowth of injured RGC axons was significantly attenuated in dectin-1-/-, but 
not CR3-/-, mice compared with WT mice (Fig. 3.5a-f).  To directly test whether the residual 
optic nerve regeneration observed in dectin-1-/- mice is TLR/MyD88-dependent, we generated 
dectin-1-/-;MyD88-/- compound mutants.  Zymosan-elicited optic nerve regeneration was 
completely abolished in dectin-1-/-;MyD88-/- mice (Fig. 3.5d, 3.5f).  To examine whether dectin-
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1 collaborates more specifically with TLR2, we generated dectin-1-/-;TLR2-/- compound mutants 
(Fig. 3.6a), and found that zymosan-elicited optic nerve regeneration was also fully abrogated 
(Fig. 3.5e-f).  Interestingly, the inflammatory responses triggered by i.o. administration of 
zymosan into WT, dectin-1-/-;MyD88-/- or dectin-1-/-;TLR2-/- compound mutants at 7 days post-
ONC are comparable, both with respect to cell number and composition (Fig. 3.5g). Thus, 
reminiscent of our findings with i.o. LPS, these experiments demonstrate that intra-ocular 
inflammation does not always result in RGC regenerative growth.  Germline ablation of dectin-1-
/-;TLR2-/- could, theoretically, adversely affect RGC health and thereby their regenerative 
capacity. In order to determine whether post-traumatic RGCs in dectin-1-/-;TLR2-/- mice can 
regenerate their axons, we knocked-down PTEN and found long-distance axon regeneration 
following ONC (Fig. 3.6b-d).  Thus, RGCs of compound mutants are capable of regenerative 
growth in a conducive setting, but fail to do so following i.o. zymosan application. 
 
β -(1,3)glucan promotes dectin-1-dependent long-distance axon regeneration 
β-glucans are the ingredient of zymosan that complex with dectin-1. They exist as large 
polymers composed of linear β-(1,3) D-glycosidic linkages with occasional side chains bound by 
β-(1,6) D-glycosidic linkages.   We found that in WT mice, i.o. administration of curdlan (Fig. 
3.7a, 3.7d), a particulate form of β-(1,3)glucan, is as effective as zymosan (Fig. 3.1b, 3.1e) in 
promoting RGC axon regeneration following ONC.  The number and composition of infiltrating 
immune cells at 7 days after ONC and i.o. curdlan or zymosan is similar (Fig. 3.8a).  Delayed 
administration of curdlan at 48 hours after ONC, was equally robust in triggering RGC axon 
regeneration (Fig. 3.9).  Curdlan binds directly to dectin-1, but not TLR2, and i.o. administration 
of curdlan in dectin-1-/- mice failed to induce RGC regeneration (Fig. 3.7b, 3.7d). This indicates 
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that curdlan, unlike zymosan, exerts its pro-regenerative effects solely through dectin-1, and that 
engagement of dectin-1 is necessary and sufficient for RGC axon regeneration.  
 
Curdlan signals in a dectin-1 and CARD9 dependent manner to activate CREB  
Ligation of dectin-1 leads to activation of multiple downstream signaling events 
implicated in fungal immune defense, including phagocytosis of fungal particles, ROS 
production and regulation of gene expression (Gross et al., 2006, Gringhuis et al., 2009, Jia et al., 
2014). One pathway, comprised of spleen tyrosine kinase (syk) and caspase recruitment domain 
9 (CARD9), couples dectin-1 to multiple downstream effectors (Ruland, 2008, Roth and Ruland, 
2013).  The role of this pathway in PAMP-induced RGC axonal regeneration was assessed in 
CARD9-/- mice.  In WT and CARD9-/-, but not dectin-1-/- mice, i.o. curdlan combined with ONC 
leads to a rapid increase in syk and p-syk, an important dectin-1 adaptor protein (Fig. 3.7e).  A 
partial, yet significant reduction in regenerative RGC growth was observed in optic nerve 
sections of curdlan injected CARD9-/- mice when compared to WT mice (Fig. 3.7c, 3.7d). This 
shows that CARD9 functions downstream of dectin-1, but also implies the existence of parallel, 
CARD9-independent signaling mechanism(s).  Dectin-1 mediated activation of the MAP kinase 
pathway in bone marrow derived macrophages leads to activation of cAMP response element-
binding protein (CREB) (Elcombe et al., 2013).  Biochemical analysis of eye lysates revealed 
rapid activation of extracellular signal-regulated protein kinase (Erk1/2) and CREB in WT, but 
not dectin-1-/-, mice 6 hours following ONC and i.o. curdlan (Fig. 3.7e, 3.7f).  CARD9-/- mice 
displayed increased activation of Erk1/2, but not of CREB (Fig. 3.7f). This places Erk1/2 
activation downstream of dectin-1 and upstream or parallel of CARD9. Dectin-1/CARD9 
signaling can activate the canonical NF-kB pathway (Gross et al., 2006), however we did not 
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observe an increase in NF-kB activity, as assessed by phosphorylation of p65 at S536 (Fig. 3.7e, 
3.7f).  Together, this suggests dectin-1/CARD9 signaling in myeloid cells participates in 
inflammation-mediated neuronal regeneration.  
 
Dectin-1 is expressed by retina-resident and blood-derived infiltrating immune cells 
We next sought to identify the cell type(s) that curdlan targets to elicit RGC axon 
regeneration.  We used flow cytometric analysis to measure dectin-1 expression on retina-
resident cells at baseline and following ONC alone, and on immune cells that infiltrate the eye in 
response to i.o. curdlan or zymosan in the setting of ONC.  These experiments were performed in 
CX3CR1GFP/+ reporter mice in which microglia are GFP+. We found that dectin-1 is 
constitutively expressed at low levels on CD11b/CX3CR1GFP/+ microglia and CD11b+/CD11c+ 
retinal DCs in naïve eyes (Fig. 3.10a), and is up-regulated on both cell types 7 days post-ONC 
(Fig. 3.10b). Following i.o. zymosan, dectin-1 is expressed on infiltrating 
monocytes/macrophages, neutrophils, and myeloid DCs, but not on lymphocytes (Fig. 3.10c).  
Immunohistochemical studies confirmed that dectin-1 is strongly expressed by myeloid cells that 
accumulate in the vitreous of zymosan-injected WT mice (Fig. 3.10d), but no labeling was 
observed in the RGC layer or on GFAP+ retinal astrocytes (Fig. 3.10e).  Hence, dectin-1 
signaling promotes RGC axon regeneration through an indirect, non-cell autonomous 
mechanism.   
 
Microglia and infiltrating myeloid cells rapidly phagocytose zymosan particles 
Dectin-1 ligation induces phagocytosis (Tsoni and Brown, 2008).  To identify the cell 
types that ingest zymosan in our experimental system, we injected Alexa-555 conjugated 
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zymosan into the eyes of CX3CR1GFP/+ reporter mice immediately following ONC.  At both, 6 
and 18 hours post-injection, CX3CR1-expressing microglia (Fig. 3.11a) and Ly6G+ neutrophils 
(Fig. 3.11b) stained positively for intracellular zymosan. GFP+ microglia are highly branched 
and negative for zymosan particles in retinal sections at 2 hours post-ONC and i.o. zymosan, 
(Fig. 3.11c, 3.11d).  By 6 hours post-injection, labeled zymosan particles are observed within 
GFP+ microglia with a more rounded morphology (Fig. 3.11e-i), indicating that retina-resident 
microglia actively phagocytose zymosan.  
 
Dectin-1 is required on both radioresistant retina-resident cells and infiltrating bone 
marrow-derived cells for curdlan-induced axon regeneration 
The broad expression of dectin-1 by infiltrating myeloid cells, retina-resident microglia 
and DCs raises the question of which of these cells contributes to immune-mediated RGC axon 
regeneration. To functionally assess the role of dectin-1 in radioresistant retina-resident cells 
(such as microglia) versus radiosensitive hematopoietic cells (such as infiltrating monocytes/ 
macrophages and neutrophils), we constructed reciprocal bone marrow (BM) chimeric mice.   
Dectin-1-/- BM was transplanted into irradiated WT hosts [KO ! WT] in order to restrict dectin-
1 expression in the eye to retina-resident cells.  Conversely, we generated [WT!KO] BM 
chimeras in which dectin-1 expression is restricted to blood-derived immune cells.   [WT! WT] 
and [KO!KO] chimeric mice served as positive and negative controls respectively.  Chimerism 
for dectin-1 was confirmed by flow cytometry (Fig. 3.12).  As expected, i.o. curdlan triggered 
regenerative growth of injured RGC axons in [WT! WT] mice (Fig. 3.13a), but not [KO!KO] 
mice (Fig. 3.13d).  A significant reduction in the number of regenerating axons was observed in 
[KO!WT] as well as in [WT!KO] chimeric mice (Fig. 3.13b, 3.13c, 3.13e).  These studies 
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show that dectin-1 function is necessary in both retina-resident and infiltrating immune cells for 
the full extent of curdlan-elicited RGC axon regeneration.   
Analysis of the immune infiltrate in the eye at 7 days post ONC revealed that i.o. curdlan 
elicits robust vitreous inflammation and accumulation of myeloid cells in [WT!KO] but not in 
[KO!WT] mice (Fig. 3.13f).  Yet, the accumulation of dectin-1+ myeloid cells in the vitreous 
of [WT!KO] mice is not sufficient to promote optimal RGC axon regeneration (Fig. 3.13c).  
Conversely, dectin-1 expression on radioresistant retina-resident cells in [KO!WT] mice is 
dispensable for curdlan-induced i.o. inflammation, but is not sufficient to support optimal RGC 
axon regeneration (Fig. 3.13b,f).  
 
3.4 Discussion  
In the current study we identify particulate β-glucan as the active ingredient in zymosan, 
capable of eliciting long-distance axon regeneration in a dectin-1 dependent manner. This is a 
novel finding since previously only TLR2 agonists have been shown to simulate the therapeutic 
effects of zymosan in the ONC model (Yin et al., 2003, Hauk et al., 2010).  Moreover, our 
studies indicate that, although TLR2 and dectin-1 act in a complementary manner to promote 
axonal regrowth, dectin-1 is dominant.  Particulate β-glucan engages dectin-1 on blood-derived 
myeloid cells, as well as on retina-resident immune cells to enable RGC axon regeneration in a 
non cell-autonomous manner.  The dectin-1 downstream effector CARD9 is required for β-
glucan-induced CREB activation and plays an important role in inflammation-mediated RGC 
axon regeneration.  Of clinical interest, administration of β-glucan at the time of ONC or two 
days later, promotes equally robust axonal growth, suggesting a large therapeutic window for β-
glucan/dectin-1 elicited neurorepair. 
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It has been widely assumed that the vitreous inflammation induced by i.o. PAMPs is 
causally linked to enhanced RGC axon growth.  Consistent with that contention, we found that β-
glucan-mediated RGC axon regeneration is mitigated in [KO!WT] chimeric mice, in which 
radiosensitive hematopoietic cells are exclusively deficient in dectin-1.  However, we also found 
regeneration to be impaired in [WT!KO] chimeric mice, implicating the participation of a 
radioresistant retina-resident cell in the repair process.  These data suggest that full blown 
neurorepair is dependent on multiple cell types that act via parallel, non-redundant mechanisms. 
The specific phenotypes of the retina-resident and infiltrating immune cells that promote 
regeneration via a dectin-1-dependent pathway remain to be elucidated.  Other investigators have 
reported that activation of retinal astrocytes and Muller cells correlates with axonal regeneration 
(Muller et al., 2007).  However, the only retinal cells that we found to express dectin-1 are 
microglia and resident DCs.  A direct role of retinal microglia in RGC regeneration is further 
supported by our observation that those cells efficiently phagocytose zymosan particles.  In 
animal models of white matter injury (Miron and Franklin, 2014) or neurodegenerative disease 
(Magnus et al., 2005), microglia facilitate remyelination and suppress destructive neuroimmune 
responses.  Thus, microglia could promote dectin-1 mediated neurorepair by clearing cellular 
debris, release of growth factors or by regulating the toxic aspects of inflammation.   
While the inflammatory response triggered by i.o. curdlan activates RGC growth 
promoting programs, we observed concurrent toxicity, reminiscent of experimental autoimmune 
uveitis (Forrester et al., 2013).  Curdlan causes retinal folding and detachment, and similar to 
zymosan in the spinal cord or DRGs (Gensel et al., 2009) is associated with tissue damage. 
Hence, β-glucan/dectin-1 signaling is sufficient to mimic the pro-regenerative effects of 
zymosan, but causes concomitant pathology. In dectin-1-/- mice, curdlan-elicited RGC 
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regeneration and retinal toxicity are no longer observed (Fig. 3.8), suggesting that the two 
processes may be coupled.  However the intensity of vitreous inflammation did not always 
correlate with extent of axonal growth.  For example, i.o. zymosan induced comparable vitreous 
infiltrates in WT, dectin-1;MyD88 and dectin-1;TLR2 compound mutant mice, yet axonal 
regeneration was only observed in WT mice. Similarly, i.o. LPS or zymosan both lead to strong 
vitreous inflammation and comparable ROS production, but LPS fails to promote RGC 
regeneration. This paradox could reflect the fact that a distinct subset of leukocytes, yet to be 
identified, possesses the pro-regenerative properties, and that this subset is relatively depleted in 
infiltrates of the compound mutants or following i.o. LPS administration. Dectin-1+ 
monocyte/macrophages and neutrophils are universally the most prominent constituents of PRR-
induced vitreous infiltrates. Both of these myeloid cells have been touted as candidates for the 
immune cell that facilitates RGC axon growth (Yin et al., 2003, Kurimoto et al., 2013).  
However, there is growing recognition of the heterogeneity of myeloid cells (Gordon and 
Martinez, 2010, Miron and Franklin, 2014, Murray et al., 2014).   For example, macrophages, 
and possibly microglia, can be polarized along a continuum of activation states including the 
well-known proinflmmatiory (M1-like) and anti-inflammatory (M2-like) phenotypes.  Myeloid 
cell polarization can positively or negatively impact repair following nervous system injury 
(Kigerl et al., 2009, Shechter et al., 2009, Kroner et al., 2014).   Stimulus-specific transcriptional 
programs downstream of PRRs can modulate the macrophage phenotype (Lawrence and Natoli, 
2011).  Transcription factors activated in a dectin-1/CARD9 dependent manner include NF-kB 
(Gross et al., 2006, Gringhuis et al., 2009), IRF5 (del Fresno et al., 2013) and CREB (Kelly et 
al., 2010, Elcombe et al., 2013, Jia et al., 2014).  Dectin-1/CARD9 dependent activation of 
CREB downstream of curdlan coincides with enhanced regenerative growth of injured RGCs.  
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Dectin-1 and CREB signaling in macrophages mediates polarization toward an M2-like 
phenotype, and in non-neural tissue, has been shown to promote repair following injury (Ruffell 
et al., 2009).  The partial loss of RGC axon regeneration in CARD9-/- mice suggests the 
involvement of additional, dectin-1-dependent pathways that function independently of CARD9.   
We propose that activation of myeloid cells through β-glucan/dectin-1 leads to the 
expression and secretion of pro-regenerative factors that ultimately enable injured RGCs to 
switch to a pro-regenerative state and extend long axons.  A growing list of molecules has been 
identified that directly or indirectly participate in inflammation mediated axonal repair, including 
chemokines, “anti-inflammatory” cytokines, growth factors and the calcium binding protein 
oncomodulin (Leibinger et al., 2009, Benowitz and Popovich, 2011, Gensel et al., 2012, Vidal et 
al., 2013).  It therefore appears likely that multiple factors participate in β-glucan-elicited RGC 
axon regeneration. Future studies, including an in-depth analysis of the cellular and molecular 
milieu under inflammatory conditions that do promote (e.g. β-glucan) or fail to promote (e.g. 
LPS) RGC axon regeneration, will be needed to identify the myeloid cell type(s), their activation 
state, and growth factors underling inflammation-mediated neuronal repair. The molecular 
framework described here provides a strong platform for future studies aimed at understanding 
the cross talk between the immune system and the nervous system and how this may be exploited 
to promote repair following injury or disease.  
 
3.5 Future Directions 
 The findings from this work provide several avenues for future study.  We have 
established the ligands and receptors necessary for immune-mediated regeneration, as well as 
demonstrated a requirement for dectin-1 expression on both retina-resident and blood-derived 
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immune cells.  However, we do not yet know what specific types of immune cell populations are 
important for immune-mediated regeneration.  Furthermore, downstream of dectin-1, the 
signaling pathways necessary for immune-mediated regeneration are yet to be elucidated.  Here I 
discuss ongoing follow-up work, and propose areas for future study. 
 
Conditional ablation of dectin-1 signaling 
 Bone marrow chimeric studies revealed a requirement for dectin-1 expression on both 
retina-resident and blood-derived immune cells.  Dectin-1 signals through spleen tyrosine kinase 
(syk) to activate several pathways, including MAPK/ERK and CARD9, as discussed above.  To 
convincingly demonstrate that dectin-1 signaling, and not just dectin-1 expression, in these 
immune cells is necessary for curdlan-induced regeneration we bred sykflox/flox mice and LysMcre/+ 
mice (purchased from Jackson labs), to deplete syk expression in myeloid cell populations.  
Preliminary results show that these mice are still capable of curdlan-induced regeneration (Fig. 
3.14).  This result is not entirely surprising, as a previous study demonstrated that LysMcre mice 
show efficient recombination in only 80% of blood-derived myeloid cell populations, and in less 
than 50% of microglia (Goldmann et al., 2013).  As better tools become available, it will be 
interesting to deplete dectin-1 and/or syk in individual myeloid cell populations, such as 
microglia, neutrophils, and monocytes/macrophages, to determine which individual cell types are 
necessary for curdlan-elicited regeneration. 
 
Do distinct subsets of myeloid cells promote regeneration? 
Intraocular injection of zymosan or curdlan causes a large and diverse population of 
immune cells to infiltrate the eye.  As detailed in the discussion section above, macrophages can 
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be polarized along a continuum of activation states including the well-known proinflmmatiory 
(M1-like) and anti-inflammatory (M2-like) phenotypes.  To assess whether macrophage 
polarization may be involved in immune-mediated neurorepair, we examined the surface 
expression of M2 markers on macrophages infiltrating the eye following i.o. injection of 
zymosan or LPS.  In zymosan-injected eyes, a significantly higher percentage of infiltrating 
macrophages stained positively for the M2 markers arginase-1 (ARG-1) and IL4 receptor-α 
(IL4Rα) compared to LPS injected eyes (Figure 3.15).  This data is correlative, but suggests that 
zymosan may facilitate the polarization of macrophages towards an M2-like phenotype.  
Additional follow up studies are also examining whether distinct subsets of neutrophils may 
facilitate immune-mediated regeneration.   
 
Examination of downstream signaling pathways 
 Biochemical analysis of whole eye lysates demonstrates that intraocular injection of 
curdlan induces phosphorylation of ERK and CREB in a dectin-1-dependent manner.  While this 
finding implicates the involvement of ERK/CREB signaling in immune-mediated regeneration, 
the data are correlative at this point.  Follow-up studies are necessary to determine whether 
activation of ERK/CREB signaling downstream of dectin-1 is necessary for immune-mediated 
regeneration.  Intraperitoneal administration of MEK or ERK inhibitors may be an effective 
strategy to block ERK activation following i.o. curdlan injection.  Application of these inhibitors 
immediately before, and for several days following ONC and i.o. injection will be necessary for 
complete inhibition.  Regeneration can then be assessed under these conditions. Whole eye 
lysates can also be collected at various time points to verify by western blot that ERK 
phosphorylation is effectively blocked. Additional strategies may include adoptive transfer of 
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peritoneal immune cells or bone-marrow-derived cultured immune cells in which ERK or CREB 
signaling has been virally manipulated, though this strategy is complicated by the fact that 
adoptively transferred cells recruit host immune cells to the site of injection.   
 A recent study demonstrated an important role for osteopontin (OPN), a secreted 
phosphoprotein, in promoting regeneration of  specific subtypes of RGCs, termed alpha-RGCs 
(αRGCs) (Duan et al., 2015).  OPN is capable of stimulating mTOR activity, and αRGCs express 
high levels of mTOR and OPN.  When regeneration is enhanced through deletion of PTEN, 
αRGCs account for nearly all of the regenerating axons.  OPN is found as both a secreted 
(sOPN) and intracellular protein (iOPN).  Interestingly, OPN is expressed in several types of 
immune cells, including macrophages, neutrophils, and dendritic cells (Wang and Denhardt, 
2008).  In immune cells, iOPN functions downstream of dectin-1 and TLR2 to promote cytokine 
production, and may be involved in zymosan-mediated activation of ERK (Inoue et al., 2011).  
Whether OPN could be a molecular link between the two most robust paradigms for eliciting 
optic nerve regeneration (PTEN deletion, and immune-mediated regeneration) will be interesting 
to explore.  OPN knockout mice are available, and should be utilized for these studies. 
 
RNA sequencing and cytokine profiling 
 The dissociation of regeneration and inflammation in the dectin-1/TLR2 compound 
mutant mice provides a ripe opportunity to separate the beneficial aspects of intraocular 
inflammation from the concurrent toxic effects.  The immune cells present in the eye following 
zymosan injection of WT mice can be compared with the immune cells in the eyes of dectin-
1/TLR2 compound mutant mice after i.o.nzymosan injection.  Any differences in gene 
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expression, cytokine expression, or immune cell composition can be further validated as a 
potential causative agent for immune-mediated regeneration.   
 
Different sources of beta-glucans promote regeneration 
 In an effort to identify commercially available substances that promote regenerative 
growth without the concurrent toxicity of zymosan or curdlan, I have tested a few other sources 
of beta-glucans.  I assessed them both for feasibility of i.o. injection, and for their ability to 
promote regenerative growth.  Scleroglucan (Invivogen #tlrl-scg) is a high molecular weight 
(>1000 kDa) fungal beta-glucan, consisting of a linear β(1-3) D-glucose backbone with one β(1-
6) D-glucose side chain every three main residues.   Schizophyllan (Invivogen #tlrl-spg) is 
another fungal beta-glucan sharing the same structure as scleroglucan, but with a smaller, though 
still quite large, molecular weight (450 kDa).  Both schizophyllan and scleroglucan are gel 
forming beta-glucans that become difficult to work with in solution, and are thus very 
challenging to inject into the eye.  Mechanical refinement does not ease this process, as is the 
case with curdlan.  While both of these beta-glucans are capable of eliciting regeneration (Fig. 
3.16c,d), the difficulty of i.o. injection makes them poor candidates for future studies. 
 A particulate form of whole glucan particles (WGP® Dispersible, Biothera) also known 
as Wellmune, is obtained from yeast cell walls following a series of alkaline and acid extractions 
(Li et al., 2007).  WGP-dispersible binds and activates dectin-1, but not TLR2 (Goodridge et al., 
2011).  Injection of WGP-dispersible into the eye is somewhat challenging, as WGP-dispersible 
does not dissolve in solution. A curdlan suspension in PBS as looks like large granules of sugar 
that don’t dissolve, whereas WGP-dispersible in PBS looks like soft floating discs.  These discs 
are not easily taken up by a 30 gauge needle.  However, since they are not rigid, they can be 
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backloaded into the syringe and forced through a 30 gauge needle with relative ease.  Injection of 
WGP-dispersible into the eye is capable of promoting regeneration (Fig. 3.16a), though to a 
lesser extent than zymosan or curdlan.  Interestingly, a soluble form of WGP, which is supposed 
to function as a dectin-1 antagonist, is also capable of promoting a robust regenerative response 
(Fig. 3.16b).  Future studies are required with both the dispersible and soluble forms of WGP to 
determine whether consistent regeneration is achieved, and whether a higher dosage can further 
enhance regeneration.  Subsequent analysis of retinal pathology is needed to determine whether 
any of these options show reduced toxicity. 
 With any form of beta-glucan that is injected into the eye, each new lot/preparation must 
be tested and compared with previous lots. This is particularly important with zymosan.  Figure 
3.17 show examples of zymosan-induced regeneration with four different lots of zymosan from 
two different companies.  To obtain accurate results in regeneration studies, experimental groups 
must always be compared to control groups treated with the exact same lot of zymosan. 
 
3.6 Methods 
Transgenic mice: All animal handling and surgical procedures were performed in compliance 
with local and national animal care guidelines and approved by the University of Michigan 
Committee on Use and Care of Animals (UCUCA).  Dectin-1 (Saijo et al., 2007), CARD9 (Hsu 
et al., 2007) , and MyD88 (Adachi et al., 1998) mutant mice on a C57BL/6 background were 
kindly provided by Tobias Hohl (Sloan Kettering Cancer Center, New York). CR3 
(CD11b/CD18) mutants (Rosenkranz et al., 1998), TLR2 mutants, CX3CR1GFP/+ reporter mice 
(Mizutani et al., 2012), LysMcre/+, Sykflox/flox, and C57BL/6 wild-type controls either CD45.1 or 
CD45.2 were purchased from Jackson Laboratories.  Mice were group housed in a 12 hour 
light/dark cycle with access to food and water ad libitum.  Breeding pairs of dectin-1;MyD88 
compound mutant mice were kept on enrofloxacin-treated water (1.9 ml of Baytril Injectable (22 
mg/ml) per 250 ml water bottle) to compensate for severe immunodeficiency.   
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Preparation of PAMPs: Zymosan (Di Carlo and Fiore, 1958) and depleted zymosan (Ikeda et 
al., 2008) from Saccharomyces cerevisiae (Invivogen) were suspended in PBS at a concentration 
of 12.5µg/µl by incubating at 37ºC for 10 min and vortexing.  Aliquots were stored at 4 ºC.  
Lipopolysaccharide (LPS) from E. coli (Sigma) was dissolved in PBS (5µg/µl).  Curdlan, a 
particulate β-(1,3)glucan and FDA approved food additive (Zhan et al., 2012) (Wako Chemicals 
USA), was obtained in powder form, and was mechanically refined using a mortar and pestle 
continuously for 5 minutes, within 24 hours before use.  Immediately before use, refined curdlan 
was suspended at 25µg/µl in sterile PBS by vortexing for 2 minutes. Immediately before eye 
injections, the solution was vigorously shaken to resuspend the curdlan. After drawing up the 
suspension into a syringe, the syringe was visually inspected to insure curdlan particles were 
present, and that the needle had not been blocked by larger particles.  The syringe was rinsed 
thoroughly with PBS after each injection. 
 
Optic nerve crush (ONC) surgery: Adult male and female mice (6-12 weeks of age) were used 
for surgical procedures (Dickendesher et al., 2012). Mice were anesthetized with 100mg/kg 
ketamine and 10mg/kg xylazine i.p., the optic nerve exposed through an incision in the 
conjunctiva and compressed for 10 seconds with curved forceps (Dumont #5, Roboz) 
approximately 1-2 mm behind the eye.  Immediately after ONC, a Hamilton syringe with a 30 
gauge removable needle was used for intraocular (i.o.) injections of ~5 µl of PAMP, including 
zymosan (12.5µg/µl in PBS), depleted zymosan (12.5µg/µl in PBS), curdlan (25µg/µl in PBS), 
~3 µl of LPS (5µg/ul in PBS), or 5µl saline (PBS).  After ONC and PAMP injection, eyes were 
rinsed with a few drops of sterile PBS, and ophthalmic ointment (Puralube) was applied on the 
operated eye.  Two weeks following surgery, mice were given a lethal dose of ketamine/xylazine 
i.p. and perfused transcardially with PBS (2 min) followed by ice-cold 4% paraformaldehyde in 
PBS (5 min).   
 
Histochemical Studies:  To visualize regenerating RGC axons, animals were perfused, optic 
nerves dissected and post-fixed in 4% paraformaldehyde in PBS overnight at 4ºC. For 
cryoprotection, nerves were transferred to a 30% sucrose/PBS solution and kept at 4ºC for at 
least two hours, and up to two weeks (Winters et al., 2011).  Optic nerves were imbedded in 
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OCT Tissue-Tek Medium and stored at -20°C. Longitudinal sections (14µm thick) were cut with 
a cryostat, mounted on superfrost+ microscope slides (Fisher), and stained with a sheep 
polyclonal anti-GAP43 antibody (Leon et al., 2000, Dickendesher et al., 2012).  Alexa-Fluor488 
conjugated donkey anti-sheep secondary antibody (Invitrogen) was used for fluorescent labeling.  
For immunofluorescence labeling of the retina, eyes were dissected, post-fixed as described 
above, cryoprotected and sectioned at 25µm.  Sections were mounted on superfrost+ microscope 
slides and stained with anti-dectin-1 (Serotec) and anti-GFAP (eBiosciences) antibodies followed 
by application of the appropriate Alexa-Fluor-conjugated secondary antibody.  Nuclear staining 
with DAPI (4’,6-Diamidino-2-Phenylindole, Dilactate at 300 nM) was used to counterstain 
sections.  Images were acquired using an inverted microscope (IX71; Olympus) attached to a 
digital camera (DP72; Olympus).  
 
Flow Cytometry: For the analysis of immune cells in the eye, mice were euthanized by 
isofluorane overdose at 7 days after ONC, perfused transcardially with PBS, eyes dissected and 
the vitreous fluid and retinae harvested.  Retinae and vitreous fluid were pooled, homogenized, 
incubated in collagenase D (1 mg/ml, Fisher Scientific) for 60 min at 37°C, and rinsed in PBS 
prior to incubation with fluorochrome-conjugated antibodies (CD11b, CD45, CD45.1, CD45.2, 
CD11c, TLR2, Dectin-1, CD3, CD4, CD8, B220, NK1.1, and F4/80 were purchased from 
eBiosciences, Ly6C and Ly6G from Pharmingen). Dihydroethidium (Sigma) was added at 0.1 
mM concentration to stain cells for ROS production. The spleen was dissected and splenocytes 
were passed through a 70-µm cell strainer.  Red blood cells in spleens and blood were lysed with 
ACK (Ammonium-Chloride-Potassium) Lysing Buffer (Quality Biological). Flow cytometry 
was performed using a BD FacsCanto II (BD Biosciences). Cells were gated on forward and side 
scatter after doublet exclusion. Immune cells were identified as follows: monocytes/macrophages 
(CD45+ CD11b+ Ly6C+ Ly6G-), neutrophils (CD45+ CD11b+ Ly6C+ Ly6G+), DCs (CD45+ 
CD11b+ CD11c+), B-cells (CD45+ CD11b- B220+), T-cells (CD45+ CD11b- CD3+ CD4+ or 
CD8+), NK cells (CD45+ CD11b- NK1.1+), microglia (CD45low CD11b+ CX3CR1+).  All flow 
cytometry experiments were carried out with at least 6 mice (both eyes receiving the same 
treatment and pooled) per group, with the exception of dectin-1-/-;TLR2-/- double-mutants (n= 3 
mice). 
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Labeled Zymosan: At the time of ONC, Alexa-555 labeled zymosan (Life Technologies) was 
injected into one eye (5µl, 12.5µg/µl) of adult CX3CR1+/GFP mice.  Animals were killed at 2, 6, 
and 18 hours after ONC, and eyeballs collected for flow cytometry of retina resident microglia 
and blood-derived neutrophils.  Some retinae were cryosectioned and analyzed by confocal 
microscopy for the presence of GFP+ microglia that have taken up Alexa-555 labeled zymosan 
particles. 
 
Western-blot Analysis:  To examine activation of signaling pathways downstream of dectin-1, 
adult mice were subjected to ONC and i.o. injection of curdlan (25ug/µl, 5µl), PBS (5µl), or LPS 
(5µg/ul, 3µl).  After 6 hours, mice were euthanized with CO2, and eyes were extracted and snap 
frozen in dry ice cooled 2-methylbutane.  Eyes were stored at -80ºC overnight.  Lysates were 
prepared by homogenizing frozen eyes in ice-cold RIPA (50mM Tris-HCl pH 8.0, 150mM NaCl, 
0.1% SDS, 0.5% sodium deoxycholate, 1% NP-40) buffer containing 50 mM beta-
glycerophosphate and 100 µM sodium orthovanadate to inhibit phosphatases, and Sigma 
Protease Inhibitor Cocktail (diluted 1:100).  Non-dissolved components were spun down at 
14,000 rpm for 5min, supernatants collected, and the protein concentration of the supernatant 
was measured (BioRad BCA Kit). Supernatants were combined with 2x Laemmli buffer, boiled 
for 10min, separated by SDS-PAGE (40 µg of protein loaded per lane), and transferred to PVDF 
membrane (Millipore).  PVDF membranes were blocked with 2% milk (BioRad) in TBS-T (Tris-
buffered saline pH 7.4, containing 0.1% Tween-20) and probed with antibodies specific for 
pERK (1:2000, Cell Signaling), ERK (1:2000, Cell Signaling), pSyk (1:1000, Cell Signaling), 
Syk (1:1000, Cell Signaling), pCREB (1:1000, Upstate), CREB (1:1000, Cell Signaling), and β-
actin (1:5000, Sigma).  Anti-mouse or anti-rabbit IgG-HRP (Millipore) were used, along with 
West Pico Substrate or West Femto Substrate (Thermo Scientific) to detect primary antibodies.  
Protein bands  were visualized and quantified with a  LI-COR C-Digit and Image Studio 
software.  Western blot band intensity in the linear range was measured with Image Studio 
software.  For quantification, pERK levels were normalized to total ERK levels, pCREB levels 
to total CREB levels, and pSyk levels to total Syk and actin levels. 
 
Generation of Dectin-1 Bone Marrow Chimeras: Chimeric mice were generated as previously 
described (King et al., 2010). Briefly, five-to-six week old recipient mice were lethally irradiated 
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(13 Gy, split dose) and given congenic (CD45.1 or CD45.2) bone marrow (BM) from donor mice 
(5 million cells in 300µl) via tail vein injection.  Six weeks after BM transplant, ONC surgery 
was performed along with i.o. injection of ~5µl of curdlan (25µg/µl) or PBS.  One group of 
animals (26 mice in total) was sacrificed 14 days after ONC surgery.  A second group of BM 
chimeric mice (21 mice in total) was sacrificed at 7 days after ONC surgery and i.o. injection of 
~5µl of curdlan (25µg/µl) or PBS.  Nerves were isolated and assessed for RGC axon 
regeneration by anti-GAP43 labeling.  Eyes were processed to assess the composition of the 
immune infiltrate by flow cytometry. Congenic markers (CD45.1 and CD45.2) were used to 
assess degree of chimerism. All BM chimeras had >97% chimerism in the myeloid compartment. 
Statistical Analysis: For quantification of RGC regeneration, GAP43+ axons in optic nerve 
sections were counted at every 0.2 mm interval past the injury site up to 1.6 mm.  For each 
nerve, at least three sections were quantified.  The number of labeled axons per section was 
normalized to the width of the section and converted to the total number of regenerating axons 
per optic nerve, as described previously (Leon et al., 2000).  All optic nerve data were analyzed 
using one-way ANOVA followed by Tukey’s post hoc comparison in Graphpad Prism 6.0.  
Unpaired Students t-test was used to analyze flow cytometric data with only two groups, and 
one-way ANOVA followed by Tukey’s post hoc was used to analyze flow cytometric data with 
more than two groups. 
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Figure 3.1:  Zymosan, but not LPS enables immune-mediated axon regeneration 
(a) Flow cytometric analysis of immune cells accumulating in the eye of wild-type (WT) mice at 
7 days post-ONC and i.o. zymosan (5µl, 12.5µg/µl) injection (n= 5 mice), i.o. LPS (3µl, 5µg/µl) 
injection (n = 3 mice), or i.o. PBS (5ul) injection. (b-d) Longitudinal sections of WT mouse 
optic nerves at two weeks following ONC and i.o. injection.  Regenerating axons are visualized 
by anti-GAP43 immunofluorescence labeling. The injury site is marked with an asterisk. Scale 
bar: 200 µm.  (b)  WT mice with i.o. zymosan (n = 6) show robust axon regeneration.  No 
significant regeneration is observed in (c) WT mice with i.o. LPS (n = 4), or (d) WT mice with 
i.o. PBS (n = 5).  (e) Quantification of the number of GAP43+ axons per nerve at 0.2-1.6 mm 
distal to the injury site.  Asterisks indicate a significant difference from zymosan-induced 
regeneration.  Results are presented as mean ± SEM. *** p<0.001, ** p<0.01, * p<0.05 (one-
way ANOVA, Tukey’s post hoc). 
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Figure 3.2:  Zymosan and LPS produce similar ROS levels in the eye 
(a)  Diagram of mouse optic nerve crush (ONC) injury model.  The optic nerve is crushed at 1-2 
mm behind the eye ball (ONC, asterisk).  PAMPs are injected into the posterior chamber (pc) of 
the eye to elicit an inflammatory response near the cell soma of RGCs.   (b) Adult WT mice were 
subjected to ONC and i.o. injection of LPS or zymosan.  Reactive oxygen species (ROS) 
production by macrophages was assessed by flow cytometry combined with dihyroethidium 
(DHE) staining at 7 days after ONC. The fraction of ROS producing (DHE+) cells was not 
significantly different between LPS and zymosan injected eyes. Values represent the mean ± 
S.E.M.  n = 4 mice (LPS) and n = 4 mice (zymosan), from two independent sets of experiments. 
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Figure 3.3 TLR2 is expressed on retina-resident and blood-derived immune cells in the eye, 
but is not necessary for zymosan-induced RGC axon regeneration 
 (a) Flow cytometic analysis of immune cells accumulating in the eye at 7 days post-ONC and 
i.o. zymosan injection. Representative dot plots of monocytes/macrophages 
(CD45+/CD11b+/Ly6C+/LyG-), neutrophils (CD45+/CD11b+/Ly6C+/LyG+), dendritic cells (DCs) 
(CD45+/CD11b+/CD11c+), and lymphocytes (CD45+/CD11b-).  (b) Histograms represent TLR2 
(blue) or isotype control (red) staining for the gated cell populations.  (c) In the naïve retina, 
microglia (CD45+/CD11b+/CX3CR1+) and DCs are present, and (d) express TLR2. (e) At 7 days 
post-ONC (without i.o. zymosan) cell counts for microglia increase from ~6,000 to ~24,000 and 
for DCs from ~700 to ~10,000.  (f) TLR2 expression on microglia and DCs at 7 days post-ONC.  
Plots and histograms are representative of 2 independent experiments. (g-k) Longitudinal 
sections of optic nerves at 14 days post-ONC stained with anti-GAP43.  The injury site is 
marked with an asterisk. Scale bar:  200 µm. (g) Wild-type (WT) mice receiving i.o. PBS (5µl) 
at the time of injury show very little regenerative growth.  (h) WT mice with i.o. zymosan (Zym, 
5µl, 12.5µg/µl) or (i) i.o. depleted zymosan (Dep. Zym, 5µl, 12.5µg/µl) show robust RGC axon 
regeneration.  (j) TLR2-/- mice with i.o. zymosan, and (k) MyD88-/- mice with i.o. zymosan show 
robust regeneration. (l) Quantification of the number of GAP43+ axons per optic nerve at 0.2-1.6 
mm distal to the injury site: WT + PBS, n=5 nerves, 5 mice; WT + zymosan, n=6 nerves, 6 mice; 
WT + dep. zymosan, n=4 nerves, 4 mice; TLR2-/- + zymosan, n=4 nerves, 4 mice; MyD88-/- + 
zymosan, n=4 nerves, 4 mice.  Data are presented as mean ± s.e.m.  Regeneration is significantly 
enhanced in all groups in comparison to WT + PBS.  ***p<0.001, **p<0.01, *p<0.05 (one-way 
ANOVA, Tukey’s post hoc). 
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Figure 3.4: Loss of TLR2 or MyD88 does not alter RGC axon regeneration 
(a) Wild type (WT) mice with i.o. PBS (5µl) show minimal RGC axon regeneration two weeks 
after ONC, as assessed by anti-GAP43 staining of longitudinal optic nerve sections.  The injury 
site in the nerve is marked with an asterisk.  Scale bar: 200 µm.  When compared to WT mice, no 
significant difference in regeneration is observed in (b) TLR2-/- (n = 4 nerves, 4 mice) or (c) 
MyD88-/- mice (n = 3 nerves, 3 mice) subjected to i.o. PBS injection. (d) Quantification of 
GAP43+ axons at 0.2 – 1.0 mm distal to the injury site. Results are presented as mean number of 
axons per nerve ± s.e.m.  
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Figure 3.5:  Dectin-1 and TLR2 operate as partially redundant zymosan receptors  
(a-e) Longitudinal sections of mouse optic nerves at two weeks following ONC and i.o. injection 
of zymosan stained with anti-GAP43.  Injury site marked with an asterisk. Scale bar: 200 µm. (a) 
WT mice with i.o. zymosan (n = 5), and (b) complement receptor 3 null mice (CR3-/-) with i.o. 
zymosan (n = 3) show robust and comparable axon regeneration. (c) In dectin-1-/- mice, i.o. 
zymosan (n = 5) results in significantly reduced regeneration.  (d-e)  I.o. zymosan fails to induce 
axon regeneration in dectin-1-/-;MyD88-/- compound mutants (n = 7) and dectin-1-/-;TLR2-/- 
compound mutants (n = 6). (f) Quantification of the number of GAP43+ axons per nerve at 0.2-
1.6 mm distal to the injury site. Data are presented as mean ± s.e.m.  Asterisks directly above 
individual bars indicate a significant difference compared to WT + zymosan. *** p<0.001, ** 
p<0.01, * p<0.05 (one-way ANOVA, Tukey’s post hoc).  (g) Comparison of the cellular 
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composite of zymosan-induced inflammation in WT (n = 6 mice), dectin-1-/-;MyD88-/- (n = 6 
mice) and dectin-1-/-;TLR2-/- (n = 3 mice) compound mutants.  Independent of mouse genotype, 
similar numbers of macrophages/ monocytes, neutrophils, DCs, B-cells, CD4+ and CD8+ T-cells, 
but not NKs were identified in the vitreous. 
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Figure 3.6: Characterization of dectin-1/TLR2 compound mutant mice 
(a) As an independent confirmation that dectin-1/TLR2 compound mutants are null for the PRRs 
dectin-1 and TLR2, we carried out flow cytometric analysis of Ly6C+ myeloid cells isolated from 
the blood.  Cells from double mutant mice (red line) are negative for TLR2 and dectin-1. Cells 
from WT mice (blue line) express TLR2 and dectin-1 on their surface.  (b-d) To verify that 
dectin-1/TLR2 compound mutant mice are capable of RGC axon regeneration in a PAMP-
independent  context, PTEN expression in WT and dectin-1/TLR2 mice was knocked-down by 
i.o. injection of  AAV2-shPTEN-GFP 14 days before ONC (Zukor et al., 2013).  (b)  
Knockdown of PTEN elicits robust RGC axon regeneration in WT mice at 14 days following 
ONC, as assessed by anti-GAP43 staining.  (c)  Similarly robust RGC axon regeneration is 
observed in dectin-1/TLR2 mutant mice following PTEN knockdown.  (d) Quantification of the 
number of GAP43+ axons per nerve at 0.2-1.6 mm distal to the injury site.  Results are presented 
as mean ± s.e.m. from at least 3 nerves per condition. 
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Figure 3.7: β-(1,3)glucan promotes dectin-1-dependent long-distance axon regeneration 
(a-c) Longitudinal sections of mouse optic nerves at two weeks following ONC and i.o. curdlan 
(5µl, 25µg/µl) stained with anti-GAP43.  Injury site marked with an asterisk. Scale bar: 200 µm. 
(a) WT mice with i.o. curdlan (n = 7) show robust axon regeneration. (b) In dectin-1-/-  mice (n = 
12),  i.o. curdlan fails to elicit a regenerative response.  (c)  In CARD9-/- mice with i.o. curdlan (n 
= 9), axon regeneration is significantly reduced, yet increased compared to dectin-1-/- mice at 0.2 
- 0.6 mm distal to the injury site.  (d) Quantification of GAP43+ axons at 0.2-1.6 mm distal to the 
injury site.  Results are presented as mean ± s.e.m.  Asterisks directly above individual bars 
indicate a significance compared to WT + curdlan. **p<0.001, *p<0.05 (one-way ANOVA, 
Tukey’s post hoc).  (e) Western blot analysis of adult mouse eye extracts at 6 hours after ONC 
and i.o. injection of PBS, or curdlan.  (f)  Quantification of western blot band intensity relative to 
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respective PBS-injected eye. Compared to PBS-injected eyes, curdlan induces a significant 
increase in levels of pERK and pSyk in WT and CARD9-/- eyes, but not in dectin-1-/- eyes.  
Curdlan significantly increases pCREB (S133) levels in WT, but not in dectin-1-/- or CARD9-/- 
eyes.  Curdlan does not increase phosphorylation of the NF-kB subunit p65 (S536) in any of the 
genotypes examined.  A total of 3-5 eyes from two separate experiments were analyzed for each 
condition and genotype.  Data shown are mean ±S.E.M.  ** p<0.01, * p<0.05. 
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Figure 3.8: Intraocular curdlan-elicited inflammation is associated with retinal damage  
Flow cytometric analysis of immune cells accumulating in the eye at 7 days post-ONC and i.o. 
PAMP injection.  (a) Injection of zymosan (5µl, 12.5µg/µl) (n = 4 mice) or curdlan (5µl, 
25µg/ul) (n = 3 mice) recruits monocytes/macrophages, neutrophils, DCs, and a small number of 
B-cells, CD4+ T cells, CD8+ T cells, and NKs. With exception of the decreased number of 
monocytes/macrophages in curdlan-treated animals, the cellular composite is very comparable.  
Differences between zymosan and curdlan-elicited inflammation likely reflect the fact that these 
two PAMPs employ partially overlapping, yet distinct receptor mechanisms to trigger 
inflammation.  In contrast to zymosan or curdlan, i.o. injection of PBS (5µl) (n = 6 mice) recruits 
few immune cells to the vitreous. For statistical analysis, the number of cells was compared to 
zymosan-injected eyes.  Values are shown as mean ± S.E.M. *** p<0.001, ** p<0.01, * p<0.05 
(one-way ANOVA, Tukey’s post hoc).   (b) Flow cytometric analysis of infiltrating immune 
cells in the eye at 7 days post-ONC and i.o. curdlan injection.  When compared to WT mice (n = 
12 eyes), dectin-1-/- mice (n = 12 eyes) show a significant reduction in the number of 
macrophages/monocytes (from 43,600± 12,000 to 8,800 ± 2,000), neutrophils (from 41,400 ± 
11,100 to 1,300 ± 200), and DCs (19,000± 3,100 to 2,600± 500). The number of lymphocytes is 
not significantly altered. * p<0.05 (unpaired Student’s t test).  (c-f)  Cross sections of whole eyes 
stained with Hoechst at 14 days after ONC and i.o. injection of PBS or curldan. The retina is 
labeled with an “r” and the accumulation of inflammatory cells in the vitreous is labeled with an 
‘i.’ Scale bar represents 100µm. (c)  The retinal morphology of WT mice with ONC and i.o. PBS 
appears largely normal after 14 days.  In contrast, (d) i.o. zymosan, or (e) i.o. curdlan causes 
choroid detachment and extensive retinal folding. The accumulation of immune cells in the 
! 82!
vitreous is clearly visible (indicated by the letter ‘i’).  (f) In marked contrast,  i.o. curdlan does 
not induce noticeable retinal pathology in dectin-1-/- mice, indicating that dectin-1 activation 
underlies both the beneficial (pro-regenerative) and detrimental (toxic) aspects of i.o. 
inflammation. 
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Figure 3.9: Curdlan has a therapeutic window of at least 48 hours 
To assess the therapeutic window of i.o. curdlan-elicited RGC axon regeneration, ONC surgery 
was performed and administration of curdlan delayed for two days.   (a,b) Longitudinal sections 
of mouse optic nerves at two weeks following ONC injury. Regenerating axons are stained by 
anti-GAP43 immunofluorescence labeling.  The injury site in the nerve is marked with an 
asterisk. Scale bar: 200 µm.  Intraocular curdlan (5µl, 25µg/µl) was administrated at (a) 0 hours 
following ONC or at (b) 48 hours following ONC.  Robust regeneration beyond the injury site 
was observed for both conditions.  (c) Quantification of GAP43+ axons at 0.2 – 1.6 mm distal to 
the injury site.  Results are presented as mean ± s.e.m. from at least 4 nerves per condition. 
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Figure 3.10:  Dectin-1 is expressed on retina-resident and blood-derived myeloid cells 
Flow cytometic analysis of dectin-1 expression in the eye (blue line), compared to an isotype 
control (red line).  (a)  Histogram of dectin-1+ microglia and DCs in the eyes of naïve mice and 
(b) 7 days post-ONC in the absence of zymosan. (c) Analysis of dectin-1+ cells in the eye at 7 
days post-ONC and i.o. zymosan. (d)  Cross-section through the eye at 14 days post-ONC and 
i.o. zymosan stained with anti-dectin-1 (red) and DAPI (blue) .  Many dectin-1+ cells are found 
in the vitreous (4), but not in the retina, including the outer nuclear layer (1), the inner nuclear 
layer (2), or the RGC layer (3). (e) Anti-dectin-1 immunolabeling is not observed on GFAP+ 
retinal cells. Scale bar: 100 µm.  (f)  Analysis of dectin-1+ cells in the optic nerve at 7 days post-
ONC. 
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Figure 3.11: Retina-resident microglia and infiltrating neutrophils rapidly phagocytose 
zymosan particles 
(a,b) Alexa555-conjugated zymosan particles were injected into the eye at the time of ONC and 
zymosan-labeled cells quantified by flow cytometry.  (a) Dot plot of zymosan-labeled microglia 
at 6 and 18 hours post-ONC and i.o. zymosan injection.  At both time points ~ 40% of CX3CR1+ 
microglia are positive for zymosan.  (b) Ly6G+ neutrophils are abundantly found in the vitreous 
at both 6 and 18 hours following ONC and i.o. zymosan injection.  Approximately 50% of 
neutrophils are positive for zymosan at both 6 and 18 hour time points.  Data are representative 
of at least 2 independent experiments.  (c-i)  Confocal images of retina of CX3CR1GFP/+ reporter 
mice after-ONC and i.o. injection of Alexa555-conjugated zymosan.  Scale bar represents 20µm.  
(c,d) At 2 hours after zymosan injection, CX3CR1GFP/+ microglia are highly branched, and 
phagocytosis of zymosan particles (red) is not observed.  (e) At 6 hours after zymosan injection, 
CX3CR1GFP/+ microglia acquire a more rounded morphology and are positive for zymosan. (f, g) 
Confocal images of double-labeled cells (box 1 in panel e) were rotated and magnified to show 
that zymosan particles are located within CX3CR1GFP/+ microglia.  (h, i) Rotated close ups of 
box 2, to demonstrate that zymosan particles are located within CX3CR1GFP/+ microglia. 
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Figure 3.12:  Bone marrow chimeric mice are chimeric for dectin-1 expression 
Flow cytometry was used to show that transplantation of WT bone marrow into dectin-1-/- (KO) 
recipients [WT!KO] results in mice that express dectin-1 on blood-derived macrophages and 
neutrophils, but not on retina-resident microglia. Conversely, KO!WT chimeric mice lack 
dectin-1 on blood-derived immune cells, but express dectin-1 on retina resident microglia.   
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Figure 3.13:  Dectin-1 expression is necessary on both radioresistant retinal cells and bone-
marrow derived infiltrating cells for curdlan-induced axon regeneration 
Reciprocal bone marrow chimeric mice we subjected to i.o. curdlan  injection (5µl, 25µg/µl) and  
regeneration was assessed two weeks later by anti-GAP43 labeling.  The injury site is marked 
with an asterisk. Scale bar: 200 µm.  (a) WT mice that received WT donor BM (WT!WT) show 
robust curdlan-induced axon regeneration. (b) In contrast, WT mice that received dectin-1-/- BM 
(KO!WT) showed significantly less regeneration, comparable to (c) dectin-1-/- mice that 
received WT BM (WT!KO), and (d) dectin-1-/- mice that received dectin-1-/- BM (KO!KO) 
(e) Quantification of GAP43+ fibers at 0.2-1.6 mm distal to the injury site (WT!WT + curdlan, 
n = 6 nerves, 6 mice; KO!WT + curdlan, n = 8 nerves, 5 mice; WT!KO + curdlan, n = 12 
nerves, 8 mice; KO!KO + curdlan, n = 6 nerves, 4 mice).  (f) Flow cytometric analysis of 
intraocular inflammation at 7 days post i.o. curdlan and ONC.  Inflammation in WT!WT and 
WT!KO mice is comparable.  Significantly decreased inflammation is observed in KO!WT 
and KO!KO mice.  Results are presented as mean ± s.e.m.  Asterisks indicate a significant 
difference from WT!WT. *** p<0.001, ** p<0.01, * p<0.05, (one-way ANOVA, Tukey’s post 
hoc).  
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Figure 3.14:  Curdlan induces regeneration in Sykf/f;LysMCre/+ mice 
Longitudinal sections of Sykf/f;LysMCre/+ mouse optic nerves at two weeks following ONC and 
i.o. injection.  Regenerating axons are visualized by anti-GAP43 immunofluorescence labeling. 
The injury site is marked with an asterisk. Scale bar: 200 µm.  Representative images from two 
different mice are shown. 
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Figure 3.15:  Intraocular injection of LPS and zymosan differentially affects macrophage 
polarization 
(a,b) Flow cytometic analysis of monocytes/macrophages isolated from LPS or zymosan injected 
eyes.  At 7 days after injection, expression of the “M2-type” markers arginase-1 (ARG-1) and 
IL4 receptor-α (IL4Rα) is more abundant in zymosan injected mice. (c) Quantification of the 
fraction of IL4Rα and ARG-1 double positive monocytes/macrophages revealed a significant 
increase zymosan versus LPS injected eyes.  Values represent the mean ± S.E.M.  * p<0.05 
**p<0.01 (unpaired t test) n= 4 mice (LPS) and n = 4 mice (zymosan), from two independent 
sets of experiments. 
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Figure 3.16:  Different sources of β-glucans promote CNS axon regeneration 
(a-d) Longitudinal sections of WT mouse optic nerves at two weeks following ONC and i.o. 
injection.  Regenerating axons are visualized by anti-GAP43 immunofluorescence labeling. The 
injury site is marked with an asterisk. Scale bar: 200 µm. (a) i.o injection of 5ul (12.5ug/ul) of 
whole glucan particle dispersable (WGP-D) or (b) WGP soluble (WGP-S) from S. cerevisiae 
stimulates optic nerve regeneration.  (c)  Injection of scleroglucan (5ul, 12.5ug/ul) from the 
filamentous fungus Sclerotium rolfsii elicits robust regeneneration  (d)  Modest regeneration is 
observed following i.o. injection of Schizophyllin (5ul, 12.5ug/ul) from the fungus 
Schizophyllum commune. 
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Figure 3.17:  Variability in zymosan-induced regeneration among different lots and sources 
of zymosan   
(a-d) Longitudinal sections of WT mouse optic nerves at two weeks following ONC and i.o. 
injection.  Regenerating axons are visualized by anti-GAP43 immunofluorescence labeling. The 
injury site is marked with an asterisk. Scale bar: 200 µm.  (a-b) Two different lots of zymosan 
purchased from Invivogen show a robust and comparable regenerative response.  (c) A batch of 
zymosan from Sigma, purchased in November 2010 (Sigma #1) shows equally robust 
regeneration.  (d) A subsequent batch purchased from Sigma in January 2013 (Sigma #2) is not 
as potent, and elicits significantly less robust regeneration. 
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CHAPTER IV: 
 
Discussion:  Interpretation of Results, and the Future of CNS Repair 
 
 Over the past few decades, our understanding of the molecular and cellular mechanisms 
that restrict or promote regeneration in the injured adult mammalian CNS has improved 
substantially.  Neurite outgrowth assays revealed that injured CNS tissue contains a diverse array 
of inhibitory ligands that bind axonal surface receptors to restrict growth and plasticity in vitro 
(Giger et al., 2010). However, blocking inhibitory mechanisms in vivo has met with only 
minimal success in promoting regenerative growth (Lee et al., 2010, Dickendesher et al., 2012).  
Conversely, genetic manipulation of neuron intrinsic pathways to promote cell growth and 
survival elicits a robust regenerative response in vivo (Sun et al., 2011).  A major caveat for 
many of these studies, however, is that genetic manipulation done prior to injury yields more 
robust regeneration than manipulation after injury, diminishing the therapeutic potential of these 
studies.  Furthermore, knockdown of tumor suppressor genes, such as PTEN, may have 
undesirable long-term consequences.  Several studies have shown that a local inflammatory 
response initiated after injury significantly enhances neuronal survival and regenerative growth.  
Until recently, the nature of this inflammatory response, and the underlying molecular 
mechanisms were unknown.  Our studies provide the first insights into the cellular and molecular 
mechanisms of immune-mediated regeneration.  Since an immune response initiated two days 
after injury promotes regeneration to a similar extent as one initiated at the time of 
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injury, exploitation of immunomodulatory mechanisms to promote regeneration holds great 
promise therapeutically. 
 
4. 1  Uncoupling Immune-Mediate Regeneration and Toxicity 
We have identified a ligand-receptor system capable of promoting robust regeneration in 
the injured rodent CNS.  Ligation of β1,3-glucan with dectin-1 on cells of the innate immune 
system is sufficient to elicit robust regeneration in the mouse optic nerve.  β-glucans from 
several different sources, including fungal (zymosan, scleroglucan, WGP) and bacterial 
(curdlan), successfully promote regeneration.  Conversely, other inflammatory compounds, such 
as the TLR4 ligand LPS, do not promote regeneration, despite causing intraocular inflammation, 
indicating that only activation of certain immune pathways leads to regenerative axonal growth. 
Unfortunately, this enhanced regeneration is accompanied by concurrent toxicity.  In both 
curdlan and zymosan-injected eyes, the retina is severely buckled and detached from the 
pigmented epithelium.  Curdlan-induced retinal pathology is dectin-1-dependent, as i.o. curdlan 
fails to induce retinal pathology in dectin-1 knockout mice.  With our current level of 
understanding of the signaling pathways important for immune-mediated regeneration 
downstream of dectin-1, we cannot uncouple regeneration from toxicity.  Separating these two 
aspects will be vital for the development of therapeutic strategies, as the detrimental aspects of 
neuroinflammation may damage existing structures and complicate repair efforts. 
Opportunities to uncouple immune-mediated regeneration from toxicity could exist at 
several different points.  Is it possible to activate dectin-1 signaling with a ligand that promotes 
regeneration, but not toxicity?  Since curdlan is bacterial in origin, there is a possibility of LPS 
contamination.  Perhaps different forms and/or sources of β-glucan are less toxic, but still able to 
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promote robust regeneration.  Any additional molecules or compounds that are known dectin-1 
agonists can easily be screened for their efficacy in promoting regeneration and/or toxicity using 
the optic nerve crush injury model.  One study demonstrated that binding of particulate β-
glucans to dectin-1 on cultured macrophages promotes formation of a “phagocytic synapse” 
(Goodridge, et al., 2011).  Specifically, particulate β-glucan promotes the clustering of dectin-1 
receptors, thereby excluding the regulatory tyrosine phosphatases CD45 and CD148 from sites of 
β-glucan contact, and allowing productive signaling of Src family and Syk kinases (Goodridge et 
al., 2011).  We observed that intraocular injection of soluble β-glucan (WGP-S) promotes optic 
nerve regeneration, suggesting that formation of a phagocytic synapse may not be necessary for 
dectin-1-mediated regeneration, and perhaps is only needed for recruitment of pro-inflammatory 
factors that mediate a classical/toxic immune response.   
Separating immune-mediated regeneration from toxicity at the receptor level may not be 
possible.  Unraveling the molecular mechanism downstream of dectin-1 will likely be necessary 
to fully understand the diverse effects of dectin-1 activation.  Our data show that curdlan-induced 
regeneration correlates with increased phosphorylation of ERK and CREB in a dectin-1-
dependent manner.  As discussed in Chapter III, follow-up studies are needed to determine 
whether activation of ERK and CREB in immune cells in the eye is necessary to promote 
regeneration.  If blocking ERK or CREB activation inhibits curdlan-induced regeneration, but 
not curdlan-induced retinal pathology, this would suggest that alternative pathways downstream 
of dectin-1 are responsible for the toxicity aspect, making ERK and CREB key targets for 
therapeutic strategies.  However, if blocking ERK or CREB inhibits both regeneration and 
toxicity, then we will need to probe deeper.  Activation of dectin-1 or ERK/CREB signaling in 
different subtypes of myeloid cells could also have different outcomes.  Given the heterogeneity 
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of immune cells that infiltrate the eye, assessing the relative contribution of ERK/CREB 
signaling in different cell types in vivo will be difficult. 
Ultimately, uncoupling immune-mediated regeneration may not be possible until much 
further downstream.  Phosphorylated CREB translocates to the nucleus where it participates in 
regulation of gene transcription (Yamamoto et al., 1988).  Downstream of dectin-1, CREB 
promotes transcription of IL-10 (Elcombe et al., 2013), a cytokine involved in “M2” type 
macrophage polarization (Martinez et al., 2008).  One hypothesis for how innate immunity leads 
to regenerative growth of RGCs is that activation of ERK/CREB signaling pathways in immune 
cells promotes transcription of cytokines and other growth factors, which are then released by 
immune cells into the vitreous of the eye.  Zymosan and curdlan may stimulate immune cells to 
produce a whole cocktail of factors, some required for promoting regeneration, and others 
required for retinal detachment and buckling.  Identifying these factors may be a daunting task, 
but if accomplished, a specific mixture of factors could be applied post injury to promote 
regenerative growth with minimal side effects. 
 
4.2  Bridging the Gap Between Inflammation and Regeneration 
 How does β-glucan/dectin-1 signaling in immune cells result in regenerative growth and 
survival of injured RGCs?  Because dectin-1 expression is not observed on RGCs, curdlan and 
zymosan-induced neuroprotection and axonal regeneration must occur through a non-cell-
autonomous mechanism.  As mentioned above, one hypothesis involves CREB-mediated 
regulation of gene transcription.  Ligation of β-glucan with dectin-1 on immune cells may result 
in a CREB-dependent increase in transcription of a specific set of cytokines and growth 
promoting factors.  These factors could help with recruiting additional types of immune cells that 
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promote regeneration, communicate with other retina-resident cells such as astrocytes, or engage 
directly with RGCs.  A few factors that mediate the beneficial aspects of inflammatory 
stimulation have already been identified, including ciliary neurotrophic factor (CNTF), leukemia 
inhibitory factor (LIF), and IL-6 (Leibinger et al., 2009, Leibinger et al., 2013b).  Follow lens 
injury, CNTF is secreted by retinal astrocytes, and contributes to RGC axon regeneration 
(Leibinger et al., 2009).  How lens injury leads to induction of CNTF expression by astrocytes is 
not known.  CNTF-mediated regeneration requires neuronal activation of STAT3 (Leibinger et 
al., 2013a), providing a link to neuron intrinsic growth programs.  Additionally, viral 
overexpression of CNTF in RGCs promotes regenerative growth, but is hampered by aberrant 
sprouting and axonal misguidance (Pernet et al., 2013).    
Several tools are currently available that allow for unbiased analysis of gene expression  
and protein content in the eyes of mice following optic nerve crush injury and i.o. injection of 
inflammatory compounds.  RNA sequencing (RNAseq) is a powerful and sensitive tool for 
quantitative analysis of RNA (mRNAs, miRNAs, lncRNAs) expression.   Additionally, RiboTag 
mice can be used to identify ribosome-associated mRNAs that are actively being transcribed 
(Sanz et al., 2009).  Proteomic analysis of the vitreous of the eye will allow for identification of 
secreted proteins, including cytokines, chemokines, and growth factors.  The dissociation of 
regeneration and inflammation in dectin-1/TLR2 compound mutant mice provides an excellent 
opportunity to identify critical players in immune-mediated regeneration.  Any mRNA or protein 
that is similarly expressed in the eyes of WT and dectin-1/TLR2 mice following i.o. zymosan is 
likely not sufficient to drive regenerative growth.  To further narrow down a list of candidates, 
we can compare additional positive and negative controls.  For example, we can exclude mRNAs 
and proteins that are similarly expressed in WT eyes injected with LPS.  Candidates from this 
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further refined list that show similar expression in curdlan-injected and zymosan-injected eyes 
will be top candidates for linking neuroinflammation with regenerative growth of RGCs.   
Does immune-mediated regeneration ultimately tie into the signaling pathways in RGCs 
that have been shown to promote CNS regeneration?  Combining PTEN deletion with i.o. 
injection of zymosan further enhances regenerative growth (de Lima et al., 2012), suggesting that 
these two methods involve different signaling pathways.  Still, there may be some amount of 
overlap, as one study found that blocking mTOR activity reduced the lengthy regeneration 
achieved with an inflammatory stimulus (Leibinger et al., 2012).  As discussed above, CNTF-
mediated regeneration requires neuronal activation of STAT3.  Work from Zhigang He’s 
laboratory has shown that deletion of SOCS3, an inhibitor of STAT3, promotes robust 
regeneration in the mouse optic nerve (Sun et al., 2011).  Whether CNTF activates STAT3 
through suppression of SOCS3 is unknown.  As discussed in Chapter 3, osteopontin (OPN) is 
another potential link between innate immunity and neuron intrinsic signaling pathways.  OPN 
stimulates mTOR activity, and regenerating αRGCs express high levels of mTOR and OPN 
(Duan et al., 2015).  In immune cells, OPN functions downstream of dectin-1 and TLR2 to 
promote cytokine production, and may be involved in zymosan-mediated activation of ERK 
(Inoue et al., 2011).  Whether OPN may be a molecular link between the two most robust 
paradigms for eliciting optic nerve regeneration (PTEN deletion, and immune-mediated 
regeneration) will be interesting to explore.  
 
4.3  What role do microglia play in the injured optic nerve? 
 Results from studies with bone marrow chimeric mice indicate that dectin-1 expression 
on radioresistent retina-resident cells, which includes microglia, is necessary for curdlan-induced 
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regeneration in the mouse optic nerve.  The role that microglia play in immune-mediated 
neuronal regeneration is unclear.  In the retina, microglia may produce cytokines or growth 
factors that stimulate growth programs in injured RGCs and support RGC survival.  Our studies 
in bone marrow chimeric mice revealed that dectin-1 expression on microglia is not necessary 
for recruitment of blood-derived immune cells into the eye.  However, this does not rule out the 
possibility that the composition of blood-derived immune cells is altered when dectin-1 
expression on retina-resident immune cells is lost. Dectin-1-expressing microglia may help to 
recruit specific subtypes of immune cells that are necessary for a robust regenerative response. 
 Growing evidence suggests that microglia assume distinct phenotypes with different 
degrees of pro- or anti-inflammatory functions (Orihuela et al., 2015), similar to the idea of 
macrophage polarization.  Following optic nerve crush injury, there is a large number of dectin-
1+ microglia in the optic nerve.  Could certain types of inflammatory stimulation improve the 
ability of microglia to phagocytose and clear myelin debris?  Improved clearance of myelin 
debris could decrease myelin-mediated growth inhibition, and allow space for newly 
regenerating axons.  Additionally, the possibility that microglia could interfere with the 
formation or integrity of the glial scar has not been examined.  Since zymosan leads to further 
enhanced regeneration upon deletion of multiple CSPG receptors, this possibility seems unlikely 
(Dickendesher et al., 2012).  As new tools for microglia manipulation become available, we will 
be able to explore these ideas and improve our understanding of the role of microglia in immune-
mediated regeneration. 
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4.4  The Long and Winding Road to Functional Recovery 
Functional recovery of damaged CNS tissue requires several steps.  First and foremost, 
there must be regenerative growth of injured axons, whether through stimulation of intrinsic 
growth potential, blockade on extrinsic inhibitory cues, or a combination of both.  Second, this 
regenerative growth must be accompanied with guidance cues to direct growing axons to their 
proper targets, and prevent them from forming improper or excessive connections.  Third, for 
any regenerative growth to have functional relevance, axons that reach their targets must form 
functional synapses. Finally, remyelination of regenerated axons is needed for rapid firing of 
electrical impulses and metabolic support of axons. All of these steps must be accomplished in 
an environment that potently inhibits aberrant growth and sprouting.   
Activation of specific immunomodulatory pathways has proven a successful method for 
stimulating robust axon regeneration after injury to the rodent CNS.  Combining immune-
mediated regeneration with activation of neuron intrinsic pathways or neutralization of inhibitory 
ligands leads to a further enhancement of regenerative growth.  In the mouse optic nerve, robust 
regeneration into optic chiasm is achieved by the combined deletion of PTEN and SOCS3 (Sun 
et al., 2011).  Once at the chiasm, however, many regenerating axons seem to get lost. A portion 
of regenerating axons make a u-turn and begin to grow into the contralateral (uninjured) nerve.  
This aberrant path-finding could be due to the absence of embryonic guidance cues that would 
normally guide growing axons to their appropriate targets.   
  Manipulation of CNS regeneration inhibitors, such as MAIs, CSPGs, and their 
receptors, is not as effective as other strategies for promoting regenerative growth in the initial 
steps towards CNS repair.  However, these molecules may have a bigger impact in combinatorial 
treatments, or at the later stages of repair, including network refinement, proper target finding, 
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and formation of functional synapses.  In fact, many CNS regeneration inhibitors play important 
physiological roles in the development, refinement, and maintenance of synaptic connections in 
the healthy brain.  The Nogo receptor family members NgR1, NgR2, and NgR3 restrict 
synaptogenesis in the juvenile mouse brain (Wills et al., 2012).  NgR1 and Nogo, along with 
CSPGs, contribute to the closure of the critical period in the developing rodent visual system 
(Pizzorusso et al., 2002, McGee et al., 2005).  NogoA, OMgp, NgR1, and CSPGs, have all been 
show to negatively regulate activity-dependent synaptic plasticity (Lee et al., 2008, Raiker et al., 
2010, Mironova and Giger, 2013).  The important function of CNS inhibitory molecules in brain 
development and plasticity raises important considerations for therapeutic strategies designed to 
promote neural regeneration following injury.  The acquisition of a large number of ligand-
receptor systems that restrict neural network plasticity may have been a prerequisite that enabled 
the evolution of larger and more powerful neural networks. Following injury to the adult CNS, 
molecules that restrict aberrant growth and plasticity may be detrimental since they limit 
attempts to modify or rebuild nearby networks to compensate for lost neural circuits.  
Manipulating these molecules to promote neurorepair could affect the integrity of intact neural 
networks. Thus, an understanding of the physiological role of these molecules in the uninjured 
CNS is of great interest both biologically and clinically. 
 The optic nerve crush injury model is an excellent tool for studying CNS regeneration in 
vivo.  In humans, however, injury to the optic nerve is much less common than spinal cord injury 
(SCI), or other damaging insults to the CNS, such as stroke.  Therefore, successful methods for 
promoting regeneration in the optic nerve need to be assessed for their ability to promote 
regeneration and repair in the injured brain and spinal cord.  While injured axons in the mouse 
optic nerve can successfully regenerate up to several millimeters, injured axons in the spinal cord 
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need to travel significantly longer distances.  With multiple ascending and descending fiber 
tracts, the spinal cord is much more complex than the optic nerve.  There is evidence that 
immune-mediated repair mechanisms can successfully promote spinal cord regeneration under 
certain conditions. Intraspinal or dorsal root ganglion (DRG) injection of zymosan activates 
macrophages, and promotes transient growth of injured ascending sensory axons with concurrent 
toxicity (Gensel et al., 2009).  A conditioning injury to the peripheral branch of DRG sensory 
neurons promotes regeneration of the central branch of DRG neurons that form the dorsal 
columns in the spinal cord.  Conditioning injury is associated with macrophage accumulation 
near DRG cell bodies, which may play a vital role in regeneration of the central branch of DRG 
neurons (Kwon et al., 2013).  Additional studies are needed to determine the whether β-
glucan/dectin-1-mediated neuroinflammation is capable of promoting spinal cord axon 
regeneration.  Concurrent toxicity must also be evaluated, and must be minimized to make 
immune-mediated regeneration a viable therapeutic option.   
We are still many years away from achieving robust functional recovery of injured CNS 
networks in humans.  Many challenges lies ahead, but regenerative growth of severed axons is a 
prerequisite for studying the later stages of CNS repair, such as target finding, synapse 
formation, and remyelination.  My dissertation work demonstrates that post-injury manipulation 
of specific immunomodulatory pathways promotes extensive growth of injured RGC axons. 
These findings have broad implications for understanding the elaborate cross-talk that occurs 
between the nervous system and the immune system, and how these pathways can be exploited 
to promote repair following CNS injury or disease. 
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Appendix: 
 
Does NogoA regulate homeostatic synaptic plasticity? 
 
 
A.1 Abstract 
Plasticity of synaptic connections in the brain is critical for learning, memory formation, 
and cognitive function.  Activity-dependent modifications in synaptic strength occur at 
individual synapses, and are balanced by homeostatic scaling mechanisms that maintain network 
stability while preserving relative changes in synaptic strength.  Several molecular links between 
Hebbian forms of synaptic plasticity and homeostatic plasticity have been identified, but the 
mechanism of how these two distinct forms of neuronal plasticity interact at the molecular level 
remains poorly understood.  NogoA is a membrane-associated reticulon protein that negatively 
regulates activity-dependent strengthening of synaptic transmission.  In this study, we examined 
whether NogoA plays a concurrent role in homeostatic plasticity.  Prolonged changes in network 
activity lead to down-regulation (TTX) or up-regulation (Bic) of Nogo-A surface levels.  The 
observed bidirectional changes in NogoA on the cell surface shows activity-dependent regulation 
of Nogo-A.  Knockdown of NogoA drastically reduces expression levels of the AMPA receptor 
subunit GluA1, and the mTORC1 target S6K.  Furthermore, loss of NogoA attenuates 
homeostatic scaling up of surface GluA1 in TTX-treated hippocampal cultures.  Collectively, 
these results suggest that NogoA serves as a point of molecular overlap between Hebbian and 
homeostatic plasticity.  Additional studies are needed to determine the molecular mechanisms of 
NogoA-mediated regulation of GluA1 expression and homeostatic scaling. 
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A.2 Introduction 
Synaptic transmission occurs at excitatory (glutamatergic) and inhibitory (GABAergic) 
synaptic connections in the brain.  Individual neurons possess finely tuned mechanisms to sense 
and respond to changes in network activity, while maintaining a proper balance between 
excitation and inhibition.  Synapses have the ability to alter their strength in response to various 
stimuli, a process known as functional synaptic plasticity.  Activity-dependent, or Hebbian, 
forms of synaptic plasticity, including long-term potentiation (LTP) and long-term depression 
(LTD) of synaptic transmission, alter the relative strength of individual excitatory synapses 
(Malenka and Bear, 2004).  These activity-dependent changes in synaptic strength are thought to 
form the cellular basis of learning and memory (Siegelbaum and Kandel, 1991).  Another form 
of synaptic plasticity, homeostatic scaling, alters the strength of many synaptic connections 
proportionally and in a uniform direction, protecting relative changes in synaptic strength 
(Turrigiano et al., 1998).  Homeostatic scaling functions to maintain neuron firing rates in a 
stable range, despite concurrent activity-dependent changes at individual synapses and chronic 
changes in network activity.  Homeostatic scaling also occurs at individual synapses (Beique et 
al., 2011), and global and local plasticity occur simultaneously.  How do these different forms of 
neuronal plasticity interact to maintain network stability while preserving newly encoded 
alterations in synaptic strength? 
Growing evidence indicates that Hebbian and homeostatic plasticity interact at the 
molecular level, but the underlying mechanisms remain incompletely understood.  To alter 
synaptic strength, LTP, LTD, and homeostatic scaling all involve regulation of the abundance of 
AMPA-type glutamate receptors (AMPARs) in the postsynaptic membrane.  Elegant work from 
the Huganir laboratory showed that homeostatic scaling induces PKA-mediated changes in 
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phosphorylation of the AMPAR subunit GluA1, interfering with the ability of cortical neurons to 
express LTP (Diering et al., 2014).  In addition to AMPARs, several other molecules have 
important roles in both Hebbian and homeostatic plasticity.  In the rat visual cortex, brain-
derived neurotrophic factor (BDNF) enhances LTP and blocks LTD (Akaneya et al., 1996, 
Akaneya et al., 1997).   BDNF also plays a critical role in homeostatic plasticity, mediating the 
effects of chronic activity blockade on the amplitude of miniature excitatory post-synaptic 
currents (mEPSCs) (Rutherford et al., 1998).   Activation of mTOR complex 1 (mTORC1)-
dependent local protein synthesis is critical for certain forms of late-LTP (Tang et al., 2002), and 
contributes to homeostatic regulation of synaptic function (Henry et al., 2012, Bateup et al., 
2013).  Collectively, these findings suggest that common molecular targets regulate the 
interaction of Hebbian and homeostatic plasticity.  
NogoA is a membrane-associated protein that belongs to the reticulon family, and was 
originally identified as a myelin-associated inhibitor of CNS axon regeneration (Huber and 
Schwab, 2000).  NogoA is expressed in neurons, present in synaptic density fractions (Lee et al., 
2008), and well-established as a negative regulator of activity-dependent synaptic strength 
(Raiker et al., 2010, Delekate et al., 2011, Kempf et al., 2014).  NogoA restricts LTP at CA3-
CA1 synapses in acute hippocampal slices through at least two different inhibitory domains, 
Nogo-66 and NogoΔ20 (Raiker et al., 2010, Kempf et al., 2014).  The molecular mechanisms 
utilized by NogoA to restrict synaptic strength are not fully understood, though work from our 
laboratory has shown that acute treatment of Nogo66 suppresses LTP in a NgR1-dependent 
manner.  Furthermore, Nogo66 attenuates BDNF-mediated activation of mTORC1 signaling in 
cultured hippocampal neurons (Raiker et al., 2010).  Chronic depletion of NogoA is associated 
with cognitive impairment and brain disorders, such as schizophrenia (Willi et al., 2010, Petrasek 
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et al., 2014a, Petrasek et al., 2014b)  Whether NogoA is regulated by chronic changes in 
neuronal activity, or whether NogoA plays a role in the regulation of homeostatic plasticity is not 
known.  Here I investigate the role of NogoA in homeostatic synaptic scaling.  
 
A.3 Results 
Surface NogoA levels are regulated by chronic changes in neuronal activity  
 Chronic manipulations to neuronal activity lead to compensatory changes in expression 
of synaptic proteins (O'Brien et al., 1998, Ehlers, 2003).  Treatment with tetrodotoxin (TTX), a 
voltage-gated sodium channel blocker, silences neuronal activity, thereby inducing homeostatic 
scaling up of surface levels of AMPAR subunits GluA1 and GluA2.  Conversely, treatment with 
the GABAA receptor antagonist bicuculline causes chronic hyperactivity and a compensatory 
scaling down of surface GluA1 and GluA2 levels (Shepherd et al., 2006).  NogoA restricts 
activity-dependent synaptic plasticity (Raiker et al., 2010), therefore chronic changes in neuronal 
activity could induce homeostatic changes in NogoA expression as a compensatory mechanism 
to aid in promoting or restricting synaptic activity.  To examine whether NogoA expression is 
regulated by chronic manipulations to neuronal activity, we treated rat primary hippocampal 
neurons for 24 or 48 hours with TTX (2µM) or bicuculline (40µM).  Immunolabeling of cell 
surface proteins in primary hippocampal neurons treated with TTX revealed a global increase in 
the surface expression of GluA1, and a decrease of surface NogoA (Figure A.1a).  To more 
accurately assess changes in surface protein levels, we performed cell surface biotinylation 
followed by streptavidin pull-down and Western blot analysis.  Following 24hr TTX treatment, 
we observed a significant reduction of Nogo-A from the cell surface (p = 0.0299) while surface 
levels of GluA1 were significantly increased (Figure A.1b,c).  Bicuculline treatment trended 
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towards increasing NogoA surface levels (p = 0.2936), while decreasing GluA1 surface levels 
(Figure A.1b,c).  Total levels of NogoA were not affected by these manipulations (Figure 
A.1c).  These findings demonstrate that surface levels of NogoA are regulated by chronic 
changes in network activity, and are consistent with a role for NogoA as a negative regulator of 
synaptic activity. 
 
Loss of NogoA reduces expression of GluA1, GluA2, and S6K 
To determine whether manipulations to NogoA protein expression regulate neuronal 
activity, we treated primary hippocampal cultures at 10 days in vitro (10 DIV) with a lentiviral 
vector  (LV) containing a shRNA directed against NogoA (LV-shNogoA) or an empty vector 
control (LV-control).  At 17 DIV, LV-treated cultures were lysed and analyzed by Western 
blotting.  In LV-shNogoA treated cultures, Nogo-A protein levels were significantly reduced 
(<3% of control levels).  Knockdown of NogoA dramatically reduced total protein levels of the 
AMPA receptor subunits GluA1 and GluA2, but not of the NMDA receptor subunit GluN2B 
(Figure A.2a,b). Levels of PSD95 were unchanged (Figure A.2a,b), suggesting that the 
decrease in AMPAR subunit expression was not due to a reduction in synaptic number or the 
size of post-synaptic densities.  We also observed a significant reduction in levels of total and 
phosphorylated S6K, a substrate of active mTOR complex 1 (mTORC1) (Figure A.2a,b).  To 
verify that changes in protein abundance were not due to off-target effects of the NogoA shRNA, 
we transduced neurons with LVs containing 3 different NogoA shRNA constructs.  Two of the 
three additional constructs tested successfully knocked down NogoA, and lead to a decrease in 
GluA1 and S6K protein levels, indicating that these changes in protein expression are not due to 
off-target effects (Figure A.2c).  
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NogoA regulates AMPAR protein expression independently of known receptors   
NogoA restricts activity-dependent synaptic plasticity through at least two separate 
domains, Nogo-66 and NogoΔ20 (Raiker et al., 2010, Delekate et al., 2011, Kempf et al., 2014).  
Nogo-66 negatively regulates activity-dependent synaptic plasticity through NgR1, and to a 
lesser extent, through PirB (Raiker et al., 2010).  To determine whether NogoA-mediated 
regulation of GluA1 protein levels depends on either of these receptors, we repeated NogoA 
knockdown experiments in mouse hippocampal cultures from mice lacking NgR1 and PirB, as 
well as mice lacking all three Nogo receptors, NgR1, NgR2, and NgR3.  Both NgR1/PirB and 
NgR1/NgR2/NgR3 knockout cultures transduced with LV-shNogoA showed a reduction in 
expression of GluA1, GluA2, and pS6K, comparable to that of WT cultures transduced with LV-
shNogoA.   This finding demonstrates that NgR1 and PirB are not involved in NogoA-mediated 
regulation of GluA1, GluA2, and pS6K (Figure A.2d).  NogoΔ20 was shown to restrict 
hippocampal LTP through Sphingosine 1 phosphate receptor 2 (S1PR2) (Kempf et al., 2014).  
Treatment of hippocampal cultures with 5µM JTE-013, and inhibitor of S1PR2, for 24 or 48 
hours did not alter surface GluA1 expression (Figure A.2e,f).  Additional studies may be needed 
to definitively exclude a role for S1PR2. 
 
NogoA regulates GluA1 expression and synaptic transmission in a cell-autonomous manner  
 In addition to a reduction in total GluA1 protein levels, surface expression of GluA1 is 
substantially reduced following NogoA knockdown (Figure A.3a,b).  To determine whether 
changes in surface GluA1 expression reflect physiological changes in synaptic transmission, we 
recorded mini excitatory post-synaptic currents (mEPSCs) from hippocampal neurons 
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transfected with a pSuperior-neo-GFP plasmid containing NogoA shRNA or control shRNA.  
LV treatment of cultured hippocampal neurons adversely affected whole cell patch clamp 
recordings independently of the transgene carried by the LV particle, therefore we utilized a 
Calcium Phosphate (CalPhos) transfection protocol to achieve NogoA knockdown in a small 
percentage (<1%) of cells.  Transfected cells were visualized by GFP expression. Using single 
cell recording from transfected pyramidal neurons,  we analyzed frequency and amplitude of 
mEPSCs.  Loss of NogoA did not alter mEPSC frequency (Figure A.3d).  In accordance with 
our biochemical data, loss of NogoA significantly reduced mEPSC amplitude (Figure A.3e).  
Importantly, because of the sparse transfection efficiency achieved with the CalPhos protocol, 
this finding indicates that NogoA regulates mEPSC amplitude in a cell-autonomous manner. 
This result also suggests that NogoA regulates expression of GluA1 cell autonomously. 
 
NogoA knockdown attenuates TTX-mediated increase in surface GluA1 
 Because loss of NogoA results in decreased GluA1 expression and a scaling down of 
mEPSC amplitude, we hypothesized that NogoA is involved in regulation of homeostatic 
synaptic scaling.  To test whether NogoA is required for upregulation of surface GluA1, we 
treated primary hippocampal cultures with LV-shNogoA or LV-control at 10 DIV, followed by 
24 hour TTX treatment at 16 DIV, and cell surface biotinylation at 17 DIV.  As expected, 
treatment of LV-control neurons with TTX scaled up surface GluA1 levels, and LV-shNogoA 
cultures had significantly reduced surface GluA1 levels (Figure A.4).  Interestingly, TTX 
treatment of LV-shNogoA cultures did not significantly increase surface levels of GluA1(Figure 
A.4).  These results indicate that loss of NogoA attenuates TTX-mediated scaling up of 
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chronically inactive neurons, and suggests that NogoA may play an important role in 
homeostatic scaling mechanisms that increase synaptic strength. 
 
Loss of NogoA selectively impairs BDNF signaling 
 Loss of NogoA could render neurons incapable of responding to subsequent changes in 
activity by adversely affecting their health or metabolism, which could account for their inability 
to scale in response to TTX treatment.  To rule out this possibility, we assessed the response of 
LV-shNogoA cultures to acute treatment with BDNF.  We have previously shown that treating 
primary neurons with BDNF (100ng/ml) for 30 minutes drastically increases phosphorylation of 
several key signaling molecules, including ERK, AKT (Ser473), and S6K (Raiker et al., 2010).  
As expected, treatment of LV-control transduced neuronal cultures with BDNF for 30 minutes 
prior to lysis strongly increased phosphorylation of ERK, AKT, and S6K (Figure A.5).  In LV-
shNogoA transduced cultures, BDNF increased levels of pERK and pAKT, but failed to affect 
pS6K levels (Figure A.5).  These results show that loss of NogoA selectively impairs the 
sensitivity of neurons to BDNF-mediated regulation of S6K phosphorylation, while leaving ERK 
and AKT singling pathways unaffected.  
 
NogoA knockdown does not impair bicuculline-mediated increase in Arc protein levels 
 Arc is an immediate early gene that is rapidly induced by increases in neuronal activity 
(Lyford et al., 1995).  Arc plays a critical role in mediating homeostatic plasticity, aiding in 
removal of AMPARs from the cell surface (Shepherd et al., 2006).   Following bicuculline 
treatment, Arc nuclear expression increases to suppress transcription of GluA1 (Korb et al., 
2013).  To assess whether activity-mediated induction of Arc expression was perturbed in LV-
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shNogoA neurons, we examined Arc expression levels following acute treatment with 
bicuculline for 4hrs.  Cultures were lysed with RIPA buffer to ensure that the nuclear membrane 
was disrupted.  In both LV-control and LV-shNogoA transduced neuronal cultures, bicuculline 
induced a robust increase in Arc expression (Figure A.6), indicating that loss of NogoA does not 
affect activity-induced Arc expression.    
 
Enhancing mTORC1 activity does not rescue expression of GluA1 or S6K in LV-shNogoA 
neurons 
 One explanation for the blockade of BDNF-mediated S6K phosphorylation in LV-
shNogoA neurons could be the increased activity of signaling pathways that inhibit mTORC1.  
Tuberous sclerosis 2 (TSC2) is an upstream inhibitor of mTORC1 (Tee et al., 2002).  In complex 
with TSC1, TSC2 functions as a GTPase activating protein (GAP) for the small GTPase Rheb  
(Inoki et al., 2003, Tee et al., 2003).  GTP-bound Rheb activates mTORC1; thus, by stimulating 
conversion of GTP-Rheb to GDP-Rheb, TSC2 functions to block activation of mTORC1.  A 
recent study from the Sabatini laboratory found that loss of TSC1/TSC2 lead to chronically high 
mTORC1 activity and hyperexcitability in hippocampal neurons, resulting in homeostatic scaling 
down of AMPAR surfaces levels, including GluA1 and GluA2, and reduced mEPSC amplitude 
(Bateup et al., 2013).  We examined whether loss of TSC1/TSC2 expression could rescue levels 
of pS6K in LV-shNogoA neurons by combining knockdown of TSC1 and NogoA.   
Treatment of primary hippocampal neurons from TSC1f/f mice with an LV containing a 
GFP-IRES-Cre construct under the control of a synapsin promoter (LV-synGFPCre) successfully 
knocked down TSC1, leading to simultaneous destabilization and depletion of TSC2 protein 
levels (Figure A.7a).  As a control, TSC1f/f  neurons were treated with LV-synGFP.  Similar to 
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previously published results, knockdown of TSC1 increased phosphorylation of the mTORC1 
targets S6K and 4EBP1, and decreased total GluA1 expression (Figure A.7a) (Bateup et al., 
2013).  In the same cultures we observed an increase in expression of the GABA synthesizing 
enzyme GAD67, indicative of a scaling up of inhibitory transmission in response to 
hyperactivity.  The combined loss of NogoA and TSC1 yielded GluA1 and pS6K levels similar 
to that of NogoA knockdown alone, suggesting that TSC1/TSC2 is not required for NogoA-
mediated decrease in GluA1, S6K, or pS6K levels (Figure A.7b,d).  However, the combined 
knockdown of TSC1 and NogoA did decrease total S6K protein levels to a further extent than 
NogoA knockdown alone.  While the absolute levels of pS6K were not different between these 
two conditions, there was a net increase in S6K phosphorylation when normalized to total S6K 
levels (Figure A.7c).  Levels of 4EBP1 and p4EBP1 were unchanged between NogoA and 
NogoA/TSC1 knockdown cultures.  Interestingly, preliminary evidence suggests that NogoA 
knockdown attenuates the increase in GAD67 observed in TSC1 knockdown neurons (Figure 
A.7a).  This finding suggests that NogoA may be involved in regulating GABAergic inhibitory 
synaptic transmission. 
 
Loss of NogoA alters gene transcription 
 Since activation of mTORC1 promotes translation of synaptic proteins (Takei et al., 
2004), the decreased levels of pS6K in LV-shNogoA transduced neuronal cultures could 
decrease translation of GluA1 and GluA2 mRNA.  To determine whether the decreased 
expression of GluA1 protein observed in LV-shNogoA neurons is due to decreased translation of 
GluA1 mRNA, or whether it is reflective of changes in gene transcription, we performed qPCR 
analysis of LV-shNogoA and LV-control transduced hippocampal cultures using RT2 Profiler 
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GABA/Glutamate PCR arrays from Qiagen. LV-shNogoA cultures displayed decreased levels of 
GluA1 mRNA levels in four separate experiments (Figure A.8a, Table A.1), suggesting that loss 
of NogoA leads to a reduction in GluA1 gene transcription. LV-shNogoA cultures also showed 
changes in the mRNA levels of other synaptic proteins, including decreases in GABAA receptor 
subunits β1 and β3, mGluR1, and Vgat (Figure A.8a, Table A.1).  We also used RT2 Profiler 
PCR Assays to analyze components of the mTOR signaling pathway.  Similar to the biochemical 
data, LV-shNogoA cultures showed a decrease in S6K mRNA (Figure A.8b, Table A.2).  
Interestingly, NogoA knockdown increased Rheb mRNA levels (Figure A.8b), possibly to 
compensate for decreased S6K activity.  NogoA knockdown also increased mRNA levels of 
RhoA (Figure A.8b), a protein involved in NogoA-mediated inhibition of neurite outgrowth 
(Niederost et al., 2002).  Collectively, qPCR analysis demonstrates that loss of NogoA results in 
changes in transcription of several genes involved in synaptic plasticity and mTOR signaling.  
Whether these changes occur directly as a result of loss of NogoA, or indirectly as a 
compensatory mechanism for other cellular changes caused by loss of NogoA, remains to be 
determined. 
 
Is the phosphorylation status of NogoA regulated by endogenous BDNF signaling? 
 Levels of BDNF expression play important roles in both activity-dependent and 
homeostatic plasticity, as discussed above. Primary hippocampal neurons prepared from E18 rat 
embryos include astrocytes and produce a certain amount of endogenous BDNF (Lang et al., 
2007).  An exogenously applied fragment of NogoA (called Nogo66) attenuates BDNF-mediated 
activation of mTORC1 signaling (Raiker et al., 2010), yet loss of NogoA impairs BDNF/S6K 
sensitivity of cultured hippocampal neurons (Figure A.5).  Do BDNF and NogoA cross-talk with 
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one another under basal conditions?  At a low dose (200 nM), K252a specifically inhibits 
activation of trk receptor kinases (Tapley et al., 1992).  The prominent ligand-receptor system in 
hippocampal cultures is the BDNF receptor trkB interaction.  Upon treatment of hippocampal 
neurons with K252a for 2 hours, Western blot analysis of cell lysates revealed a small, but 
persistent downward shift in the molecular weight (MW) of NogoA (Figure A.9a,b).  Incubation 
of hippocampal cultures with lambda phosphatase produced an identical downward shift in the 
MW of NogoA that was not further shifted upon treatment with K252a (Figure A.9a). This 
suggests that NogoA is a phospho-protein.  Interestingly, 24hr treatment with K252a reduced 
surface levels of both NogoA and GluA1 (Figure A.9c). NogoA is ubiquitinated (Figure 
A.9d,g), but not sumoylated, under basal conditions (Figure A.9i,j).  The K252a-induced MW 
shift of NogoA was not due to de-ubiquitination of NogoA, as NogoA remained ubiquitinated in 
K252a-treated cultures (Figure A.9d).  As an independent approach to assess Nogo-A post-
translation modification (PTM), we used affinity purification from primary hippocampal neurons 
followed by Mass Spectrometry analysis.  We found that NogoA undergoes post-translational 
modification (phosphorylation) at several serine residues under basal conditions (Table A.3).  
Taken together, these results suggest that endogenous BDNF may regulate the phosphorylation 
status of NogoA.  Further experiments are necessary to determine whether NogoA 
phosphorylation has any functional consequence. 
 
Do changes in activity cause post-translation modification of NogoA? 
 In addition to the K252a-induced NogoA MW shift, we observed a striking separation of 
NogoA into two distinct bands following treatment with TTX (Figure A.9e).  Interestingly, 
treatment with AMPA (10µM, 1hr) produced a similar NogoA band separation (Figure A.9b).  
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Whether this band separation is indicative of NogoA PTM remains to be determined.  
Comparison of NogoA phosphorylation sites between untreated cultures and TTX-treated 
cultures did not reveal any differences (Table A.3, Table A.4), though mass spec analysis 
covered only 80% of the total NogoA protein sequence.  TTX-treatment did not increase NogoA 
ubiquitination (Figure A.9g), and NogoA was not observed to be sumoylated (Figure A.9i,j).  
Additional studies are needed to confirm the nature of this band separation, and whether it 
represents a functionally relevant modification to NogoA protein. 
 
NogoA overexpression is unsuccessful in neuronal cultures 
 Attempts to overexpress NogoA in cultured hippocampal neurons have thus far been 
unsuccessful. LV transduction of myc-tagged Human NogoA into HEK293T cells, which 
normally express very little NogoA, resulted in robust NogoA overexpression (Figure A.10a).  
Transduction of hippocampal neurons with the same LV did not increase expression of NogoA, 
though a low level of myc signal could be detected via Western blot (Figure A.10b).  Mutating 
several C-terminal lysine residues to alanine, in an attempt to block NogoA ubiquitination and 
degradation, also failed to enhance NogoA expression in neurons (Figure A.10b).  Do neurons 
possess mechanisms not present in HEK293T cells that actively repress excessive expression of 
NogoA?  If so, this would suggest that neurons tightly regulate total NogoA protein levels, and 
perhaps do not tolerate overexpression of NogoA. 
 
A.4 Discussion and Future Directions 
 The results presented here in the Appendix of my thesis constitute a large amount of data 
surrounding the physiological role of NogoA in cultured hippocampal neurons.  I have shown 
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that NogoA surface expression is regulated bidirectionally by chronic changes in network 
activity, and that loss of NogoA reduces GluA1 and S6K protein and mRNA levels.  
Furthermore, loss of NogoA attenuates TTX-mediated scaling up, and alters BDNF-sensitivity.  
Collectively, these findings suggest that NogoA may play an important role in homeostatic 
synaptic plasticity.  However, there are still many gaps in our knowledge, especially with regard 
to the underlying molecular mechanisms of how NogoA is involved in these processes.  
Additional studies will be necessary to complete this story.   
 
The restrictive role of NogoA in synaptic plasticity 
The role of NogoA as a negative regulator of activity-dependent synaptic plasticity is 
well-established (Raiker et al., 2010, Delekate et al., 2011, Kempf et al., 2014).   We observed 
that surface levels of NogoA are significantly decreased in response to chronic inactivity (Figure 
A.1b).  Could NogoA function as a molecular break for synaptic activity?  If so, then reducing 
NogoA surface levels would help facilitate synaptic upscaling in response to activity blockade.  
Furthermore, increasing NogoA surface levels in response to chronic hyperactivity would aid in 
scaling down of synaptic activity.  Following this logic, we should expect that decreasing surface 
NogoA would cause hyperactivity of neuronal networks, resulting in a compensatory scaling 
down of synaptic activity.  LV-shNogoA cultures displayed decreased expression of GluA1 and 
S6K (Figure A.2), and were impaired in their ability to scale up GluA1 levels following TTX 
treatment (Figure A.4).  Furthermore, loss of NogoA in individual neurons decreased mEPSC 
amplitude (Figure A.3).  Together, these findings suggest that NogoA regulates homeostatic 
plasticity by functioning as a molecular break on neuronal activity. 
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Does NogoA regulate inhibitory synaptic transmission? 
Knockdown of NogoA could activate or repress downstream signaling pathways that 
directly affect the transcription of GluA1.  Alternatively, loss of NogoA could result in 
hyperactivity or an imbalance between excitation and inhibition, leading to the induction of 
offsetting homeostatic scaling mechanisms that decrease GluA1 expression.  Some evidence 
exists for the latter possibility.  Treating acute hippocampal slices with pictrotoxin (PTX) to 
block GABAA receptor activity enhances LTP at WT CA3-CA1 synapses.  Antibody blockade of 
NogoA also enhances LTP, but is not further enhanced when combined with PTX treatment 
(Delekate et al., 2011), suggesting that NogoA may regulate inhibitory synaptic transmission. 
We observed that loss of TSC1 in primary hippocampal neurons increased levels of GAD67, but 
this increase was blocked with loss of NogoA (Figure A.7a).  This finding suggests that NogoA 
could be involved in promoting inhibitory synaptic transmission.  Perhaps loss of NogoA leads 
to decreased inhibitory synaptic transmission (similar to treatment with bicuculline or PTX), 
resulting in over-excitation, and initiating homeostatic downscaling mechanisms.  RT-PCR 
analysis revealed that LV-shNogoA transduced cultures have decreased mRNA levels of the 
GABAA receptor subunits β1 and β3, and increased levels of GABAA receptor subunit ε (Figure 
A.8a, Table A.1).  Interestingly, a study of GABAA receptor subunit expression in human brain 
tissue revealed decreased expression of subunit β1 and increased expression of subunit ε in 
patients suffering from schizophrenia or major depression (Fatemi et al., 2013). 
An important follow-up experiment for our studies is to examine the combined effect of 
NogoA knockdown and bicuculline treatment.  Based on our preliminary results, NogoA 
knockdown should occlude bicuculline-mediated scaling down of surface GluA1.  This would 
provide further evidence for a role of NogoA in regulating inhibitory synaptic transmission.  RT-
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PCR results should be confirmed at the protein level, by examining GABAA receptor expression 
via Western blot.  We can also record mIPSCs from neurons following NogoA knockdown, to 
determine whether NogoA regulates inhibitory synaptic transmission in a cell autonomous 
manner.  To determine whether NogoA regulates global network activity, LV-shNogoA and LV-
control transduced cultures can be examined via multi-electrode array (MEA) recordings.   
 
Differential effects of acute vs. chronic manipulation of NogoA expression 
The slow and gradual nature of the LV-mediated shRNA knockdown makes it difficult to 
observe early cellular events that result from NogoA knockdown.  A reduction in NogoA protein 
levels is not observed until 72hrs after transduction with LV-shNogoA (Figure A.11).  A much 
larger decrease in NogoA expression is observed at 7 days after transduction.  GluA1 expression 
gradually decreases with NogoA knockdown.  Perhaps acute antibody blockade of NogoA would 
be more useful in observing the more immediate effects of NogoA knockdown on GluA1 
expression and synaptic transmission.  One study observed that depletion of NogoA with  a 
mixture of siRNAs lead to an increase in GluA1 expression in cultured hippocampal neurons in 
an mTORC1-dependent manner (Peng et al., 2011).  The mixture of siRNAs used in this study 
has not been validated for off-target effects, but if these results are real, perhaps the more rapid 
knockdown achieved with siRNA transfection produces an initial increase in mTORC1 activity.  
Given our previous finding that acute Nogo-66 treatment blocks BDNF-mediated increase in 
pS6K levels (Raiker et al., 2010), acute depletion of NogoA may have the opposite effect. 
 
Does NogoA cross-talk with other master regulators of synaptic plasticity? 
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 As discussed above, Arc is a critical regulator of synaptic homeostasis.  Arc is 
dynamically regulated by changes in activity; bicuculline treatment increases Arc expression, 
while TTX treatment reduces Arc expression (Shepherd et al., 2006).  Arc overexpression blocks 
homeostatic scaling up induced by chronic inactivity, while Arc knockout neurons display 
increased surface expression of AMPARs, similar to TTX-treated neurons (Shepherd et al., 
2006).  In addition to its established role in removal of AMPARs from the cell surface, Arc was 
more recently shown to play an important role in the nucleus, decreasing transcription of GluA1 
following treatment with bicuculline (Korb et al., 2013).  Is Arc responsible for the decreased 
GluA1 transcription observed in LV-shNogoA cultures?  While we did not observe global 
changes in Arc expression in LV-shNogoA cultures (Figure A.6), perhaps Arc nuclear 
localization or transcriptional activity is altered in some manner that is not visible by Western 
blot analysis of whole cell lysates. Initial attempts to knockdown Arc expression using LV-
shRNAs were unsuccessful, so we need to find alternate constructs to deplete Arc expression, or 
utilize Arc knockout neurons to determine whether Arc expression is required to decrease 
transcription of GluA1 in LV-shNogoA cultures. 
 Multiple lines of evidence suggest that NogoA and BDNF participate in some sort of 
cross-talk, but the mechanisms are unclear.  Acute treatment with Nogo66 blocks BDNF-
mediated activation of S6K (Raiker et al., 2010), while loss of NogoA expression selectively 
impairs BDNF-mediated activation of S6K in primary hippocampal neurons (Figure A.5).  
Endogenous BDNF may regulate the phosphorylation state of NogoA.  K252a blocks BDNF 
signaling, and causes a NogoA MW shift that is mimicked by treatment with lambda 
phosphatase (Figure A.9a).  Furthermore, long term (24hr) treatment with K252a reduces 
surface expression of both GluA1 and NogoA (Figure A.9c).  Does NogoA act as a sensor of 
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endogenous BDNF levels?  Is NogoA phosphorylation functionally significant?  To establish that 
BDNF signaling through TrkB drives phosphorylation of NogoA, we can treat cultured 
hippocampal neurons with a soluble TrkB-IgG fusion protein to block endogenous BDNF 
signaling. If successful,  this would also rule out the possibility of a K252a off-target effect.  To 
determine whether K252a truly affects the phosphorylation state of NogoA, we can utilize mass 
spec analysis of NogoA PTM.  NogoA phosphopeptides that are not detected in K252a treated 
cultures will be good candidates for sites that are regulated by BDNF/K252a.  Depending on the 
nature of the phosphorylation site that are identified, we may be able to predict specific kinases 
and/or phosphatases that regulate phosphorylation at these residues. 
 
Concluding Remarks 
 Hebbian and homeostatic forms of synaptic plasticity occur simultaneously to maintain 
balanced network activity, while allowing for activity-dependent modifications in synaptic 
strength.  Proteins such as GluA1, BDNF, and Arc serve as molecular points of contact between 
these two distinct forms of plasticity.  However, our understanding of the cellular and molecular 
mechanisms that enable this cross-talk is still incomplete.  NogoA is well-established as a 
negative regulator of activity-dependent synaptic plasticity.  In the current study, I have shown 
that NogoA is regulated by chronic changes in neuronal activity, and may participate in 
regulation of homeostatic plasticity.  Additional studies are necessary to determine the cellular 
and molecular nature of NogoA’s involvement in homeostatic plasticity.  Since NogoA restricts 
plasticity in the injured CNS, and has been associated with human brain disorders, such as 
schizophrenia, an intricate understanding of the physiological role of NogoA is of great interest 
both biologically and clinically. 
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A.5 Methods: 
 
Rat Primary Neuronal Culture:  Primary hippocampal and cortical neurons were obtained 
from rat embryos at E18.5  (time pregnant Sprague-Dawley rats, from Charles River).  For 
hippocampal cultures, care was taken to dissect out the entire hippocampus, including the dentate 
gyrus (DG) and CA1.  Dissected tissue was incubated at 37C for 5 minutes (hippocampal) or 10 
minutes (cortical) in L15 media containing 1x Trypsin/EDTA (0.05%) and DNaseI.  Following 
trypsin incubation, cells were washed twice in DMEM containing 10% FBS, then resuspended in 
1ml of neuronal growth medium (NGM:  Neurobasal, B27, Glutamax, Pen/Strep, Glucose) by 
pipetting up and down 20 times with a P1000 pipet .  Cells were pelleted by centrifugation at 800 
rpm for 4 minutes, then resuspended in 1mL of NGM, counted, and plated on PDL-coated plates 
or coverslips (PDL from Sigma #P7886, 100ug/ml in water).  For biochemistry, hippocampal 
neurons were plated at 200,000 cells/well of a 12 well plate, and 600,000 cells/well of a 6 well 
plate.  Cortical neurons were plated at 250,000/well (12 well) and 750,000 (6 well).  For 
imaging, hippocampal neurons were plated on 18mm (100,000 cells) or 12mm (50,000 cells) 
glass coverslips.   One-third of the media was changed every 7 days. 
 
Mouse Primary Neuronal Culture:  Primary hippocampal neurons were prepared from WT, 
NgR1/PirB, NgR1/NgR2/NgR3, or TSC1f/f neonatal mice at P0 or P1.  Dissected hippocampi were 
incubated in HBSS with Trypsin, glucose, and DNase I for 15min at 37˚C to digest tissue.  
Tissue was pelleted by centrifugation at 100 rcf for 3min, and subjected to 3 washes with HBSS, 
and resuspended in Mouse-NGM (same recipe as NGM above, but without the glucose).  Cells 
were plated on PDL-coated 12-well plates at 400,000-500,000 cells/well.  One-third of the media 
was changed every 7 days. 
 
Lentiviral Transduction:  Every Lentivirus (LV) used in this study was produced by the 
University of Michigan Vector Core.  All LV transductions were performed at least 7 days prior 
to analysis, with the exception of time course experiments (Figure A.12).  Cultures were 
transduced by adding concentrated LV (either 10x or 500x stock) directly into the media at an 
amount equal to a 1x working concentration (either 1:10 or 1:500, respectively).  48-72hrs after 
LV treatment, approximately 1/3 of the medium was replaced with fresh NGM. Treatment with 
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1x LV resulted in transduction of ~80% of cells in primary hippocampal cultures.  For 
knockdown of NogoA, an shRNA plasmid was obtained from Dr. Christine Bandtlow and cloned 
into the pLentilox3.7 plasmid (UM vector core) packaged into an LV, and concentrated to a 500x 
stock.  Other shRNA constructs were obtained from commercial sources.  See below for 
sequences.  Syn-GFP-IRES-Cre and Syn-GFP containing plasmids were obtained from the 
Sabatini laboratory.  Human NogoA was PCR amplified and cloned into pLentilox EV plasmid 
obtained from the UM vector core, along with a myc tag. 
Sequences of NogoA shRNAs 
1: Bandtlow: AAGATTGCTTATGAAAC 
2: OpenBiosystems (V2LMM_33110):  TCTCTTCCTAGTTTATGTG 
3: Origene (TL711619B):  CAGCAGTGTCATCCTCAGAAGGAACAATT  
4: Origene (TL711619C): GATACCTTGGTAACTTATCAGCAGTGTCA 
 
Pharmacological Treatments:  BDNF (Sigma) was prepared as a 500x stock in water (50ug/ul) 
and stored aliquoted at -20˚C. Cultures were treated with BDNF (100ug/mL) for 30 minutes 
prior to lysis.  K252a (CalBiochem) (200nM) was added to cultures at 2hrs or 24hrs before lysis, 
depending on the experiment.  AMPA (10uM, Sigma) was added to cultures 1hr prior to lysis.  
TTX (2uM) (Calbiochem), and Bicuculline (Sigma) (40uM) were added to cultures at 48, 24, or 
4 hrs prior to lysis, depending on the experiment.  JTE-013 (5uM, Tocris) was added to cultures 
for 24 or 48hr prior to lysis.  
 
Cell Surface Biotinylation:  Cell surface biotinylation experiments were performed on primary 
hippocampal neurons at 17 DIV (days in vitro).  Neurons were placed on ice and washed 3x with 
cold PBS containing 100mM CaCal2 and 50mM MgCl2.  EZ-Link Sulfo-NHS-LC-Biotin (Life 
Technologies) was warmed to room temperature and dissolved in PBS (with Ca/Mg) at 1mg/ml.  
Neurons were incubated in biotin for 30min on ice, and the reaction was quenched by washing 
3x in cold Tris-Buffered Saline (50mM Tris, 150mM NaCl, pH 7.4).  Neurons were lysed for 20 
min on ice using cooled Brij lysis buffer (BLB) (10 mM potassium phosphate, pH 7.2, 1 mM 
EDTA, 10 mM MgCl2, 50 mM β-glycerophosphate (BGP), 1 mM Na3V04, 0.5% NP40, and 
0.1% Brij-35) containing protease inhibitor cocktail (PIC) (Sigma) at a 1:100 dilution. Cell 
lysates were cleared by centrifugation in a cooled centrifuge for 5 min at maximal speed.  High 
! 128!
Capacity Streptavidin Agarose Resin (Thermo Scientific/Pierce) was washed 3x in PBS, and 
tumbled with cell lysates at 4C for 3hrs to overnight to pulldown biotinylated proteins.  Beads 
were then washed 3x in PBS and 1x in BLB.  Following the final wash, the lysate/bead slurry of 
approx. 50ul was combined with 50ul of 2x Laemmli Sample buffer containing βME and boiled 
for 10min.  Surface and total protein levels were analyzed via Western Blot (15ul loaded per 
well).  Surface protein expression was normalized to surface levels of Transferrin receptor (TfR).   
 
Western Blot:  Cells were lysed in BLB containing PIC, as described above, or lysed in RIPA 
buffer containing 50mM BGP and PIC for analysis of Arc protein levels.  Supernatants were 
combined with 2x Laemmli buffer, boiled for 10min, separated by SDS-PAGE (5 µg of protein 
loaded per lane), and transferred to PVDF membrane (Millipore).  PVDF membranes were 
blocked with 2% milk (BioRad) in TBS-T (Tris-buffered saline pH 7.4, containing 0.1% Tween-
20) and probed with primary antibodies diluted in 2% BSA or 2% milk in TBS-T, depending on 
the antibody (see below for description of antibodies and respective dilutions).  Anti-mouse, anti-
rabbit, or anti-goat IgG-HRP (Millipore) secondary antibodies were diluted in the same buffer as 
the respective primary antibody. HRP signal was developed with West Pico Substrate or West 
Femto Substrate (Thermo Scientific).  Protein bands were visualized and quantified with using 
LI-COR C-Digit and Image Studio software.  Western blot band intensity in the linear range was 
measured with Image Studio software. 
 
Antibodies for Western Blot:  The following primary antibodies were used.  From R&D 
systems: anti-Nogo (1:5000 in milk, R&D #AF3098).  From Cell Signaling Technologies: anti-
phospho-p70S6K (Thr389) (1:1000, #9234), p70S6K (1:500, #9202), pAKT (Ser473, #4060) 
(1:2000), AKT (1:10,000, #4691), pERK (1:2000, #4695), ERK (1:2000 #4376), p4EBP1 
(1:1000, #9459), 4EBP1 (1:1000, #9452),  TSC1 (Tuberin) (1:2000), TSC2 (Hamartin) (1:2000, 
#4308), Sumo2/3 (1:1000, #4971).  From Promega:  BetaIII Tubulin (TUJ1) (1:50,000, 
#PRG7121).  From Millipore:  GluA1 (N terminal) (1:2000, MAB2263), GluA1 (Cterminal) 
(1:2000, #AB1504), GluA2 (1:1000, #MABN71), PSD95 (1:2000, #AB9708), GAD67 (1:2000, 
#MAB5406), GluN2B (1:1000).  From Santa Cruz: Arc (1:200, #sc-17839), Sumo1 (1:1000, sc-
5308).  From Sigma:  Actin (1:5000), Transferrin Receptor (1:2000, #C2063), Ubiquitin (1:200, 
#U5379).  
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NogoA Immunoprecipitation:  Primary hippocampal or cortical cultures were lysed in BLB as 
described above.  Protein A/G Beads (Calbiochem) were prepared by washing 3x in PBS.  
Lysates were pre-cleared by tumbling at 4C with washed protein A/G beads for 30min.  Beads 
were spun down at 5,000 rpm for 3min, and pre-cleared lysate supernatant was transferred to a 
new 1.5ml tube.  Anti-Nogo antibody (R&D Systems) was added at 2-4ug/mL per 1mg of lysate, 
along with protein A/G beads, and tumbled overnight at 4C.  Beads were washed 3x with PBS 
and 1x with BLB.  For analysis by western blot, beads were boiled in 2x Laemmli sample buffer 
containing βME for 10min, spun down at 5,000 rpm, and 20ul of supernatant loaded per lane.   
 
Immunocytochemistry:  Cells were fixed with cold 4% PFA for 15min, washed 2x with PBS, 
and incubated in blocking solution for 1hr at room temp.  For labeling of surface proteins, a non-
permeabilizing blocking solution of PBS containing 3% horse serum was used.  For total protein 
labeling, a permeabilizing blocking solution of PBS, 3% horse serum, and 0.1% Triton X-100 
was used.  Cells were incubated overnight at 4C in blocking buffer containing primary antibodies 
against Nogo (1:1000, R&D Systems) and GluA1-NT (1:500, Millipore).  The following day, 
cells were washed 3x 5min with PBS, then incubated in the appropriate Alexa-Fluor conjugated 
secondary antibody (1:1000, Life Technologies) in blocking buffer for 1-2 hr at room temp.  
Coverslips were washed 3x in PBS and 1x in dH2O, then mounted on slides using ProLong Gold 
DAPI (Life Technologies).  Images were acquired using an inverted microscope (IX71; 
Olympus) attached to a digital camera (DP72; Olympus).  
 
RT-PCR:  RNA was isolated from rat primary hippocampal cultures at 16 DIV (LV treatment at 
9 DIV) using the RNeasy Mini Kit (Qiagen) with the QiaShredder Kit (Qiagen) and on column 
DNase I digestion option (Qiagen).  1ug of RNA was used to synthesis first strand cDNA using 
the Superscript III First Strand Synthesis Systerm (Invitrogen).  mRNA levels of target genes 
were assessed using RT2 Profiler PCR Arrays from Qiagen according to the manufacturers 
instructions:  Rat mTOR Signaling  (PARN-098ZC-12), GABA & Glutamate (PARN-152ZC-
12).  Reactions were carried out on an Applied Biosystems StepOne Plus RT-PCR 
Thermocycler, and data collected and analyzed with StepOne Software (v.2.2.3). Cycle 
thresholds for each sample were normalized to actin levels.  The relative quantity of mRNA in 
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NogoA shRNA treated cultures was compared to control treated cultures.  Four independent 
experiments were performed. 
 
CalPhos Transfection:  Rat primary hippocampal cultures were transfected with 1ug of a 
plasmid containing NogoA shRNA or control shRNA at 17 DIV using a modified CalPhos 
Transfection kit (Clontech) protocol. After incubation with DNA, cells were briefly incubated in 
a 10% CO2 incubator and DNA-containing medium was discarded.  Electrophysiological 
analysis was performed at 3-4 days after transfection (20-21 DIV). 
 
Electrophysiology:  Whole-cell patch-clamp recordings of mEPSCs were made with an 
Axopatch 200B amplifier from cultured hippocampal neurons bathed in Hepes-buffered saline 
[HBS; 119 mM NaCl, 5 mM KCl, 2 mM CaCl2, 2mM MgCl2, 30mM glucose, 10 mM Hepes 
(pH 7.4)] plus 1µM TTX and 10µM bicuculline. The pipette internal solution contained 100 mM 
cesium gluconate, 0.2 mM EGTA, 5 mM MgCl2, 40 mM Hepes, 2 mM Mg-ATP, 0.3 mM Li-
GTP, and 1 mM QX314 (pH 7.2), and had a resistance of 3–5MΩ. mEPSCs were analyzed off-
line using MiniAnalysis (Synaptosoft). 
 
Mass Spec/Proteomics:  For proteomic analysis of NogoA post-translation modification, 70ul of 
supernatant was loaded into a 1.5mm thick 7.5% gel, and separated by SDS-PAGE.  The gel was 
stained with Imperial Protein Stain (Life Technologies, #24615) according to the manufacturers 
instructions, in a clean Stainease Staining Tray (Life Technologies, #NI2400).  The NogoA band 
excised, digested with trypsin, and analyzed by liquid chromatography tandem mass 
spectrometry (LC-MS/MS) using an Orbitrap Fusion Tribrid Mass Spectrometer (Thermo 
Scientific).  Samples were run in both collision-induced dissociation (CID) and higher-energy 
collisional dissociation (HCD) fragmentation methods.  Data were analyzed using 
X!Tandem/TPP software suite and Proteome Discoverer 1.4. 
 
Lambda Phosphatase Experiment:  Primary hippocampal neurons were lysed in BLB 
containing no phosphatase inhibitors.  Since BLB normally contains the phosphatase inhibitor β-
glycerophosphate, a new solution of BLB was prepared without this inhibitor.  Lambda 
Phosphatase (NEB) treatment was completed according to manufacturers instructions.  Briefly, 
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39ul of protein lysate was combined with 5ul of 10x Buffer for Metallophosphatases, 5ul of 10x 
MnCl2, and 1ul of lambda phosphatase (400U, from 400,000 U/mL stock).  This solution was 
then incubated at 30˚C for 30 minutes, then combine with 50ul of 2x Laemmli sample buffer 
containing βME and boiled for 10min.  As a control, the an additional 39ul of the same protein 
lysates treated as describe above, but without the addition of the lambda phosphatase.  15ul of 
sample was analyzed by western blot. 
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Figure A.1: Chronic changes in neuronal activity regulated NogoA surface levels 
Rat primary hippocampal neurons (17-19 DIV) were treated with TTX (2µM) or Bicuculline 
(40µM) for 24 or 48 hours.  (a) After 48hr of TTX or Bic treatment, neurons were fixed and 
stained under non-permeabilizing conditions for immunofluorescence labeling of surface GluA1 
(green) and surface NogoA (red).  TTX treatment caused a noticeable increase and Bic a 
decrease in GluA1 surface labeling.  TTX appeared to decrease surface NogoA on neurites, but 
not on cell bodies.  Scale bar 200µm.  (b) Western blot analysis of total and surface protein 
levels of NogoA and GluA1 after TTX or Bic treatment and cell surface biotinylation.  
Transferrin receptor (TfR) was used as a loading control for surface proteins, while AKT and 
TUJ1 were used as intracellular controls.  (c) Quantification of Western blots from averaged 
duplicates. At total of three independent experiments (n= 3) for each condition were carried out 
and quantified.  Signal was acquired using a LICOR C-Digit scanner.  Band intensity in the 
linear range was determined using Image Studio Software.  NogoA and GluA1 total protein 
levels were normalized to TUJ1.  NogoA and GluA1 surface levels were normalized to TfR.  
Data are presented as mean ± SEM.  * P<0.05, one-way ANOVA, Dunnett’s multiple 
comparisons test. 
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Figure A.2:  Loss of NogoA reduces expression of GluA1, GluA2, and S6K 
(a) Rat primary hippocampal neurons  treated with LV-shNogoA or LV-control at 10 DIV, lysed 
at 17 DIV, and cell lysates were analyzed by Western blot.  Levels of GluA1, GluA2, and pS6K 
are significantly reduced with NogoA knockdown, while NogoB, GluN2B, and PSD95 levels are 
not affected.  (b) Quantification of western blots from averaged triplicates from 3 independent 
experiments.  Data are presented as mean ± SEM, the relative intensity of each protein in LV-
shNogoA treated cultures to LV-control treated cultures. *** p<0.001, **p<0.01, unpaired 
student’s t-test. (c) Comparison of LVs containing different NogoA shRNA constructs or various 
controls.  G=LV-GFP, 1=LV-shNogoA, 2=NogoA shRNA from OpenBiosystems, 3=NogoA 
shRNA Origene #1, 4=NogoA shRNA Origene #2, Sc=scrambled shRNA, 0=no LV treatment.  
Constructs 1, 3, and 4 effectively reduced levels of NogoA, and decreased levels of GluA1, 
pS6K, and S6K.  (d) Western blot of primary hippocampal cultures from WT NgR1/PirB, or 
NgR123 mutant mice.  Cultures were treated with LV at 10 DIV and analyzed at 17 DIV.  Loss 
of NogoA decreased levels of GluA1, GluA2, and pS6K regardless of genotype. (e) Western blot 
analysis of surface proteins from primary hippocampal cultures treated with JTE-013 (5uM) for 
24 or 48hr, followed by cell surface biotinylation.  No significant change in GluA1 or NogoA 
surface levels was observed.  Results are presented as mean ± SEM.  
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Figure A.3:  NogoA regulates GluA1 expression and synaptic transmission in a cell-
autonomous manner 
(a) Rat primary hippocampal neurons transduced with LV-shNogoA or LV-control and stained 
under non-permeabalizing conditions to label surface NogoA or surface GluA1.  Transduced 
cells are GFP positive.  Scale bar 100µm.  (b)  Western blot analysis of surface protein levels in 
LV-control and LV-shNogoA cultures following cell surface biotinylation.  NogoA knockdown 
leads to a significant reduction in surface GluA1 levels. ***p<0.001, unpaired student’s t-test.  
(c)  Representative traces of mEPSCs from primary hippocampal neurons at 20-21 DIV 
following CalPhos transfection of shNogoA or shcontrol DNA plasmids.  (d)  Frequency of 
mEPSCs is unchanged between shcontrol (n = 14), shNogoA (n = 17), and naïve (n = 7) 
hippocampal neurons   (e) Amplitude of mEPSCs in shNogoA neurons  (n = 17) is significantly 
reduced compared to shcontrol neurons (n = 14).   *p<0.05, unpaired student’s t-test. 
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Figure A.4: NogoA knockdown attenuates TTX-mediated scaling up of surface GluA1 
Cell surface biotinylation of primary hippocampal neurons transduced with LV-control or LV-
shNogoA at 10 DIV and lysed at 17 DIV following 24hr TTX (2µM) treatment.  (a) Western 
blot analysis of GluA1 surface levels.  (b)  Quantification of surface GluA1 levels normalized to 
surface TfR levels.  TTX increases surface GluA1 in LV-control, but not in LV-shNogoA 
neurons.  Data are presented as mean ± SEM from averaged triplicates from five independent 
experiments (n=5).  *p<0.05, **p<0.01, ***p<0.001 one-way ANOVA Tukey’s post hoc. 
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Figure A.5:  Loss of NogoA selectively impairs BDNF signaling 
(a) Rat primary hippocampal neurons transduced with LV-control or LV-shNogoA at 10-11 DIV 
and lysed 7 days later at 17-18 DIV following treatment with BDNF (100ng/ml) for 30 minutes. 
(b) Quantifaction of pS6K levels normalized to TUJ1.  In LV-control, but not in LV-shNogoA 
transduced cultures, BDNF significantly increases pS6K levels. (c) Quantification of pERK 
levels normalized to TUJ1.  BDNF significantly increases pERK levels in both LV-control and 
LV-shNogoA transduced cultures.  Data are presented as mean ± SEM of averaged duplicates 
from three independent experiments.  * p<0.05, one-way ANOVA, Fisher’s post test. 
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Figure A.6:! NogoA knockdown does not impair bicuculline-mediated increase in Arc 
protein levels 
Rat primary hippocampal neurons transduced with LV-control or LV-shNogoA at 10-11 DIV 
and lysed 7 days later at 17-18 DIV following treatment with bicuculline (bic) (40µM) for 4hrs.  
Bic treatment increased Arc expression in both LV-control and LV-shRNA cultures.  Blots are 
representative of three independent experiments. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
! 139!
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A.7: Enhancing mTORC1 activity does not rescue expression of GluA1 or S6K in 
LV-shNogoA neurons 
(a) Western blot analysis of total protein content in mouse primary hippocampal cultures from 
TSC1f/f mice transduced at 3 DIV with LVsynGFP-Cre to deplete TSC1, or LVsynGFP as a 
control.  Cultures were transduced with LV-shNogoA or LV-control at 10 DIV, and lysed at 17 
DIV. (b)  Quantification of GluA1 protein levels normalized to TUJ1.  GluA1 levels are 
significantly reduced in LV-shNogoA transduced cultures, but not further decreased upon loss of 
TSC1.  (c)  Quantification of pS6K levels normalized to total S6K levels.  Since total S6K 
decreases in LV-shNogoA cultures, loss of NogoA does not alter the ratio of pS6K to S6K.  (d) 
Quantification of pS6K levels normalized to TUJ1.  Overall, the total cellular amount of pS6K 
decreases in LV-shNogoA cultures compared to control, and is not significantly changed upon 
depletion of TSC1.  Results are presented as mean ± SEM from three separate experiments.  
*p<0.05, **p<0.01 one-way ANOVA, Fisher’s post test. 
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Figure A.8: Loss of NogoA alters gene transcription 
Relative quantity of mRNA in LV-shNogoA transduced hippocampal cultures, compared to LV-
control transduced cultures.  Rat primary hippocampal cultures were transduced with LVs at 9 
DIV and RNA was collected at 16 DIV.  First strand cDNA was synthesized and analyzed using 
RT2 Profiler PCR arrays (Qiagen) for (a) GABA/Glutamate related and (b)  mTOR-related 
genes.  Results are presented mean +/- SEM from four independent experiments for (a), and 
from two independent experiments for (b).  A complete list of analyzed transcripts and their 
respective levels are presented in Table A.1 and Table A.2 
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Figure A.9: Post-translational modification of NogoA 
(a) Western blot analysis of protein lysates from 24 DIV rat hippocampal cultures, lysed in BLB 
without the presence of phosphatase inhibitors, and blotted for NogoA on a 7.5% gel.  Cultures 
were treated with K252a (200nM) for 2hrs or TTX (2µM) for 24hr prior to lysis, or were 
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untreated (control).  Following lysis, an aliquot of each sample was incubated with lambda 
phosphatase (λpp) for 30min. at 30˚C to remove sites of phosphorylation.  Control samples 
treated with λpp display a slight downward shift in the molecular weight (MW) of NogoA, 
similar to K252a treated samples without λpp treatment.  λpp  does not further alter the MW of 
NogoA in K252a-treated samples.  (b) 5% gel detailing NogoA MW shifts with greater 
resolution.  Treatment with AMPA (10uM) for 1hr causes the NogoA signal to separate into two 
distinct bands.  K252a (200nM, 2hr) treatment alone decreases the MW of NogoA.  K252a also 
attenuates the MW shift induced by AMPA.  Pre-treatment with MG132 (10µM) does not affect 
the AMPA-mediated band shift. (c) Western blot of surface proteins following cell surface 
biotinylation.  Treatment with K252a (200nM, 24hrs) decreases surface levels of NogoA and 
GluA1 relative to control.  Data from two separate experiments of averaged triplicates are 
presented as mean +/- SEM. (d)  Western blot analysis of immunoprecipitated (IP) NogoA 
following treatment with K252a (200nM, 2hr) or PKA inhibitor KT5720 (2µM, 4hr). anti-
NogoA antibody pulls down both NogoA (~200 kDa and NogoB ~50 kDa).  NogoA is 
ubiquitinated under control conditions and following treatment with K252a or KT5720. (e) 5% 
gel showing an example of TTX-induced separation of NogoA into two distinct bands, following 
24hr TTX (2uM) treatment.  (f-j) NogoA IP following treatment with TTX (2uM, 4hr or 24hr), 
and immunoblotted for various post-translation modifications. (g, h) NogoA is ubiquitinated 
under control conditions and following TTX treatment.  (i, j) NogoA is not sumoylated.  (k)  
Example of an Imperial Protein (Coomassie) Stain of a 7.5% gel showing the amount of NogoA 
protein obtained following IP of 1mg of protein lysate.  1) Lysate, 2) NogoA IP, 3) Lysate, 4) 
1µg BSA, 5) 0.5µg BSA.  The square indicates the NogoA band.  
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Figure A.10: NogoA overexpression is unsuccessful in neuronal cultures 
(a) HEK 293T cells transduced with LV-mycNogoA for 72hrs (+) show robust overexpression of 
NogoA, compared to cells transduced with LV-control (-).  (b)  Rat hippocampal neurons 
transduced with LV-control LV-mycNogoA (mycNogo), or a mutant form of myc-tagged 
NogoA in which several C-terminal lysines are mutated to alanine (mycNogo-Ub).  While a low 
level of myc signal is detected by Western blot, overall levels of NogoA do not increase with 
either LV-mycNogoA or LV-myNogo-Ub. 
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Figure A.11:   Time course of LV-mediated NogoA knockdown 
Rat primary hippocampal cultures were transduced with LV-control or LV-shNogoA beginning 
at 3, 10, or 14 DIV.  Cultures were lysed at 17 DIV an analyzed via western blot.  NogoA 
knockdown is very robust with LV transduction at 3 DIV or 10 DIV.  LV transduction at 14 DIV 
reveals the gradual nature of LV-mediated gene knockdown, as NogoA levels are only partially 
reduce.  NogoA knockdown leads to a reduction in GluA1, GluA2, and pS6K at all time points.  
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Table A.1:  qPCR analysis of GABA/glutamate plates 
Summary of the relative quantity (RQ) of mRNA transcripts (target) in four separate experiments 
for LV-shNogoA transduced hippocampal cultures, compared to LV-control transduced cultures.  
Cultures were transduced with LVs at 9 DIV, RNA collected at 16 DIV, first strand cDNA 
synthesized and analyzed using the GABA/glutamate RT2 Profiler PCR Array (Qiagen).  
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Table A.2:  qPCR analysis of mTOR plates 
Summary of the relative quantity (RQ) of mRNA 
transcripts (target) in two separate experiments for LV-
shNogoA transduced hippocampal cultures, compared 
to LV-control transduced cultures.  Cultures were 
transduced with LVs at 9 DIV, RNA collected at 16 
DIV, first strand cDNA synthesized and analyzed using 
the mTOR RT2 Profiler PCR Array (Qiagen).  
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Description 
ΣCo
vera
ge 
Σ# PSMs Coverage A3 
Reticulon OS=Rattus 
norvegicus GN=Rtn4 PE=1 
SV=1 - [F1LQN3_RAT] 
78.9
3 
2055 71.71 
Sequence 
# 
PSM
s 
Modifications phosphoRS Site Probabilities 
AQIITEK 3     
AQIITEKTSPK 10 S9(Phospho) T(5): 0.1; T(8): 50.0; S(9): 50.0 
ASISPSNVSALEPQTEMGSIVK 8     
ASISPSNVSALEPQTEMGSIVK 23 M17(Oxidation)   
ASISPSNVSALEPQTEMGSIVK 23 S4(Phospho) S(2): 0.6; S(4): 98.9; S(6): 0.6; S(9): 0.0; T(15): 0.0; 
S(19): 0.0 
ASISPSNVSALEPQTEMGSIVK 25 S2(Phospho); 
M17(Oxidation) 
S(2): 78.4; S(4): 10.8; S(6): 10.8; S(9): 0.0; T(15): 0.0; 
S(19): 0.0 
ATNPFVNR 21     
AYITCASFTSATESTTANTFPLLED
HTSENK 
8 C5(Carbamidomethyl)   
AYITCASFTSATESTTANTFPLLED
HTSENKTDEK 
14 C5(Carbamidomethyl)   
AYLESEVAISEELVQK 103     
CLEDSLEQK 5 C1(Carbamidomethyl)   
DAASNDIPTLTK 18     
DAASNDIPTLTK 1 K12(GlyGly)   
DAASNDIPTLTKK 1     
DEVHVSDEFSENR 44     
DKEDLVCSAALHSPQESPVGK 6 C7(Carbamidomethyl)   
DKEDLVCSAALHSPQESPVGK 3 C7(Carbamidomethyl); 
S13(Phospho) 
S(8): 0.0; S(13): 100.0; S(17): 0.0 
DKEDLVCSAALHSPQESPVGKED
R 
3 C7(Carbamidomethyl)   
DKEDLVCSAALHSPQESPVGKED
R 
3 C7(Carbamidomethyl); 
S13(Phospho); 
S17(Phospho) 
S(8): 3.4; S(13): 96.6; S(17): 100.0 
DKEDLVCSAALHSPQESPVGKED
R 
1 C7(Carbamidomethyl); 
S13(Phospho) 
S(8): 0.2; S(13): 99.5; S(17): 0.2 
DLAEFSELEYSEMGSSFK 21     
DLAEFSELEYSEMGSSFK 51 M13(Oxidation)   
DLAEFSELEYSEMGSSFKGSPK 10 M13(Oxidation); 
S20(Phospho) 
S(6): 0.0; Y(10): 0.0; S(11): 0.0; S(15): 0.0; S(16): 0.0; 
S(20): 100.0 
DSEGRNEDASFPSTPEPVK 7     
DSEGRNEDASFPSTPEPVK 11 T14(Phospho) S(2): 0.0; S(10): 0.7; S(13): 49.6; T(14): 49.6 
DSEGRNEDASFPSTPEPVK 2 S10(Phospho); 
S13(Phospho) 
S(2): 0.1; S(10): 99.3; S(13): 50.3; T(14): 50.3 
DSEGRNEDASFPSTPEPVKDSSR 9     
DSEGRNEDASFPSTPEPVKDSSR 15 T14(Phospho) S(2): 0.0; S(10): 0.0; S(13): 11.7; T(14): 88.3; S(21): 
0.0; S(22): 0.0 
DSEGRNEDASFPSTPEPVKDSSR 3 S10(Phospho); 
S13(Phospho) 
S(2): 0.1; S(10): 99.8; S(13): 16.8; T(14): 83.4; S(21): 
0.0; S(22): 0.0 
EEYADFKPFEQAWEVK 29     
EEYADFKPFEQAWEVKDTYEGSR 4     
EGIKEPESFNAAVQETEAPYISIAC
DLIK 
34 C25(Carbamidomethyl)   
EHGYLGNLSAVSSSEGTIEETLNE
ASK 
51     
EKISLQMEEFNTAIYSNDDLLSSK 7 M7(Oxidation)   
EKISLQMEEFNTAIYSNDDLLSSK 4     
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EKISLQMEEFNTAIYSNDDLLSSK
EDK 
3 M7(Oxidation)   
EPESFNAAVQETEAPYISIACDLIK 9 C21(Carbamidomethyl)   
ESETFSDSSPIEIIDEFPTFVSAK 7     
ESETFSDSSPIEIIDEFPTFVSAK 19 S8(Phospho) S(2): 0.0; T(4): 0.0; S(6): 8.5; S(8): 82.9; S(9): 8.5; 
T(19): 0.0; S(22): 0.0 
ESETFSDSSPIEIIDEFPTFVSAK 2 S2(Phospho); S6(Phospho) S(2): 75.4; T(4): 43.9; S(6): 43.9; S(8): 18.3; S(9): 18.3; 
T(19): 0.2; S(22): 0.1 
ESLTEVSETVAQHK 24     
ESLTEVSETVAQHK 11 K14(GlyGly)   
ESLTEVSETVAQHKEER 58     
ESLTEVSETVAQHKEER 3 K14(GlyGly)   
ETKLSTEPSPDFSNYSEIAK 2 S5(Phospho); S9(Phospho) T(2): 0.1; S(5): 86.7; T(6): 13.2; S(9): 100.0; S(13): 0.0; 
Y(15): 0.0; S(16): 0.0 
ETKLSTEPSPDFSNYSEIAK 3 T6(Phospho) T(2): 0.3; S(5): 49.8; T(6): 49.8; S(9): 0.1; S(13): 0.0; 
Y(15): 0.0; S(16): 0.0 
ETKLSTEPSPDFSNYSEIAK 1     
EYTDLEVSDK 23     
EYTDLEVSDKSEIANIQSGADSLP
CLELPCDLSFK 
15 C25(Carbamidomethyl); 
C30(Carbamidomethyl) 
  
GESAILVENTK 22     
GESAILVENTK 2 K11(GlyGly)   
GESAILVENTKEEVIVR 113     
GPLPAAPPAAPER 23     
GPLPAAPPAAPERQPSWER 4 S16(Phospho) S(16): 100.0 
GSGSVDETLFALPAASEPVIPSSA
EK 
12 T8(Phospho) S(2): 33.3; S(4): 33.3; T(8): 33.3; S(16): 0.0; S(22): 0.0; 
S(23): 0.0 
GSGSVDETLFALPAASEPVIPSSA
EK 
2     
GSPKGESAILVENTK 1 S2(Phospho) S(2): 88.9; S(7): 11.1; T(14): 0.0 
GVIQAIQK 6     
HQVQIDHYLGLANK 88     
IKESETFSDSSPIEIIDEFPTFVSAK 13     
IKESETFSDSSPIEIIDEFPTFVSAK 20 S11(Phospho) S(4): 0.0; T(6): 0.0; S(8): 0.2; S(10): 10.8; S(11): 89.0; 
T(21): 0.0; S(24): 0.0 
IKESETFSDSSPIEIIDEFPTFVSAK 28 S8(Phospho); 
S10(Phospho) 
S(4): 70.5; T(6): 81.9; S(8): 27.1; S(10): 16.0; S(11): 
4.6; T(21): 0.0; S(24): 0.0 
IMDLMEQPGNTVSSGQEDFPSVL
LETAASLPSLSPLSTVSFK 
12 M2(Oxidation); 
M5(Oxidation) 
  
IMDLMEQPGNTVSSGQEDFPSVL
LETAASLPSLSPLSTVSFK 
30 M2(Oxidation)   
IMDLMEQPGNTVSSGQEDFPSVL
LETAASLPSLSPLSTVSFK 
28 M2(Oxidation); 
S34(Phospho) 
T(11): 0.0; S(13): 0.0; S(14): 0.0; S(21): 0.0; T(26): 0.0; 
S(29): 0.0; S(32): 5.7; S(34): 93.7; S(37): 0.4; T(38): 
0.1; S(40): 0.1 
IMDLMEQPGNTVSSGQEDFPSVL
LETAASLPSLSPLSTVSFK 
11 M2(Oxidation); 
M5(Oxidation); 
S34(Phospho) 
T(11): 0.0; S(13): 0.0; S(14): 0.0; S(21): 0.1; T(26): 1.3; 
S(29): 1.3; S(32): 18.3; S(34): 72.9; S(37): 4.8; T(38): 
1.3; S(40): 0.1 
IMDLMEQPGNTVSSGQEDFPSVL
LETAASLPSLSPLSTVSFK 
3     
IMDLMEQPGNTVSSGQEDFPSVL
LETAASLPSLSPLSTVSFK 
4 S34(Phospho) T(11): 0.0; S(13): 0.0; S(14): 0.0; S(21): 0.0; T(26): 0.2; 
S(29): 0.1; S(32): 0.5; S(34): 1.2; S(37): 32.7; T(38): 
32.7; S(40): 32.7 
ISLQMEEFNTAIYSNDDLLSSK 23 M5(Oxidation)   
ISLQMEEFNTAIYSNDDLLSSK 26     
ISLQMEEFNTAIYSNDDLLSSKED
K 
3     
ISLQMEEFNTAIYSNDDLLSSKED
K 
2 M5(Oxidation); 
S20(Phospho) 
S(2): 0.0; T(10): 0.0; Y(13): 0.1; S(14): 1.2; S(20): 18.6; 
S(21): 80.1 
KAQIITEK 18     
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KAQIITEKTSPK 16 S10(Phospho) T(6): 0.0; T(9): 7.1; S(10): 92.9 
KCLEDSLEQK 7 C2(Carbamidomethyl)   
KLPSDTEK 1     
KLPSDTEKEDR 14     
KPAAGLSAAAVPPAAAAPLLDFSS
DSVPPAPR 
46     
LEPENPPPYEEAMNVALK 10     
LEPENPPPYEEAMNVALK 32 M13(Oxidation)   
LFLVDDLVDSLK 4     
LPEDDEPPARPPPPPPAGASPLAE
PAAPPSTPAAPK 
30     
LPEDDEPPARPPPPPPAGASPLAE
PAAPPSTPAAPK 
10 S20(Phospho) S(20): 100.0; S(30): 0.0; T(31): 0.0 
LPSDTEKEDR 4     
LSASPQELGKPYLESFQPNLHSTK 41 S4(Phospho) S(2): 50.0; S(4): 50.0; Y(12): 0.0; S(15): 0.0; S(22): 0.0; 
T(23): 0.0 
LSASPQELGKPYLESFQPNLHSTK 40     
LSTEPSPDFSNYSEIAK 20     
LSTEPSPDFSNYSEIAK 12 S6(Phospho) S(2): 0.0; T(3): 0.0; S(6): 100.0; S(10): 0.0; Y(12): 0.0; 
S(13): 0.0 
LSTEPSPDFSNYSEIAK 1 K17(GlyGly)   
MEDIDQSSLVSSSTDSPPRPPPAF
K 
2 M1(Oxidation); 
S7(Phospho) 
S(7): 49.9; S(8): 49.9; S(11): 0.1; S(12): 0.0; S(13): 0.0; 
T(14): 0.1; S(16): 0.0 
NEDASFPSTPEPVK 10     
NEDASFPSTPEPVK 13 S8(Phospho) S(5): 0.0; S(8): 50.0; T(9): 50.0 
NEDASFPSTPEPVK 8 S5(Phospho); S8(Phospho) S(5): 100.0; S(8): 50.0; T(9): 50.0 
NEDASFPSTPEPVKDSSR 21     
NEDASFPSTPEPVKDSSR 22 T9(Phospho) S(5): 0.0; S(8): 90.4; T(9): 9.6; S(16): 0.0; S(17): 0.0 
NEDASFPSTPEPVKDSSR 6 S5(Phospho); S8(Phospho) S(5): 100.0; S(8): 1.7; T(9): 98.3; S(16): 0.0; S(17): 0.0 
NIYPKDEVHVSDEFSENR 7     
QPSWERSPAAPAPSLPPAAAVLPS
K 
2 S3(Phospho) S(3): 96.8; S(7): 3.2; S(14): 0.0; S(24): 0.0 
QPSWERSPAAPAPSLPPAAAVLPS
K 
1 S3(Phospho); S7(Phospho) S(3): 100.0; S(7): 100.0; S(14): 0.0; S(24): 0.0 
RGSGSVDETLFALPAASEPVIPSS
AEK 
11 S3(Phospho) S(3): 79.6; S(5): 10.2; T(9): 10.2; S(17): 0.0; S(23): 0.0; 
S(24): 0.0 
RRGSGSVDETLFALPAASEPVIPS
SAEK 
35 S6(Phospho) S(4): 14.6; S(6): 85.4; T(10): 0.0; S(18): 0.0; S(24): 0.0; 
S(25): 0.0 
SDEGHPFR 11     
SEIANIQSGADSLPCLELPCDLSFK 13 C15(Carbamidomethyl); 
C20(Carbamidomethyl) 
  
SKDKEDLVCSAALHSPQESPVGK 11 C9(Carbamidomethyl)   
SKDKEDLVCSAALHSPQESPVGK 7 C9(Carbamidomethyl); 
S15(Phospho) 
S(1): 0.0; S(10): 0.0; S(15): 100.0; S(19): 0.0 
SKDKEDLVCSAALHSPQESPVGK 3 C9(Carbamidomethyl); 
S15(Phospho); 
S19(Phospho) 
S(1): 0.0; S(10): 0.0; S(15): 100.0; S(19): 100.0 
SLGKDSEGR 1     
SLSAVLSAELSK 21     
SPAAPAPSLPPAAAVLPSK 19     
SPAAPAPSLPPAAAVLPSK 1 S1(Phospho) S(1): 100.0; S(8): 0.0; S(18): 0.0 
SVPEHAELVEDSSPESEPVDLFSD
DSIPEVPQTQEEAVMLMK 
2 M39(Oxidation); 
M41(Oxidation) 
  
SVPEHAELVEDSSPESEPVDLFSD
DSIPEVPQTQEEAVMLMK 
3 M39(Oxidation)   
TMDIFNEMQMSVVAPVR 28 M2(Oxidation); 
M8(Oxidation); 
M10(Oxidation) 
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TMDIFNEMQMSVVAPVR 27 M2(Oxidation)   
TMDIFNEMQMSVVAPVR 7     
TMDIFNEMQMSVVAPVR 5 M8(Oxidation); 
M10(Oxidation) 
  
TMDIFNEMQMSVVAPVREEYADF
KPFEQAWEVK 
9 M8(Oxidation); 
M10(Oxidation) 
  
TMDIFNEMQMSVVAPVREEYADF
KPFEQAWEVK 
4 M2(Oxidation); 
M8(Oxidation); 
M10(Oxidation) 
  
TMDIFNEMQMSVVAPVREEYADF
KPFEQAWEVK 
12 M8(Oxidation)   
TMDIFNEMQMSVVAPVREEYADF
KPFEQAWEVK 
2     
TSNPFLVAVQDSEADYVTTDTLSK 44     
TSVVDLLYWR 33     
VTEAAVSNMPEGLTPDLVQEACE
SELNEATGTK 
9 M9(Oxidation); 
C22(Carbamidomethyl) 
  
VTEAAVSNMPEGLTPDLVQEACE
SELNEATGTK 
6 C22(Carbamidomethyl)   
VTEAAVSNMPEGLTPDLVQEACE
SELNEATGTK 
4 M9(Oxidation); 
T14(Phospho); 
C22(Carbamidomethyl) 
T(2): 0.0; S(7): 0.0; T(14): 100.0; S(24): 0.0; T(30): 0.0; 
T(32): 0.0 
VVSPEKTMDIFNEMQMSVVAPVR 8 S3(Phospho); 
M8(Oxidation) 
S(3): 11.2; T(7): 88.8; S(17): 0.0 
VVSPEKTMDIFNEMQMSVVAPVR 5 S3(Phospho); 
M8(Oxidation); 
M14(Oxidation); 
M16(Oxidation) 
S(3): 99.9; T(7): 0.1; S(17): 0.0 
VVSPEKTMDIFNEMQMSVVAPVR 6 T7(Phospho); 
M8(Oxidation); 
M14(Oxidation) 
S(3): 12.0; T(7): 88.0; S(17): 0.0 
VVSPEKTMDIFNEMQMSVVAPVR
EEYADFKPFEQAWEVK 
5 S3(Phospho); 
M8(Oxidation); 
M14(Oxidation); 
M16(Oxidation) 
S(3): 95.5; T(7): 4.5; S(17): 0.0; Y(26): 0.0 
YQFVTEPEDEEDEEEEEDEEEDD
EDLEELEVLER 
27     
YSNSALGHVNSTIK 40     
YSNSALGHVNSTIK 1 K14(GlyGly)   !!
Table A.3: NogoA post-translational modification in control cultures 
NogoA was immunoprecipiatated from rat primary hippocampal neurons and subject to LC-
MS/MS.  This table summaries the peptides identified from both CID and HDC fragmentation 
methods.  The column on the right indicates the probability that each serine, threonine, or 
tyrosine residue is phosphorylated, for a given phosphopeptide. 
 
 !!!!!!!!
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Description 
ΣCo
vera
ge 
Σ# PSMs Coverage A3 
Reticulon OS=Rattus 
norvegicus GN=Rtn4 PE=1 
SV=1 - [F1LQN3_RAT] 
79.0
2 
1888 68.10 
Sequence 
# 
PSM
s 
Modifications phosphoRS Site Probabilities 
EHGYLGNLSAVSSSEGTIEETLNE
ASK 
64     
RRGSGSVDETLFALPAASEPVIPS
SAEK 
36 S4(Phospho) S(4): 98.3; S(6): 1.7; T(10): 0.0; S(18): 0.0; S(24): 0.0; 
S(25): 0.0 
KPAAGLSAAAVPPAAAAPLLDFSS
DSVPPAPR 
29     
ESLTEVSETVAQHKEER 46     
DLAEFSELEYSEMGSSFKGSPK 5 S20(Phospho) S(6): 0.0; Y(10): 0.0; S(11): 0.0; S(15): 0.0; S(16): 0.0; 
S(20): 100.0 
GESAILVENTKEEVIVR 138     
DLAEFSELEYSEMGSSFKGSPK 12 M13(Oxidation); 
S20(Phospho) 
S(6): 0.0; Y(10): 0.0; S(11): 0.0; S(15): 1.0; S(16): 1.0; 
S(20): 98.0 
LSASPQELGKPYLESFQPNLHSTK 33 S4(Phospho) S(2): 50.0; S(4): 50.0; Y(12): 0.0; S(15): 0.0; S(22): 0.0; 
T(23): 0.0 
DLAEFSELEYSEMGSSFK 37     
EGIKEPESFNAAVQETEAPYISIA
CDLIK 
21 C25(Carbamidomethyl)   
ISLQMEEFNTAIYSNDDLLSSK 31 M5(Oxidation)   
SPAAPAPSLPPAAAVLPSK 22     
LSASPQELGKPYLESFQPNLHSTK 24     
RGSGSVDETLFALPAASEPVIPSS
AEK 
22 S3(Phospho) S(3): 97.0; S(5): 1.5; T(9): 1.5; S(17): 0.0; S(23): 0.0; 
S(24): 0.0 
TSNPFLVAVQDSEADYVTTDTLS
K 
68     
SEIANIQSGADSLPCLELPCDLSF
K 
8 C15(Carbamidomethyl); 
C20(Carbamidomethyl) 
  
LPEDDEPPARPPPPPPAGASPLAE
PAAPPSTPAAPK 
20     
NEDASFPSTPEPVKDSSR 20     
HQVQIDHYLGLANK 38     
YSNSALGHVNSTIK 22     
AYITCASFTSATESTTANTFPLLE
DHTSENKTDEK 
7 C5(Carbamidomethyl)   
ESLTEVSETVAQHK 17     
DAASNDIPTLTK 20     
AYLESEVAISEELVQK 115     
DSEGRNEDASFPSTPEPVKDSSR 5     
NEDASFPSTPEPVK 16     
DEVHVSDEFSENR 25     
GESAILVENTK 19     
KAQIITEKTSPK 30 S10(Phospho) T(6): 0.0; T(9): 6.6; S(10): 93.4 
LSTEPSPDFSNYSEIAK 6     
LEPENPPPYEEAMNVALK 30 M13(Oxidation)   
SLSAVLSAELSK 15     
KLPSDTEKEDR 19     
LEPENPPPYEEAMNVALK 11     
IKESETFSDSSPIEIIDEFPTFVSA
K 
12     
ASISPSNVSALEPQTEMGSIVK 15     
DLAEFSELEYSEMGSSFK 38 M13(Oxidation)   
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KAQIITEK 9     
NEDASFPSTPEPVK 7 S8(Phospho) S(5): 4.0; S(8): 48.0; T(9): 48.0 
DSEGRNEDASFPSTPEPVK 10     
GPLPAAPPAAPER 15     
SKDKEDLVCSAALHSPQESPVGK 7 C9(Carbamidomethyl); 
S15(Phospho) 
S(1): 0.0; S(10): 0.0; S(15): 100.0; S(19): 0.0 
DSEGRNEDASFPSTPEPVKDSSR 16 T14(Phospho) S(2): 0.0; S(10): 0.0; S(13): 12.2; T(14): 87.8; S(21): 
0.0; S(22): 0.0 
ISLQMEEFNTAIYSNDDLLSSKED
K 
7     
TSVVDLLYWR 20     
EEYADFKPFEQAWEVK 21     
ISLQMEEFNTAIYSNDDLLSSK 41     
TMDIFNEMQMSVVAPVR 19 M2(Oxidation); 
M8(Oxidation); 
M10(Oxidation) 
  
TMDIFNEMQMSVVAPVREEYAD
FKPFEQAWEVK 
6 M2(Oxidation); 
M8(Oxidation); 
M10(Oxidation) 
  
ASISPSNVSALEPQTEMGSIVK 35 M17(Oxidation)   
NIYPKDEVHVSDEFSENR 9     
LSTEPSPDFSNYSEIAK 4 S6(Phospho) S(2): 0.0; T(3): 0.0; S(6): 99.2; S(10): 0.8; Y(12): 0.0; 
S(13): 0.0 
EKISLQMEEFNTAIYSNDDLLSSK 5 M7(Oxidation)   
VTEAAVSNMPEGLTPDLVQEACE
SELNEATGTK 
4 M9(Oxidation); 
C22(Carbamidomethyl) 
  
ESLTEVSETVAQHK 4 K14(GlyGly)   
ESETFSDSSPIEIIDEFPTFVSAK 9     
TMDIFNEMQMSVVAPVR 24 M2(Oxidation)   
EYTDLEVSDK 24     
CLEDSLEQK 14 C1(Carbamidomethyl)   
NEDASFPSTPEPVKDSSR 14 S8(Phospho) S(5): 0.0; S(8): 88.6; T(9): 11.3; S(16): 0.0; S(17): 0.0 
ATNPFVNR 21     
KCLEDSLEQK 4 C2(Carbamidomethyl)   
EEYADFKPFEQAWEVKDTYEGSR 3     
TMDIFNEMQMSVVAPVR 12 M8(Oxidation); 
M10(Oxidation) 
  
YQFVTEPEDEEDEEEEEDEEEDD
EDLEELEVLER 
43     
DKEDLVCSAALHSPQESPVGK 8 C7(Carbamidomethyl)   
LFLVDDLVDSLK 6     
ASISPSNVSALEPQTEMGSIVK 11 S4(Phospho) S(2): 8.6; S(4): 91.3; S(6): 0.1; S(9): 0.0; T(15): 0.0; 
S(19): 0.0 
LPSDTEKEDR 4     
VVSPEKTMDIFNEMQMSVVAPV
R 
12 S3(Phospho); 
M8(Oxidation); 
M14(Oxidation); 
M16(Oxidation) 
S(3): 90.1; T(7): 9.9; S(17): 0.0 
TMDIFNEMQMSVVAPVR 4     
EKISLQMEEFNTAIYSNDDLLSSK 2     
LPEDDEPPARPPPPPPAGASPLAE
PAAPPSTPAAPK 
13 S20(Phospho) S(20): 100.0; S(30): 0.0; T(31): 0.0 
IKESETFSDSSPIEIIDEFPTFVSA
K 
38 S10(Phospho); 
S11(Phospho) 
S(4): 0.5; T(6): 86.6; S(8): 37.6; S(10): 37.6; S(11): 
37.6; T(21): 0.0; S(24): 0.0 
SKDKEDLVCSAALHSPQESPVGK 8 C9(Carbamidomethyl)   
ASISPSNVSALEPQTEMGSIVK 45 S4(Phospho); 
M17(Oxidation) 
S(2): 47.4; S(4): 47.4; S(6): 5.3; S(9): 0.0; T(15): 0.0; 
S(19): 0.0 
IKESETFSDSSPIEIIDEFPTFVSA 28 S11(Phospho) S(4): 0.0; T(6): 0.0; S(8): 0.1; S(10): 9.4; S(11): 90.5; 
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K T(21): 0.0; S(24): 0.0 
VVSPEKTMDIFNEMQMSVVAPV
R 
13 T7(Phospho); 
M8(Oxidation); 
M14(Oxidation) 
S(3): 2.0; T(7): 98.0; S(17): 0.0 
VVSPEKTMDIFNEMQMSVVAPV
REEYADFKPFEQAWEVK 
4 S3(Phospho); 
M8(Oxidation); 
M14(Oxidation); 
M16(Oxidation) 
S(3): 93.2; T(7): 6.6; S(17): 0.1; Y(26): 0.1 
AYITCASFTSATESTTANTFPLLE
DHTSENK 
6 C5(Carbamidomethyl)   
EYTDLEVSDKSEIANIQSGADSLP
CLELPCDLSFK 
4 C25(Carbamidomethyl); 
C30(Carbamidomethyl) 
  
VTEAAVSNMPEGLTPDLVQEACE
SELNEATGTK 
2 C22(Carbamidomethyl)   
ESETFSDSSPIEIIDEFPTFVSAK 24 S8(Phospho) S(2): 0.0; T(4): 0.0; S(6): 1.1; S(8): 89.1; S(9): 9.7; 
T(19): 0.0; S(22): 0.0 
VTEAAVSNMPEGLTPDLVQEACE
SELNEATGTK 
5 M9(Oxidation); 
T14(Phospho); 
C22(Carbamidomethyl) 
T(2): 0.0; S(7): 0.2; T(14): 99.8; S(24): 0.0; T(30): 0.0; 
T(32): 0.0 
GSGSVDETLFALPAASEPVIPSSA
EK 
11 T8(Phospho) S(2): 10.4; S(4): 10.4; T(8): 79.1; S(16): 0.0; S(22): 0.0; 
S(23): 0.0 
EPESFNAAVQETEAPYISIACDLI
K 
11 C21(Carbamidomethyl)   
DKEDLVCSAALHSPQESPVGK 1 C7(Carbamidomethyl); 
S13(Phospho) 
S(8): 0.0; S(13): 100.0; S(17): 0.0 
GSGSVDETLFALPAASEPVIPSSA
EK 
4     
VVSPEKTMDIFNEMQMSVVAPV
R 
1 S3(Phospho); 
M8(Oxidation) 
S(3): 1.5; T(7): 98.5; S(17): 0.0 
IMDLMEQPGNTVSSGQEDFPSVL
LETAASLPSLSPLSTVSFK 
2 M2(Oxidation); 
M5(Oxidation) 
  
SPAAPAPSLPPAAAVLPSK 2 S1(Phospho) S(1): 100.0; S(8): 0.0; S(18): 0.0 
TMDIFNEMQMSVVAPVREEYAD
FKPFEQAWEVK 
5 M8(Oxidation); 
M10(Oxidation) 
  
NEDASFPSTPEPVKDSSR 11 S5(Phospho); S8(Phospho) S(5): 99.9; S(8): 50.0; T(9): 50.0; S(16): 0.0; S(17): 0.1 
IMDLMEQPGNTVSSGQEDFPSVL
LETAASLPSLSPLSTVSFK 
7 M2(Oxidation); 
M5(Oxidation); 
S37(Phospho) 
T(11): 0.0; S(13): 0.0; S(14): 0.0; S(21): 0.0; T(26): 0.0; 
S(29): 0.0; S(32): 0.6; S(34): 5.5; S(37): 58.6; T(38): 
17.6; S(40): 17.6 
DKEDLVCSAALHSPQESPVGKED
R 
2 C7(Carbamidomethyl); 
S13(Phospho); 
S17(Phospho) 
S(8): 50.1; S(13): 50.1; S(17): 99.9 
DKEDLVCSAALHSPQESPVGKED
R 
1 C7(Carbamidomethyl)   
SVPEHAELVEDSSPESEPVDLFSD
DSIPEVPQTQEEAVMLMK 
2 M39(Oxidation); 
M41(Oxidation) 
  
QPSWERSPAAPAPSLPPAAAVLP
SK 
3 S3(Phospho); S7(Phospho) S(3): 100.0; S(7): 100.0; S(14): 0.0; S(24): 0.0 
QPSWERSPAAPAPSLPPAAAVLP
SK 
2 S3(Phospho) S(3): 84.4; S(7): 15.6; S(14): 0.0; S(24): 0.0 
DSEGRNEDASFPSTPEPVK 5 S10(Phospho); 
S13(Phospho) 
S(2): 0.0; S(10): 66.7; S(13): 66.7; T(14): 66.7 
ETKLSTEPSPDFSNYSEIAK 2 S5(Phospho) T(2): 0.2; S(5): 49.2; T(6): 49.2; S(9): 1.3; S(13): 0.0; 
Y(15): 0.0; S(16): 0.0 
EKISLQMEEFNTAIYSNDDLLSSK
EDK 
1 M7(Oxidation)   
GPLPAAPPAAPERQPSWER 2 S16(Phospho) S(16): 100.0 
ETKLSTEPSPDFSNYSEIAK 3 S5(Phospho); S9(Phospho) T(2): 1.1; S(5): 49.5; T(6): 49.5; S(9): 100.0; S(13): 0.0; 
Y(15): 0.0; S(16): 0.0 
TSNPFLVAVQDSEADYVTTDTLS
K 
2 S2(Phospho) T(1): 23.0; S(2): 76.8; S(12): 0.1; Y(16): 0.1; T(18): 0.1; 
T(19): 0.0; T(21): 0.0; S(23): 0.0 
SDEGHPFR 12     
AQIITEKTSPK 6 S9(Phospho) T(5): 0.1; T(8): 49.9; S(9): 49.9 
SKDKEDLVCSAALHSPQESPVGK 2 C9(Carbamidomethyl); S(1): 0.0; S(10): 0.0; S(15): 100.0; S(19): 100.0 
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S15(Phospho); 
S19(Phospho) 
ESETFSDSSPIEIIDEFPTFVSAKD
DSPK 
3 T19(Phospho) S(2): 0.0; T(4): 0.0; S(6): 0.0; S(8): 0.0; S(9): 0.0; T(19): 
78.8; S(22): 17.2; S(27): 4.0 
IMDLMEQPGNTVSSGQEDFPSVL
LETAASLPSLSPLSTVSFK 
7 M2(Oxidation); 
S34(Phospho) 
T(11): 0.7; S(13): 2.8; S(14): 2.8; S(21): 13.3; T(26): 
2.8; S(29): 0.7; S(32): 13.3; S(34): 31.0; S(37): 13.3; 
T(38): 13.3; S(40): 6.0 
IMDLMEQPGNTVSSGQEDFPSVL
LETAASLPSLSPLSTVSFK 
1 M5(Oxidation)   
DAASNDIPTLTK 1 K12(GlyGly)   
GVIQAIQK 3     
DSEGRNEDASFPSTPEPVK 4 T14(Phospho) S(2): 0.0; S(10): 0.0; S(13): 2.7; T(14): 97.3 
ESLTEVSETVAQHKEER 2 K14(GlyGly)   
DSEGRNEDASFPSTPEPVKDSSR 4 S10(Phospho); 
S13(Phospho) 
S(2): 2.6; S(10): 97.3; S(13): 13.8; T(14): 86.3; S(21): 
0.0; S(22): 0.0 
NEDASFPSTPEPVK 4 S5(Phospho); S8(Phospho) S(5): 99.9; S(8): 50.0; T(9): 50.0 
KLPSDTEK 1     
IKESETFSDSSPIEIIDEFPTFVSA
KDDSPK 
1 T6(Phospho); 
S29(Phospho) 
S(4): 3.9; T(6): 3.9; S(8): 12.1; S(10): 40.0; S(11): 40.0; 
T(21): 2.9; S(24): 8.6; S(29): 88.5 
SVPEHAELVEDSSPESEPVDLFSD
DSIPEVPQTQEEAVMLMK 
1     
DKEDLVCSAALHSPQESPVGK 2 C7(Carbamidomethyl); 
S13(Phospho); 
S17(Phospho) 
S(8): 0.0; S(13): 100.0; S(17): 100.0 
DAASNDIPTLTKK 2     
AQIITEK 3     
GSPKGESAILVENTK 2 S2(Phospho) S(2): 100.0; S(7): 0.0; T(14): 0.0 
ESETFSDSSPIEIIDEFPTFVSAK 1 S6(Phospho); S8(Phospho) S(2): 12.1; T(4): 27.6; S(6): 69.9; S(8): 81.1; S(9): 8.8; 
T(19): 0.2; S(22): 0.2 
ESETFSDSSPIEIIDEFPTFVSAKD
DSPK 
1 S9(Phospho); 
S22(Phospho) 
S(2): 0.8; T(4): 0.8; S(6): 2.3; S(8): 7.4; S(9): 88.7; 
T(19): 47.9; S(22): 47.9; S(27): 4.1 
YSNSALGHVNSTIK 1 K14(GlyGly)   
MEDIDQSSLVSSSTDSPPRPPPA
FK 
1 M1(Oxidation); 
S7(Phospho) 
S(7): 27.7; S(8): 27.7; S(11): 7.4; S(12): 7.4; S(13): 
27.7; T(14): 2.1; S(16): 0.1 
SVPEHAELVEDSSPESEPVDLFSD
DSIPEVPQTQEEAVMLMK 
2 M39(Oxidation)   
LSTEPSPDFSNYSEIAK 1 K17(GlyGly)   !
Table A.4: NogoA post-translation modification in TTX-treated cultures 
NogoA was immunoprecipiatated from rat primary hippocampal neurons following 24hr 
treatment with TTX (2µM) and subject to LC-MS/MS.  This table summaries the peptides 
identified from both CID and HDC fragmentation methods.  The column on the right indicates 
the probability that each serine, threonine, or tyrosine residue is phosphorylated, for a given 
phosphopeptide.!!!!!!!!!!
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